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ABSTRACT 
  
The healthcare system in this country is currently unacceptable. New technologies 
may contribute to reducing cost and improving outcomes. Early diagnosis and treatment 
represents the least risky option for addressing this issue. Such a technology needs to be 
inexpensive, highly sensitive, highly specific, and amenable to adoption in a clinic. This 
thesis explores an immunodiagnostic technology based on highly scalable, non-natural 
sequence peptide microarrays designed to profile the humoral immune response and 
address the healthcare problem. The primary aim of this thesis is to explore the ability of 
these arrays to map continuous (linear) epitopes. I discovered that using a technique 
termed subsequence analysis where epitopes could be decisively mapped to an eliciting 
protein with high success rate. This led to the discovery of novel linear epitopes from 
Plasmodium falciparum (Malaria) and Treponema palladium (Syphilis), as well as 
validation of previously discovered epitopes in Dengue and monoclonal antibodies. Next, 
I developed and tested a classification scheme based on Support Vector Machines for 
development of a Dengue Fever diagnostic, achieving higher sensitivity and specificity 
than current FDA approved techniques. The software underlying this method is available 
for download under the BSD license. Following this, I developed a kinetic model for 
immunosignatures and tested it against existing data driven by previously unexplained 
phenomena. This model provides a framework and informs ways to optimize the platform 
for maximum stability and efficiency. I also explored the role of sequence composition in 
explaining an immunosignature binding profile, determining a strong role for charged 
residues that seems to have some predictive ability for disease. Finally, I developed a 
database, software and indexing strategy based on Apache Lucene for searching motif 
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patterns (regular expressions) in large biological databases. These projects as a whole 
have advanced knowledge of how to approach high throughput immunodiagnostics and 
provide an example of how technology can be fused with biology in order to affect 
scientific and health outcomes.  
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CHAPTER 1 
INTRODUCTION 
The Need for Preventative Medical Technologies 
The rise in healthcare expenditures has historically and consistently outpaced 
general inflation (Staff, 2013) despite record research expenditures aimed at better and 
more efficient treatments. This suggests a failure in existing paradigms in delivering care 
to an ever larger population. Instead of identifying disease early thereby making existing 
treatments more efficient, the focus is on creating new treatments for late-stage disease, 
resulting in a very poor return on investment for dollars spent on care, research and 
development. Healthcare spending in the United States is approximately 17.9% of GDP, 
the highest in the rich world (Martin, Lassman, Washington, Catlin, & Team, 2012). This 
systemic problem has stabilized in recent years at this level, but in the words of former 
President Bill Clinton “we are ahead by a country mile” compared to the rest of the rich 
world in terms of just how much we spend on healthcare. Despite this enormous burden, 
outcomes are only middling. This unacceptable situation has been met with only 
lukewarm political intervention and the situation shows no signs of improving in the 
future. Only new technology and more importantly, new ways of thinking about 
healthcare, can slow or reverse this trend. This chapter outlines the problems and trends 
facing modern healthcare and healthcare research, advocates for a new approach based on 
prevention and early detection, reviews the literature on antibody based diagnostic 
technologies that could meet this need, and outlines the specific contributions of this 
thesis aimed at addressing a small part of this larger challenge.  
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Figure 1.1: Healthcare Inflation versus General Inflation: Historically, general 
inflation (blue) has been outpaced consistently by healthcare inflation (red). Recently, 
this has stabilized, but expenditures 17.9% of GDP: the highest in the rich world by far. 
Source: (Staff, 2013) (Public Domain) 
 
 Despite the need for new approaches and ways of thinking about healthcare, a 
new paradigm has yet to emerge. Research dollars that ought to focus on reducing these 
costs through prevention, early detection and risk-assessment technologies are instead 
spent on expensive interventional projects with low success rates that, even if successful 
may only extend lives by months due to their interventional focus. Despite increased 
investment between 1998 and 2008, the number of approved new molecular entities 
(drugs) has declined significantly (Pammolli, Magazzini, & Riccaboni, 2011), and 
clinical trial attrition rates have increased dramatically (Pammolli et al., 2011) (Figure 
1.2). Put simply, it is becoming harder to develop new drugs, indicating that a change is 
needed in which treatments to pursue preclinically. These attrition rates are market 
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driven, because incentive schemes are geared toward drugs that are profitable. The 
profitable classes of drugs are interventional, and a more effective drug (one that passes 
phase III trials) is a more profitable drug. The investment piles on, which drives profits 
(if at the cost of increased attrition) under the current system. 
 
 
Figure 1.2: Attrition Rates Over Time for All Clinical Trial Phases: There has been a 
dramatic increase in clinical trial attrition rates since 1990, suggesting that new drug 
interventions are becoming more difficult and expensive. Reproduced with permission: 
(Pammolli et al., 2011) 
 
Prevention: Return on Investment 
 The conventional wisdom on preventative medicine (which includes early 
diagnostic screening) is that it tends to add to healthcare expenditures rather than 
decrease them. This is based on hundreds of studies showing that less than 20% of 
preventative healthcare options are cost-saving, while 80% add cost (Russell, 2009). 
Though the same studies predict prevention approaches are more effective than 
intervention approaches in terms of health outcomes, the approach is unviable if 
prevention increases costs. The system simply cannot afford quality prevention at this 
time for all but the wealthiest in society. 
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 This conventional wisdom, though accurate, typically draws the flawed 
conclusion that research into preventative and early diagnostic approaches is not worthy 
of intense investment. Instead, interventional treatments receive billions in yearly 
investments from pharmaceutical companies (Mestre-Ferrandiz, Sussex, & Towse, 2012), 
in addition to the $30.1 billion budget of the NIH (Loscalzo, 2006), which has had almost 
no impact on the incidence, prevalence or number of days spent in the hospital for any 
disease (Gross, Anderson, & Powe, 1999). Why is the public spending so much for so 
little?  
With this level of investment in interventional treatments, these should be much 
more effective and cost saving than preventative treatments. Instead, the impact is 
marginal, the efficiency is getting worse, and healthcare costs continue to spiral 
unnecessarily out of control, burdening every American healthy or otherwise. While 
prevention and early screening is at this time is a risky bet, in the author’s opinion it is far 
less risky than the current regime, which has proven to be expensive, ineffective and most 
beneficial to the small class of wealthy individuals and companies that are able to profit 
off of desperate people in the late stages of fatal disease. 
 It is time to give prevention, early diagnostics, and early treatments a serious look. 
The failures of the past regarding prevention are hurdles that can be overcome. A 
preventative approach can be cost saving only if it is inexpensive, highly specific, highly 
sensitive, and approachable to the clinician to encourage wide adoption. Smart allocation 
of research dollars and an honest acknowledgement of these requirements, if met, can 
change the situation. Modern biology allows us to take very detailed measurements at 
annually decreasing costs (Shendure & Ji, 2008).  
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Through effective analysis and good platforms, these measurements can be turned 
into valuable information which can be used to affect real reductions in the incidence and 
prevalence of disease.  For the first time in history, cheap, highly sensitive and highly 
specific diagnostic technologies are within our grasp. This is due to major advances in the 
tools we use, our understanding of basic biology, and of disease processes. This thesis 
covers in detail one such technology aimed at this lofty but noble goal, but it is important 
to note that this is just one of many possibilities in an ever growing ecosystem. In the 
skilled hands of clinicians who are currently “flying blind” due to an outdated healthcare 
delivery and research model, modern biology combined with technology could have a 
revolutionary impact on how the human race approaches disease, diagnostics and 
treatment. 
Biomarkers for Prevention 
One such class of modern measurements that could shift healthcare towards 
prevention and early diagnostics are biomarkers. These are typically (but not limited to) 
circulating molecules that indicate, correlate with or predict disease. Cholesterol (LDL, 
HDL) for example is an important biomarker for cardiovascular disease (Sharrett et al., 
2001). More recently, a mutation in the BRCA1 gene has emerged as an important 
predictor for breast cancer (James, Quinn, Mullan, Johnston, & Harkin, 2007). Most of 
these molecules, however, must overcome the blood dilution problem. This means that in 
order for a biomarker to be a useful predictor of disease, there has to be so much of it 
present that often disease has progressed to a troublesome state where easy intervention is 
impossible (Hori & Gambhir, 2011). Due to the amount of blood in the body combined 
with the relatively small systemic effect of early stage fatal disease, if a biomarker is 
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present in sufficient concentration to be detectable above normal range, something has 
already gone seriously wrong. What is needed is a class of biomarkers that can amplify 
signals before symptoms arise, enabling cheaper, more effective diagnostics and early 
interventions. Though not biomarker based, one of the few examples where this approach 
is widely practiced is that of colorectal cancer screening. Treatment for stage I or stage II 
colon tumor (or any in-situ carcinoma) is a relatively straightforward surgery and 
effectively a cure, but this is only possible if it is caught early enough through regular 
screening. This is currently not possible for most lethal diseases. Developing the proper 
biomarker-based diagnostics could change this. 
Antibody Biomarkers 
 Of all the molecules in the human body, there is one class that stands out as an 
ideal biomarker. Antibodies are generated by the humoral immune system, which is 
constantly monitoring and reacting changes in the blood and most organ systems of the 
body. B-cells which produce antibodies go through a rapid process of hypermutation, 
selection and clonal expansion (Teng & Papavasiliou, 2007) in response to a potentially 
dangerous foreign entity (antigen). One B-cell clone can rapidly secrete many 
immunoglobulin molecules (Halperin, 2011), meeting the amplification requirement for 
overcoming the blood dilution problem. Traditionally these antibodies have been thought 
of as a response only to infectious diseases and autoimmune diseases, the evidence for 
which has been reviewed in detail by others (Halperin, 2011; Kukreja, 2012; Navalkar, 
2014). However, it is fairly clear at this point that there is an immune response to many 
different chronic diseases and cancers. Some argue that natural anti-cancer antibodies are 
generally germline or near-germline IgM molecules which bind to carbohydrates 
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expressed on cancer cells (Vollmers & Brändlein, 2007). Other, more recent papers claim 
that natural and specific self-IgG molecules are abundant and ubiquitous in human sera, 
and respond to chronic diseases such as cancer (Nagele et al., 2013; Stafford et al., 2014). 
Antigen specific IgG molecules have been isolated in stage IV breast cancer patients (M. 
H. Hansen, Ostenstad, & Sioud, 2001), prostate cancer patients (Dunphy & McNeel, 
2005) and in lung cancer patients (Klotz et al., 1999). There is also some evidence that 
carcinomas can produce and secrete their own IgG molecules in the absence of any 
contribution from B-cells or the typical humoral immune system (Chen & Gu, 2007). 
Despite the many studies showing evidence of specific IgG molecules associated with 
cancer, the traditional view still holds with many scientists that natural antibodies 
directed against cancer are primarily nonspecific, near germ-line IgM molecules. Recent 
data challenges this assumption, and very recent attempts at using these specific “non-
traditional” antibodies as tools for diagnostics have shown promise (Anders, 1986; 
"DENV DetectTM IgM CAPTURE ELISA," 2012; Restrepo et al., 2011a; Scherf, 
Lopez-Rubio, & Riviere, 2008). 
Detecting Antibody Biomarkers 
 The various methods of detecting circulating antibodies as biomarkers have been 
thoroughly reviewed by others (Arnon, Tarrab-Hazdai, & Steward, 2000; Halperin, 2011; 
Navalkar, 2014).These include phage display techniques, which express millions to 
billions of random peptides displayed on phage particles and use various enrichment 
rounds to find populations of peptides which bind the molecule of interest with high 
affinity (Fack et al., 1997; Krumpe et al., 2006; Paschke, 2006; Rodi, Soares, & 
Makowski, 2002; Wang & Yu, 2004; Yip & Ward, 1999). This is probably the most well 
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known and widely adopted antibody profiling technology. Another important method 
uses protein arrays (Ramachandran et al., 2004; Schweitzer, Meng, Mattoon, & Rai, 
2010). These typically spot or synthesize recombinant proteins on various surfaces using 
various methods and apply serum or monoclonal antibodies to the resulting arrays. Using 
a fluorescently labeled secondary antibody, protein-antibody complexes can be identified. 
The other major class of antibody profiling technologies is peptide arrays. These arrays 
either tile known antigens or epitopes in a targeted, designed way (Chen et al., 2010; 
Forsström et al., 2014), seek to represent a large portion of pathogen proteome space in 
an attempt at a high throughput multiplexed diagnostic(Navalkar, 2014), or simply spot 
or synthesize non-natural random sequence peptides en-masse with the hope that 
antibodies will bind in a reproducible specific way (Halperin, Stafford, & Johnston, 2011; 
Kukreja, Johnston, & Stafford, 2012; Legutki, Magee, Stafford, & Johnston, 2010; 
Legutki et al., 2014; Reineke, 2004; Reineke & Sabat, 2009; Restrepo, Stafford, & 
Johnston, 2012; Restrepo et al., 2011a; Sykes et al., 2013). The latter type of arrays will 
be introduced and tested in detail throughout this thesis, but first it is important to 
consider the characteristics and properties of the antibody-epitope interactions, with a 
special emphasis on continuous (linear) peptide interactions.  
Antibody-Epitope Interactions 
 Antibodies can bind a wide class of molecules, including carbohydrates, small 
molecules and peptides/proteins. The remainder of this thesis focuses on antibody-
peptide and antibody-protein interactions, but it is important to note that antibodies are 
not limited to these. When an antibody is raised against and binds strongly to a protein, 
that protein is called the antigen. The region on the protein to which the antibody binds is 
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the epitope, and the corresponding region on the antibody side is called the paratope. 
Since proteins are folded in all sorts of ways, the antibody paratope may bind a 
continuous (linear) portion of the protein or a discontinuous (two or more separate linear 
sections) portion of the protein. Even if an epitope is continuous, it may require a 
particular structure supported by the rest of the antigen (constrained continuous epitope), 
meaning a peptide fragment from the epitope existing outside the context of the rest of 
the antigen would not bind the paratope. 
 
Figure 1.3: Crystal Structure Example of Linear Epitope Bound to Paratope: This is 
a partial view of the crystal structure for the monoclonal antibody 10E8 (purple, green) in 
complex with HIV protein gp41 (red, grey). This interaction is an example of a 
continuous epitope. Note that bound residues from the epitope are linearly close together 
(W680, L679, W672, etc). Reproduced with permission from (Huang et al., 2012). 
 
Both situations are commonly found in nature, and crystal structures exist of both 
types (Huang et al., 2012; Karpusas et al., 2001). An example of each is shown in Figure 
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1.3 (continuous) and Figure 1.4 (discontinuous). The evidence shows that most epitopes 
are somewhat discontinuous (they don’t bind all residues in a row), but many of these 
residues are spaced closely enough together such that they are effectively linear. 
 
 
Figure 1.4: Example of a Discontinuous Epitope Space Filling Model: This space 
filling model is from the crystal structure of CD40 in complex with a neutralizing 
humanized antibody. Mutational studies of the residues around the binding pocket 
revealed the residues important to complex formation (red, yellow). Note the labels on 
the residues, and that that some are hundreds of positions apart (H249, E129). 
Reproduced with permission from (Karpusas et al., 2001).  
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The exact ratio between continuous and discontinuous epitopes in nature is 
unknown, but a survey of the literature on crystal structures (along with data presented in 
this thesis) shows that continuous, linear and semi-linear epitopes are a very important 
and common class of epitopes (Huang et al., 2012; Niederfellner et al., 2011; Stegmann, 
Lührmann, & Wahl, 2010). 
Size and Characteristics of Linear Epitope Interactions 
 If one wants to capture and measure antibodies, one ought to know the types of 
structures that an antibody binds. To simplify the problem, we limit ourselves to 
considering only the linear epitopes. Note that in Figure 1.3 not all the residues in the 
complex contribute equally to binding. Few studies have been done to determine the 
number and distribution of residues required for a mature monoclonal antibody paratope 
to bind with high affinity to its epitope. One good way to do this with linear epitopes is to 
do a complete substitution study. This is where, for each position si on the linear epitope 
sequence S, the amino acid at that position is replaced by every other amino acid, and a 
fluorescent binding assay is conducted for each “mutated” peptide against the antibody of 
interest. The ratio of fluorescence between the original sequence and the position specific 
mutated sequence provides a measure of the contribution to the amino acid at position si. 
More precisely, for each position in the sequence S 
 
and each amino acid aj from the possible amino acids A 
 
form an n x 20 matrix of peptides P where 
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Using a fluorescence assay (ELISA, arrays, others) a measurement is taken that is 
correlated to binding strength of an antibody with the sequence Pi,j, forming an n x 20 
matrix of fluorescence values F. Dividing F by the measurement obtained from the 
fluorescence assay of antibody with the original sequence S gives the position specific 
scoring matrix (PSSM). This measures the relative effect of each amino acid substitution 
on observed binding. An example of a PSSM in the context of antibody-epitope 
interactions is given in Figure 1.5. 
In the Center for Innovations in Medicine this approach has been used to optimize 
ligands for synbodies (Greving et al., 2010), but has also been used by others to estimate 
the lengths and number of amino acids contributing to epitope-paritope complex 
formation. Possibly the most comprehensive study undertaken to answer this question 
was conducted by Buus et al. in 2012 (Buus et al., 2012b). They raised polyclonal rabbit 
antibodies against 22 protein fragments (PrESTs) ranging from 50 to 150 amino acids 
long. They found and defined 49 15-mer epitopes against these anti-PrEST antibodies 
through exhaustive subsequence searching on arrays, and then did the substitution 
process described above for each of these 49 epitopes with its target PrEST. Using this 
process they were able to create a PSSM and identify the important amino acids 
contributing to epitope-paratope complex formation. After repeating this process for all 
the PrEST-epitope combinations, they estimated a distribution for epitope lengths. This is 
reproduced in Figure 1.6.  
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Figure 1.5: An Example of a Position Specific Scoring Matrix (PSSM) For a 
Polyclonal Antibody Against a Defined Epitope: (A): By doing comprehensive 
substitutional analysis, important amino acids can be determined for epitope-paratope 
complexes and the length of the interaction can be estimated with a PSSM. Low values 
indicate substitutions that inhibited complex formation. (B) The corresponding motif 
cartoon for the interaction as determined by the PSSM. There are four contributing 
residues with various allowable substitutions. Reproduced with permission from (Buus et 
al., 2012b). The figure was adapted from its original form. This is permissible under the 
Creative Commons 3.0 License http://creativecommons.org/licenses/by/3.0/. 
 
 
Figure 1.6: Estimate of Linear Epitope Lengths Through Comprehensive 
Substitutional Analysis: This distribution represents the range of possible interaction 
lengths for epitope-paritope complexes. Reproduced with permission from (Buus et al., 
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2012b). The figure was adapted from its original form. This is permissible under the 
Creative Commons 3.0 License http://creativecommons.org/licenses/by/3.0/. 
 
 A re-analysis of the Buus data revealed that though continuous epitope length is 
centered on 8 amino acids, there are fewer residues within the total length that are 
actually important. Depending on the PSSM cutoff, there are on average between 4 and 7 
residues contributing to binding in an epitope-paratope complex. These results are 
summarized in Figure 1.7. 
 
Figure 1.7: Estimate the Number of Important Binding Residues in Epitope-
Paratope Interactions: These distributions are based on reanalysis of the Buus data. It 
concludes that on average, 4 to 7 epitope residues are important to binding in an epitope-
paratopecomples. Reproduced with permission from (Buus et al., 2012b). The figure was 
adapted from data contained within. This is permissible under the Creative Commons 3.0 
License http://creativecommons.org/licenses/by/3.0/. 
 
To summarize, epitopes exist in continuous and discontinuous forms. It is not 
clear what proportion of antibody epitopes is continuous, but it is clear that they are 
common. These “linear” epitopes consist of a number of binding residues with an average 
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length covering 8 amino acids, 4 to 7 of which actually contribute to epitope-paratope 
complex formation. 
Mimotope Interactions 
In addition to specific epitope-paratope interactions, another type of interaction exists. 
These are the mimotopes, and they are often uncovered during phage display 
experiments. These are sequences that bind paratopes with high affinity but do not share 
sequence similarity with the epitope from which an antibody was raised (Smith & 
Petrenko, 1997). This explains the common problem of cross reactive monoclonal 
antibodies, and often confounds epitope mapping experiments. However, these 
interactions may be useful to immunosignatures because they expand the space to which 
an antibody can bind. There have been many attempts to use mimotopes discovered in 
phage display experiments as vaccines (Arnon et al., 2000; Riemer et al., 2005; Wagner 
et al., 2005). The properties of these interactions (crystal structures, substitution analysis) 
have not been widely studied, but the few crystal structures that exist suggest that 
mimotopic peptides bind a paratope in a similar fashion to a true epitope (Saphire et al., 
2007). See Figure 1.8 for a schematic of a mimotope-paratope interaction based on a 
crystal structure. It is interesting to note that for this particular interaction, the number of 
residues and length of the interaction is longer than that predicted by the Buus data. 
Perhaps mimotopes rely on more but weaker residue contacts than true epitopes.  
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 Figure 1.8: Mimotope-Paratope Interaction Schematic Based on Crystal Structure: 
This schematic shows the residue interactions between an anti-gp120 monoclonal 
antibody and a mimotope peptide that competes with gp120 for binding. Figure 
reproduced with permission from (Saphire et al., 2007). Note that this interaction is 
longer and involves more residues than that predicted by the Buus data. 
 
Random Peptide Arrays and Immunosignatures 
Now after a thorough review of antibodies, epitopes, and the details of how they 
interact, we return to the topic of using peptide arrays as a diagnostic device for early 
detection and preventative medicine. This approach was pioneered by Dr. Stephen Albert 
Johnston, Dr. Phillip Stafford and Dr. Neal Woodbury in the Center for Innovations in 
Medicine at Arizona State University. The basic idea relies on the fact that there are 
innumerable antibodies circulating in the blood at any given time. These antibody 
populations are constantly changing and adapting to new threats and circumstances 
within the body. Though the scope of this surveillance is unclear, given the wide body of 
evidence reviewed earlier in the chapter, one can assume the antibody repertoire responds 
in some way to most disease states a human will face.  
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 Assuming this (and it is not a big leap given the evidence already discussed), the 
problem becomes how to detect these changes robustly and reproducibly. The number of 
possible linear epitopes is large, but given that the length and number of important 
residues has a known distribution, it is not infinite. Therefore, if enough peptides could 
be assayed against the antibodies contained in a person’s blood, one could develop a 
profile, or “immunosignature” of that person’s antibody repertoire at any given time. By 
monitoring this signature over time, or comparing it to a population of signatures from 
many people, one could associate patterns in the signature with (theoretically) any 
disease state. The requirements for such a technology are that it be cheap, robust, and 
highly sensitive and specific so that it could be used for routine monitoring. If these 
requirements are met, there is hope that the era of expensive and ineffective late-
interventional medicine will end.   
 The solution developed in the Center for Innovations in Medicine for achieving 
these goals relies on randomized, non-natural sequence peptide arrays. The idea is to 
immobilize as many short peptides (12 to 17 aa) as possible on a surface, and use this 
complex surface to profile antibody repertoires. This is a combinatorial approach, and the 
elegance lies in the fact that the peptide need not map to any known epitope or antigenic 
protein. The only object of consideration is the signature, or binding profile observed on 
the array. The process for developing a diagnostic based on this complex surface is 
simple: probe a population of patients, some with a disease of interest and some without. 
Using this collected dataset, identify aspects of the immunosignature that predict disease, 
and use that model to predict correctly new samples. Such a scheme could be adapted to 
any disease to which the humoral immune system responds. 
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 Over the past 10 years, there has been much progress in this endeavor by 
individual contributors and by the group as a whole. Dr. Bart Legutki published the first 
results from immunosignatures, showing that an array of 10,000 non-natural sequence 
peptides could distinguish vaccinated from unvaccinated mice, and that this effect was 
amplified over time (Legutki et al., 2010). He followed this up with another study 
showing that the same arrays can predict whether a vaccine will be effective (Legutki & 
Johnston, 2013), a tool that would reduce development time for vaccines. 
 The methods for analyzing these complex high dimensional data are constantly 
evolving. Muskan Kukreja reviewed machine learning algorithms for achieving 
maximum accuracy in immunosignature data, and found Naïve Bayes classifiers to be 
most effective (Kukreja, 2012). This approach was not widely adopted by subsequent 
studies, with lab members instead gravitating towards SVM based methods. Justin Brown 
developed methods based on latent variables and hierarchical models common in 
psychology research (Brown, Stafford, Johnston, & Dinu, 2011), but these also have not 
been tested on subsequent datasets. 
 There have also been publications evaluating immunosignatures from the 
perspective of a clinical diagnostic. Lucas Restrepo established that there is an 
immunosignature for Alzheimer’s disease, and this could be a feasible method for 
diagnosis (Restrepo et al., 2012; Restrepo et al., 2011a). The largest study to date 
conducted for immunosignatures as diagnostics was published by Phillip Stafford, 
showing near perfect classification in a panel of several cancers using similar arrays that 
Dr. Legutki used in the original publication (Stafford et al., 2014). 
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 Since these efforts new, much larger and more complex arrays have been 
developed (CIM330K arrays). These contain over 330,000 unique peptide sequences and 
over 27% of all possible pentamers in triplicate within those sequences (Legutki et al., 
2014). This represents the second generation of tools for immunosignatures, and most of 
the data and experiments presented in this thesis focus on these new arrays. The 
manufacturing process for these is fundamentally different from the first iteration in that 
they are synthesized in-situ on the surface of a silicon wafer. This enables mass-
manufacturing and the opportunity to do high resolution epitope mapping in a similar 
manner of Buus discussed earlier. Using these new arrays for epitope mapping is a major 
component of this thesis. 
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Figure 1.9: Definitions and Sizes of Various Epitope Spaces: Linear epitopes can be 
defined in various ways. Each of these “spaces” has a different size and different 
characteristics. Some of these spaces are covered very well by the arrays used in this 
thesis, others are not. In subsequent chapters, these definitions will be tested and used to 
identify epitopes related to disease, characterize array results, and develop software to 
rapidly databases for motifs within these spaces. 
 
Project Overview 
 This thesis explores, characterizes and establishes the limits of the new generation 
of immunosignature technology. It builds on the work others have done with the smaller 
arrays, and expands this in terms of the new ones, while incorporating sequence 
information in new ways. Previously, individual peptides were considered simply as 
“black box” features, with no regard to the content of those sequences. This thesis 
changes that, by elucidating the role of sequences in immunosignatures. The first 
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question, addressed in chapter 1, is whether the new arrays have sufficient complexity 
needed to map epitopes in monoclonal antibodies and sera. Depending on how one 
defines an epitope, these arrays contain a high proportion of all possible epitopes, so I 
develop methods to resolve these from the complex data. Figure 1.8 summarizes the 
coverage of the various “sequence spaces” by version 7 of the CIM330K arrays.  
 The next chapter concerns itself with developing a diagnostic for Dengue Fever. 
This is evaluated against existing methods, revealing distinct advantages to the 
immunosignature approach. In the course of this development, a robust classification 
methodology and software based on SVM was developed and made available under the 
BSD License.  
 The third chapter develops a kinetic theory for how multiple antibodies bind 
multiple array peptides. From this, a testable hypothesis is derived and tested against 
existing data. This model represents the best guess to the underlying kinetic properties of 
the assay, and experiments are suggested to further validate and refine the model. 
 The fourth chapter is a meta analysis considering amino acid content and how 
well the patterns observed on the arrays are explained by a simple compositional linear 
model. There is remarkable stability across many different types of arrays and 
experimental conditions. There is a strong role for charged residues in determining the 
overall immunosignature pattern, and this effect seems to have some predictive ability for 
disease. 
 The final chapter develops a novel indexing strategy and software for rapidly 
searching through large sequence databases for linear epitope-like patterns. This was 
developed for a specific project whereby an unknown pathogen should be identified using 
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only sequence data gleaned from array experiments. Such an approach required rapid 
pattern searching technology that did not yet exist. Though the original project for which 
the software was designed did not yield the expected results, the software itself is the 
fastest known search method and indexing strategy for certain types of patterns. 
 The overarching theme in this thesis is that sequence information provides 
unprecedented detail and a new dimension to immunosignatures which still needs further 
exploration. I lay the groundwork and uncover some important results, particularly with 
regards to epitope mapping. However, there is always more work to do, and it is my hope 
that the work laid out here will be yet another pebble upon which others can build. 
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CHAPTER 2 
EPITOPE IDENTIFICATION USING PEPTIDE MICROARRAYS 
Abstract:   
Antibodies play an important role in modern science and medicine. They are 
essential in many biological assays, and have emerged as an important class of 
therapeutics. Unfortunately, current methods for mapping antibody epitopes require 
costly synthesis or enrichment steps, and no low cost universal platform exists. In order 
to address this, we tested a random sequence peptide microarray consisting of over 
330,000 unique peptides sequences sampling 83% of all possible tetramers and 27% of 
pentamers. It is a single, unbiased platform capable of performing many different types of 
tests, it does not rely on informatic selection of peptides for a particular proteome(s), and 
it does not require iterative rounds of selection. 
In order to optimize the platform, we developed an algorithm that considers the 
significance of k-length peptide subsequences (k-mers) within selected peptides that 
come from the microarray.  We tested eight monoclonal antibodies and seven infectious 
disease cohorts.  The method correctly identified 5/8 monoclonal epitopes, and identified 
both reported and unreported epitope candidates in the infectious disease cohorts. This 
algorithm may greatly enhance the utility of random-sequence peptide microarrays, by 
enabling rapid epitope mapping and antigen identification. 
Introduction: 
Antibodies play a central role in the immune system and in modern healthcare and 
medical research. They are commonly used as affinity reagents in research and diagnostic 
applications, and have emerged as an important class of therapeutics (Stafford et al., 
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2014). When generating new affinity reagents, it is useful to know the target sequence 
(epitope) bound by the antibody in question. Many methods have been developed to 
accomplish this, including peptide tiling and phage, bacteria and mRNA display (Ballew 
et al., 2013; Fack et al., 1997; Reineke, 2004). In disease diagnosis, especially for newly 
discovered diseases like MERS (Zaki, van Boheemen, Bestebroer, Osterhaus, & 
Fouchier, 2012), knowing the epitope(s) that elicits a humoral response enables 
production of diagnostics and vaccines. Large-scale mapping of cohorts infected with the 
same disease may guide development of universal vaccines for flu and other infections. 
Crystal structures provide the most information about antibody–antigen binding for linear 
or conformation epitopes, but in practice this is cost prohibitive and rarely done. Display 
or library panning-type approaches use bacteria or phage to display peptide sequences, 
avoiding costly crystallization or synthesis steps and area common approach for linear 
epitope mapping (Fack et al., 1997; Paschke, 2006). Recently, bacterial display methods 
have been used to discover antigens to Celiac disease (Ballew et al., 2013). Tools for 
probing the “memory” of the immune system could reveal a wealth of information about 
an individual’s health status and antibody repertoire. While display techniques are 
effective and result in highly accurate and specific linear epitope determination (Wang & 
Yu, 2004; Yip & Ward, 1999), they have hidden and poorly understood biases regarding 
sequence populations (Krumpe et al., 2006; Luck & Travé, 2011; Rodi et al., 2002) and 
rely on selection steps that eliminate certain sequences in favor of others. This process 
creates issues with cost and reliability at scale, and information is discarded as the 
selection process becomes increasingly stringent. As a rapid identification method, 
panning is non-optimal.  
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Peptide array technologies provide an alternative approach. They are simple, 
reproducible and low cost if mass produced, but represent a smaller sequence library than 
phage display and only contain linear sequences. This is an apparent disadvantage, but in 
practice, linear epitopes are actually quite common in nature and even mimotopes could 
provide useful, if indirect, information about non-linear epitopes. Microarrays of random-
sequence peptides are amenable to antibodies that strongly and specifically bind peptides 
consisting of short, gapped sequences containing four to six anchor residues, which seem 
to cover a sizable class of antibodies (Buus et al., 2012a; Sivalingam & Shepherd, 2012).  
To date the most common approach to designing peptide microarrays has been to tile 
sequences from a known protein or proteome of interest, and find sequences that bind the 
target (Edfors et al., 2014; Forsström et al., 2014; Hansen, Buus, & Schafer-Nielsen, 
2013; Reineke, 2004; Reineke & Sabat, 2009). Recently this technique has been scaled to 
whole proteomes using arrays containing millions of sequences (Forsström et al., 2014; 
Hansen et al., 2013). This approach is effective on a single protein scale, but problems 
arise when looking for specific epitope sequences in the presence of millions of other 
peptides. Cross-reactivity of antibodies to non-target peptides often obscures the eliciting 
antigen (Forsström et al., 2014). This may be due in part to the fact that tiled peptides are 
fundamentally different from folded proteins, and inaccessible parts of a protein are 
likely to be exposed when linear pieces of it are tiled. Additionally, there are many 
common n-mers across apparently unrelated pathogens (Halperin, 2011; Navalkar, 2014). 
It may be possible to address this problem using motif-based discovery rather than 
peptide-based discovery. Brief motifs (4-5mers) should appear redundantly in a given 
peptide library. Longer (6-12mers) exact sequences should appear more rarely. There 
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may be some way to leverage the higher confidence in short but redundant motifs in lieu 
of long but rarer sequences. A platform is needed that focuses on representing as many 
sequences as possible on an array, rather than accumulating sequences from a particular 
set of proteins which may or may not mimic the folded structure. 
Previously our group has used random-sequence peptide microarrays to diagnose 
disease using immunosignatures (Stafford et al., 2012; Sykes et al., 2013). The effect 
relies on the interaction of serum antibodies with random-sequence peptides bound to a 
microarray to provide information about a disease state (Hughes et al., 2012; Legutki et 
al., 2010; Restrepo et al., 2012; Restrepo et al., 2011b; Sykes et al., 2013). While 
immunosignatures are sensitive and specific as a diagnostic, there has not been a link 
established between the immunosignature profile consisting of peptides differentially 
bound between healthy and disease cohorts, and the actual sequences of those peptides. 
This was attempted in a previous study from our group which evaluated an array of 
10,000 17-mer peptides as a platform for epitope mapping. We found that while useful 
for predicting linear sequences to some monoclonal antibodies, it offered virtually no 
predictive power in serum samples from mice immunized to a known antigen (Halperin 
et al., 2011). Since then, advances in in-situ synthesis techniques have produced arrays 
containing over 330,000 peptides with the possibility of scaling to several million 
peptides per array (Legutki et al., 2014). These new arrays contain over 27% of possible 
pentamers and 83% of possible tetramers. While still lacking the majority of pentamers, 
this is a fairly dense sampling of short peptide sequences that may be useful for epitope 
mapping. 
 27 
Here we report on a general approach to using random sequence peptide arrays to map 
epitopes. We demonstrate this by recovering eliciting sequences in a set of monoclonal 
antibodies, and then apply it to a set of disease sera containing antibodies of unknown 
specificity, revealing both previously discovered and new epitopes. The study described 
here is the first attempt at deciphering a microarray with fixed but random peptide 
sequences for epitopes that does not a priori assume a set of eliciting proteins. 
Methods 
Array Construction 
Peptide microarrays are manufactured using in-situ synthesis of 330,000 random-
sequence peptides per 0.5cm2 region. Each 75mmx25mm slide contains24 sub-arrays, 
each containing 330,000 peptides. The average length of each peptide is 11.2 amino acids 
with a standard deviation of ±1.3, normally distributed. The longest peptide is 22aa long, 
the shortest is 1aa, with 95% of peptides between 8aa and 14aa.Peptides are synthesized 
from C-terminal to N-terminal, with the amine group furthest from the array surface. 
Prior to assay, they are washed in 100% DMF for one hour, then introduced to PBST 
incubation buffer (3% BSA in Phosphate Buffered Saline, 0.05% Tween 20) over a 
period of six hours to allow the solvent phase to be completely transitioned to aqueous 
phase. The arrays are then processed by incubating in the presence of antibodies or serum 
and detected by fluorescent antibody (see methods in (Legutki et al., 2014)). 
Binding of antibodies to the array 
Residual DMF was removed by two 5 min. washes in distilled water. Arrays were 
equilibrated in PBS for 30 min and blocked in incubation buffer (3% BSA in Phosphate 
Buffered Saline, 0.05% Tween 20 (PBST). Arrays were washed and briefly spun dry 
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prior to loading into the multi-well gasket (Array-It, Santa Clara, CA). Incubation buffer 
was added to each well (100ul) and 100 ul of 1:2500 diluted sera was added for a final 
concentration of 1:5000. Arrays were incubated for 1hr at 23oC with rocking, and then 
washed with PBST and 1% BSA in PBST using a BioTek 405TS plate washer. Anti-
human IgG-DyLight 549(KPL, Gaithersburg, MD) was added to a final concentration of 
5.0 nM. Unbound secondary was then removed by washing in PBST followed by 
washing in distilled water. The arrays were removed from the gasket while submerged, 
dunked in isopropanol and centrifuged dry (800xG, 5 min).Arrays were scanned at 
533nm using an Innoscan 910 array scanner (Innopsys, Carbonne, France). Features were 
aligned and extracted using GenePix Pro 6.0 (Molecular Devices, Sunnyvale, CA). 
Monoclonal Antibodies 
Eight monoclonal antibodies were used in this study. Anti-human HA (Rockland 
Antibodies, Rockland, MD, [YPYDVPDYA]), DM1A (anti-human tubulin, 
Invitrogen/Life Technologies, [AALEKDYEEVGV]), Ab1 (anti-human TP53 antibodies, 
Clonetech, Palo Alto, CA, [TFRHSVVV]), FLAG (Invitrogen, Madison, WI, 
[DYKDDDDK]), 4C1 (anti-human TSHR, Santa Cruz Biotech, Dallas, TX, 
[QAFDSHY]), A10 (Acris Antibodies GmbH, Hiddenhausen, Germany, [EEDFRV]), 
Ab8 (Anti-human P53, Thermo Fisher Scientific, Waltham, MA, [TFSDLWKLLPE]), 
and 2C11 (Acris Antibodies GmbH, Hiddenhausen, Germany, [NAHYYVFFEEQE]). 
Serum Samples 
Sera from seven different disease cohorts were provided by Seracare Life 
Sciences (Milford, MA) as well as 10 pools of healthy persons designated as HNP, plus 
one group of 32 different non-infected sera samples collected from consented volunteers 
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by the Center for Innovations in Medicine at Arizona State University under IRB# 
0905004024 (renewed April, 2014) were used for this study. There were 32 healthy 
donors (Normals), 9 Dengue Fever (DEN1 Flaviviridae), 8 Lyme disease (Borrelia 
burgdorferii), 7 Syphillis (Treponema palladium), 13 Malaria (Plasmodium falciparum), 
12 Whooping cough (Bordetella pertussis), 15 Hepatitis B virus (Hepadnavirus), and 10 
mixed pools of normals called HNP (Healthy Normal Pool) that comprised the 8 cohorts. 
Analytical methods 
Finding Antibody Specific Peptides 
The goal of this study is to find sequence motifs corresponding to an epitope. 
Thus, the first step of an analysis is to identify peptides that bind specifically to the 
sample of interest without regard to the peptide sequence. First, arrays are normalized to 
the median intensity value to account for small differences in serum or dye 
concentrations. Then, fold-change is calculated per peptide across the sample of interest 
and the median of control samples. In the case of serum samples, the controls were a 
cohort of non-diseased patient samples. In the case of monoclonal antibodies, the controls 
were a mix of all other monoclonal antibodies being examined. Based on these 
transformed values, the top 500 peptides were used as seed sequences for epitope 
discovery. 
Maximal Subsequence Algorithm 
The algorithm used to find high binding subsequences was designed to find short 
consensus motifs within a large set of random peptides. It can be divided into two parts: 
motif identification and significance testing. Seed sequences are computationally divided 
into all possible subsequences within a certain range of lengths (3 to 7 amino acids).The 
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set of these subsequences Sx are ranked and evaluated for significance in subsequent 
steps. 
The input to the algorithm is a set of sequences S = {s1 , s2 , ..., sn }, and 
associated preprocessed array intensity values Q = {q1, q2, …, qn}. To find a set of 
significant subsequences, the sequences in S are divided into all possible subsequences 
containing between three and seven amino acids each. For example, the sequence 
AVHAD would be divided into the set {AVH, VHA, HAD, AVHA, VHAD, AVHAD}. 
All the subsequences in S constitute a new set S’. Members in S’ have one or more 
associated values in Q corresponding to the intensities from parent sequences containing 
that subsequence. We define the function Qsub: S’ Qm , where m is the number of 
peptides excepting the top 500 seed peptides containing the input subsequence. This 
gives all intensity values associated with a subsequence. 
Sequences si∈Sx are ranked according to their associated values ti = Qsub(si). A 
subsequence is only considered if it appears in at least three peptides (|ti| > 3). We term 
this value the support of the subsequence. The ranking function considers the support and 
the median intensity value median(ti), such that the highest ranked subsequences have at 
least three appearances on the array and have high median intensities . This criterion is 
not strictly necessary, but it simplifies significance testing by throwing out non-
significant, poorly represented sequences. Once subsequences are filtered and ranked, 
their significance can be established. This occurs for a given subsequence i using the 
following nonparametric procedure: 
1. Draw |ti| values from Q at random. Call this vector t’i.  
2. Compute median(t’i). 
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3. Repeat steps one and two 10,000 times, resulting in a nonparametric estimate of a 
ti null distribution. Call this vector D. 
4. A p value is computed for subsequence si according to: 𝑝𝑖 =
∑ 𝐼(𝑚𝑒𝑑𝑖𝑎𝑛(𝑡′𝑖) >𝑘)𝑘∈𝐷
|𝐷|
  
where I is the indicator function. 
5. Correct the p values for multiple hypotheses. This work used the following 
correction function: 𝑝′
𝑖
=
𝑝𝑖
∑ |𝑄𝑠𝑢𝑏(si∈𝑆𝑥 si)|
. For example, if 1000 subsequences are 
considered, alpha is
1
1000
, resulting in one expected false positive. 
 
Calling Epitope Candidates 
Significant subsequences were identified for each individual per disease cohort. In 
order to determine the most likely epitope candidates, sequences were ranked in terms of 
the number of subjects in which they were called significant. The sequences that 
appeared most often in different individuals within the same group were deemed the most 
likely epitope candidates (Figure 2.4A). 
Mapping Epitope Candidates to Pathogen Proteomes 
The most common significant subsequences (query sequences) were searched 
against the pathogen proteome for 100% identity. The probability of a match was 
assessed by searching randomly drawn array sequences of the same length as the query 
sequence against the proteome, and comparing the expected number of matches to those 
observed with the query. 
Pathogen Identification 
Our objective was to identify an unknown pathogen based on array sequence 
information alone. The (n) significant subsequences from the same cohort were pairwise 
aligned using the BLOSUM62 substitution matrix, producing an (n x n) matrix of 
alignment scores. This matrix was hierarchically clustered by single linkage, producing a 
dendrogram of related subsequences. This analysis revealed peaks of central 
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subsequences which were presumed to be most closely related to the true epitope. These 
peak sequences were searched against a database of 596 proteomes (hereafter called the 
Pathogen Proteome Database) from various strains pathogenic bacteria, viruses, and 
protists causing over 100 different diseases. Those proteins and organisms matching all 
queried sequences within 100% or 80% identity were noted. Probabilities were 
determined by querying the database with randomly drawn sequences as above. 
Minimum Required Sequence Information 
In order to find the point at which pathogen proteins could be resolved from a 
database given fixed epitope information, we generated several sets of random sequences 
ranging in lengths from four to seven amino acids. Pairs of sequences with set lengths 
were drawn from this set, and queried against two databases: one containing 596 human 
pathogens, and another containing over 5000 Bacteria, Viruses, and Eukaryotes, in order 
to determine the point at which pathogens could be uniquely resolved. For example, a 
trimer sequence would be present in most pathogen proteins, but two heptamer sequences 
are much less likely to appear in multiple pathogens by chance due to more available 
sequence information. 
Sequence Logo Generation 
Significant subsequences were collected together into a FASTA-formatted list. 
Multiple alignments were produced with ClustalW2 (Chaddock et al., 1995). Multiple 
alignment text file was used as input to WebLogo 3 (Bähler & Rhoads, 2002) using 
default settings, producing the motif figure.  
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E Value Calculations 
The reported E-values were calculated by searching random re-orderings (with 
replacement) of the candidate subsequence against the target proteome, using the mean 
number of occurrences of 10,000 re-orderings as the E-value. 
Results: 
We first asked whether we could predicatively map epitopes to well-characterized 
monoclonal antibodies. Eight antibodies with reactivity to a known linear sequence were 
chosen and analyzed. 
Epitope Determination in Monoclonal Antibodies 
Epitope Ab Name Immunogen Isotype pI GRAVY 
Mean 
Signal 
Intensity 
Mapped 
Predicati
vely 
EEDFRV A10 Human Pol II IgG2b 4.1 -1.3 4911 No 
SDLWKL p53ab8 Human p53 
IgG2b, 
IgG2a 5.6 -0.3 6243 No 
QAFDSH 4C1 
Human Insulin 
Receptor IgG2a 5.1 -1.1 971 Yes 
RHSVV p53ab1 Human p53 IgG1 9.8 0 5074 Yes 
DYKDDDDK FLAG FLAG peptide IgG1 4 -3.3 1167 Yes 
AALEKD DM1A 
Human Tubulin 
- alpha IgG1kappa 4.7 -0.6 5798 Yes 
YPYDVPDYA HA HA peptide IgG1 3.6 -0.9 905 Yes 
NAHYYVFFEEQ 2C11 
Human Insulin 
Receptor IgG1 4.5 -1 827 No 
 
Table 2.1: Table of Monoclonal Antibodies Used in this Study -- Monoclonal 
antibodies used to test subsequence analysis. IgG2 was less likely to reveal an epitope 
than the IgG1 mAbs. Predictive mapping means that the top subsequences were both 
related to the true epitope and related to each other to an extent that a clear, dominant 
motif emerged with strong association to the epitope sequence. GRAVY stands form 
grand average of hydropathicity index(Legutki et al., 2014). 
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Table 2.1 lists peptides and binding intensities for the 8 different monoclonal 
antibodies. The linear epitope for each monoclonal is known, and was used as the basis 
for algorithm development and testing. In most cases, simply sorting peptides by intensity 
per monoclonal was insufficient to reveal epitope motifs amongst the highest binding 
peptides. Variation in binding to a specific target comes in part from the amount of non-
cognate binding. Highly promiscuous antibodies like anti-HA bind large numbers of 
peptides with low similarity to the target, creating a lack of specificity in these datasets  
(Table 2.2).  
  Total Binders On Target Fraction 
AB1 42386 466 1.10 x 10-02 
HA 1608 53 3.30 x 10-02 
4C1 2561 276 1.08 x 10-01 
FLAG 7563 0 0 
DM1A 44821 207 4.62 x 10-03 
A10 44924 37 8.24 x 10-04 
AB8 46327 1 2.16 x 10-05 
2C11 671 0 0 
 
Table 2.2: On Target versus Off Target Binding – This table shows the number of 
peptides for each antibody that yielded a signal greater than 5-fold above background 
(Total Binders), and of those how many had at least 80% sequence identity with the true 
epitope (On Target). See Table 2.1 for list of true epitopes. A very low percentage 
(<11%) of the binding peptides had strong sequence similarity with the true epitope, in 
agreement with previous studies (Halperin et al., 2011). 
 
However, transforming the data in terms of peptide subsequences revealed highly 
specific and consistent sequences that corresponded to epitope targets in five of the tested 
antibodies. Motifs were similar to the exact eliciting peptide sequence. Even when the 
exact sequence was not present on the array, sequences very similar to the eliciting 
peptide predominated (Figure 2.1, Figure 2.2). Three of the tested antibodies did not 
generate a specific response to the expected target sequence. In one of these cases 
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(P53Ab8), the epitope SDLWKL was bound, but due to the high degree of cross 
reactivity to non sequence-similar peptides, one would not expect to map the epitope 
based on these results alone (Figure 2.3A). 
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Figure 2.1: Top Binding Subsequences and Peptides for Selected Monoclonals: 
These bar plots show the top binding subsequences (top) and subsequences (bottom) for 
two of eight tested monoclonal antibodies. P53Ab1 (RHSVV) and FLAG (DYDDDK) 
each had on-target motifs throughout the top peptides, and these were made clearer 
through subsequence analysis (shown in red).  
 
 37 
 
Figure 2.2: Monoclonal Antibody Motifs and their Corresponding Epitopes: (A): 
These five motifs were revealed after incubating monoclonal antibodies on the peptide 
microarrays and performing subsequence analysis on the resulting dataset. Sequence 
logos were created using the top 10 most highly ranked subsequences. Note the positional 
dependency of the sequences, showing anchor residues as well as regions of apparently 
low importance to antibody binding. The true epitopes were determined by the 
manufacturer, and inter-alignment is the expected value of pairwise gapless alignment 
scores (BLOSUM62 matrix) between any two significant subsequences pulled from the 
arrays. Fold change indicates the relative binding strength of the peptides making up the 
cartoon versus the median value for that peptide in the other monoclonals tested. 
Antibodies for which consensus motifs could not be found were A10 (EEDFRV), p53Ab8 
(SDLWKL) and 2C11 (NAHYYVFFEEQE). Additional information about these 
antibodies and their immunogens can be found in Table 1. (B): Histograms of each 
monoclonal antibody tested, where the x-axis is log normalized signal intensity. 
Antibodies varied in their binding profile, with some such as HA, 4C1 and FLAG 
showing a narrow distribution around low intensities, while others bound many peptides. 
See Table 2 for an analysis of on target versus off target binding. 
mAb Name p53Ab1 HA 4C1 FLAG DM1A
Motif Cartoon
True epitope RHSVV YDVPD   FDSH DYDDDDK AALEKDY
Inter-alignment 23.6 17.4 26.7 16.7 15.9
N subseq. 100 419 678 184 67
Fold Change 13.7 ± 2.7 35.4 ± 3.8 25.9 ± 6.6 45.1 ± 20.55 4.7 ± 0.53
(A)
(B)
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The success rate in mapping linear epitopes on monoclonal antibodies was encouraging 
in that it implied the possibility of quickly mapping disease associated epitopes in patient 
sera. In order to test this hypothesis, we next performed similar experiments using sera 
from patients infected with various diseases. 
 
Figure 2.3: Sequence Representation and Predictive versus Nonpredictive 
Subsequences: (A) In order for the arrays to predict an epitope motif, two conditions 
must be met. First, the array must sufficiently bind a collection of true epitope or near 
epitope subsequences. Second, the bound sequences must be stronger than any cross 
reactions observed on the array. The sequences most related to the true epitope (Table 
2.3) are circled in red. The left figure shows the top 25 subsequences and fold changes for 
the HA monoclonal antibody. While small differences occur, the sequences share a 
consensus pattern. In contrast, p53Ab1 (right) showed clear binding to the true epitope 
but cross-reacted with other sequence clusters, preventing good prediction. This result 
may still be informative when assessing antibodies in a drug or affinity reagent pipeline 
when specific antibodies are needed. (B) The fraction of all possible k-mers present on 
the array as a function of k-mer length. The arrays represent 27% of all possible 5-mers 
in at least 3 different peptides. A higher coverage of sequence space should result in 
better epitope prediction and more comprehensive analysis of cross reactivity. 
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Groupwise Epitope Determination in Patient Sera 
Eight cohorts representing seven different diseases and one group of healthy 
volunteers, each consisting of between 7 and 15 individual samples, were tested using the 
\described methods. Several of the cohorts performed similarly to the monoclonal 
antibodies in that they identified a relatively small number of peptides with highly 
homogenous sequence motifs that were obvious by simple text matching. These cohorts 
produced a noticeably homogenous list of peptide sequences that deviated little from a 
single motif. The multiple alignments of the top 10 sequences for each of these disease 
cohorts are shown in Figure 2.4B. Of the seven disease cohorts tested, five of these 
revealed a consensus sequence. 
Consensus sequences in pathogen proteomes 
In order to test whether the groupwise consensus motifs (Figure 2.3) 
corresponded with true epitopes, we searched the immune epitope database 
(http://www.iedb.org) for exact substring matches to sequences from our lists. Despite the 
small size of this database, the sequence AVHAD from Dengue was present in the 
database and indicated as an epitope from the NS1 protein in two Dengue strains (E-
value: 5x10-4). Further analysis of the other cohorts revealed additional matches to 
antigenic proteins. The sequence EDAK from Borrelia mapped to known antigen OspF 
(E-value: 4.6), and DYAFG from Syphilis maps to a lipoprotein in several strains of 
Treponema pallidum (E-value: 0.27). Malaria contained sequences (SNKQG, RLKEP) 
which both mapped to the ring-infect erythrocyte surface antigen (RESA) protein in 
Plasmodium falciparum 3D7 (E-value: 0.072), and another sequence (DAFEY) mapping 
to one of the pfEMP1 variants in P. falciparum (E-value: 3.5). The sequence FKEG 
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mapped to an MDR efflux protein in Bordetella pertussis (E-value: 3.5). These results are 
summarized in Table 2.3.  
A 
Sequence Infection Organism Antigen Known Antigen 
AVHAD Dengue Dengue virus (1 - 4) NS1 
Yes (Y. Chen et al., 
2010) 
REGEK Dengue Dengue virus 4 
Serine protease 
NS3 Yes (Garcia G, 1997) 
DYAFG Syphilis Treponema pallidium Lipoprotein No  
EDAK 
Lyme's 
Disease Borrelia burgdorferii OspF 
Yes (Pasternak & 
Dzikowski, 2009) 
FKEG Pertussis Bordetella pertussis 
Multidrug 
Resistance 
Protein No 
SNKQG/RLKEP Malaria Plasmodium falciparum RESA-like protein 
Yes (Anders, 1986; 
Gardner et al., 2002) 
DAFEY Malaria Plasmodium falciparum pfEMP1 
Yes (B. Wagner et 
al., 2012) 
 
 
B 
Sequence In IEDB 
Membrane 
Protein E Value P Value 
AVHAD Yes N/A 5.00E-04 0.0004 
REGEK Yes N/A 8.30E-04 0.0007 
DYAFG No Yes 0.027 0.026 
EDAK No Yes 4.6 0.98 
FKEG No Yes 3.5 0.96 
SNKQG/RLKEP No Yes 7.20E-02 0.067 
DAFEY No Yes 3.5 0.96 
 
Table 2.3: Proposed Epitope Mappings for Disease Cohorts: Table of discovered 
epitope sequences and their proposed antigen mappings. The two dengue epitopes were 
previously verified using peptide tiling of the NS1 and NS3 proteins against Dengue sera. 
A further two (EDAK, DAFEY) map to well known and characterized antigens in 
Borrelia burgdorferii and Plasmodium falciparum respectively. The rest showed 
characteristics on the array consistent with epitopes, but map to proteins only discovered 
in high throughput experiments (hypothetical). E value refers to the expected number of 
matches to the presumed epitope sequence(s) within the proteome of interest, and the 
corresponding P Value refers to the chance of encountering at least one instance of the 
sequence within the proteome of interest. Not all proposed epitopes mapped to the 
proteome with significant P-values, but they are reported here as a “best guess” to explain 
the high response to these sequences on the arrays. 
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These sequences are short due to platform limitations, and the E-values for these 
matches varied based on the size of the proteome. The Dengue sequences are unlikely to 
arise by chance, with E-values of less than 10-3. Likewise, the two matches to the RESA 
protein in P. falciparum together had a low E-value of 0.072 corresponding to a p-value 
of 0.067. These sequences were remarkably specific to a disease, and could possibly be 
used as a diagnostic (Table 2.4) or as leads for vaccines. 
 
Sequence Infection Sensitivity Specificity 
AVHAD Dengue 1 1 
REGEK Dengue N/A N/A 
DYAFG Syphilis 1 1 
EDAK 
Lyme's 
Disease 0.125 1 
FKEG Pertussis 0.83 1 
SNKQG, 
RLKEP Malaria 0.69 1 
DAFEY Malaria 0.46 1 
 
Table 2.4: Sensitivity and Specificity of Epitope Candidates: Table of sensitivity and 
specificity calculations for the top epitope candidates from Table 2.3. The selection 
algorithm picks sequences such that sensitivity values are maximized, and may not be a 
reliable estimate of performance . Still, they do seem to map to antigenic proteins, and are 
remarkably specific to the cohort of interest. A blinded dataset is needed to achieve more 
reliable sensitivity and specificity values. Estimates for the REGEK sequence from 
Dengue could not be computed, as this was discovered using a separate set of arrays on 
which few samples were run. 
 
Individual Epitope Determination in Patient Sera 
In order to test the heterogeneity within disease groups, we asked which 
subsequences were differentially bound between an individual in a disease cohort versus 
normal. We found that epitope sequences revealed in the groupwise analysis were present 
 42 
in most of the individuals from that group. All nine Dengue samples contained AVHAD 
as a significant subsequence. To visualize the extent of this overlap, we calculated the 
pairwise overlap of significant subsequences between individuals across disease groups 
(Figure 2.4B). This showed that individuals within the same group had a high degree of 
commonality with respect to the sequences seen by their immune system. These 
sequences were unlikely to appear in individuals from different disease groups, indicating 
these could be highly specific biomarkers for presence of a pathogen. The sequences with 
a high degree of overlap between individuals tended to have a very high fold change 
versus normal sera, while those with low overlap had lower fold changes.  
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Figure 2.4: Top Significant Subsequences for Disease Cohorts: (A) Shows the top 10 
most commonly appearing significant subsequences showing up in serum samples from 
the indicated disease cohorts. The number of patients within that cohort for which that 
sequence was called as significant is shown in parentheses on the left. The total number 
of samples in each cohort is given as a fraction next to the top significant subsequence 
and also on the figure legend to the right. Subsequences with exact matches to proteins 
within the pathogen are indicated with red bars (top sequences are listed in Table 2.3). 
Control data points show binding to the same collection of subsequences by the other 
tested cohorts. (B) Shows the pairwise fractional overlap in significant subsequences. A 
colored, saturated cell represents a pair of patients in the same cohort that shared at least 
50% of their significant subsequences. Grayscale cells represent pairs of patients from 
different cohorts whose immune systems see similar sequences. Individuals within the 
same disease cohort show a much higher overlap between their significant subsequences 
than those in different cohorts or the normal cohort, indicating an association between the 
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discovered sequences and the disease state. BPE stands for Bordetella pertussis and HNP 
stands for Human Normal Pools, which consisted of pools of normal serum. 
 
Additional Library Complexity Reveals Additional Epitopes 
This assay relies on many simultaneous measurements of antibody/peptide 
interactions. It is useful to know how changes in library content affect results. Since only 
27% of pentamers were represented on the original arrays, we hypothesized that a 
different random library would result in additional targets that were invisible to the 
original experiments due to not being present on the arrays. To test this, we created 
another array with a different set of 330,000 sequences. We then attempted to find 
epitopes using a dengue infected serum sample. This analysis revealed an additional 
epitope (REGEK, Dengue 4, E-value: 8.3𝑥10−4) which was previously mapped in the 
IEDB and not present on the original array (Figure 2.5). This result shows that larger 
arrays could find additional antibodies that are already present in patient sera whose 
epitopes are not represented in smaller libraries. This argues for larger array libraries that 
would capture more sequences, revealing additional epitopes and giving a higher 
resolution picture of the immune response. 
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Figure 2.5: Motifs found in Single Patients -- These motifs were associated with single 
patients within a disease cohort. (Left) was found in a Dengue patient and maps to NS3 
(Garcia, 1997). It is a previously mapped epitope and observable on the peptide arrays. 
(Right) was present in a Borrelia patient and maps to the OspF protein, known to be 
associated with an immune response in dogs (Wagner et al., 2012).  FC stands for fold 
change between the individual serum sample and a cohort of normal samples, and n 
refers to the number of peptides associated with that subsequences. 
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Mapping Epitope Information to a Database 
We set out with the goal of being able to find epitopes in patient sera from 
unknown origin, and using that sequence information to identify the antibody eliciting 
proteins from a database. Having demonstrated that peptide microarrays are capable of 
resolving epitopes, we wanted to know if these sequences could predict the eliciting 
protein from a database of pathogen protein sequences.  
Resolving a pathogen in a database given a few short sequences depends both on 
the size of the database and the length of the consensus motif. Using pairs of randomly 
generated sequences of varying lengths, we predict that a pair of pentamers if known 
exactly, or a pair of heptamers if known within 80% identity, are sufficient for resolving 
a pathogen in the Pathogen Proteome Database (Figure 2.6).  
 
  
 48 
 
 
Figure 2.6: Finding Arbitrary Sequences in a Pathogen Database: These plots show 
the distribution of hits to pairs of arbitrary sequences of fixed lengths. Pairs of k-mers 
with specified lengths were drawn at random from the distribution associated with array 
sequences. These were searched against two databases: One containing over 4000 
bacteria and viruses, and another containing 596 human pathogen strains. These plots 
show that when two 7-mer linear epitopes from the same protein antigen are known 
within 80% identity, unique pathogen identification should be possible. 
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Deciphering Eliciting Pathogen Proteins 
To improve sensitivity, we opted for a restrictive search, relying on exact or near 
exact (80%) identity and matches in the same protein to multiple pentamer queries. Using 
significant subsequences from Malaria subjects, three epitope candidates were revealed 
(SNKQG, RLKEP, SNKQG). Searching these candidates against the Pathogen Proteome 
Database (multiple strains of each pathogen) resulted in uniquely identified membrane 
proteins from P. falciparum matching all three query sequences with 80% identity 
(Figure 2.7). Two of the query sequences matched with 100% identity to a RESA-like 
protein, a known antigen in Plasmodium infections. The probability of two randomly 
drawn pentamers matching to one or more proteins globally in this database of over 1 
million sequences is<0.01. 
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Figure 2.7: Using Significant Subsequences to Identify an Eliciting Pathogen: 
Sample specific significant subsequences from the Malaria cohort were combined, 
aligned and hierarchically clustered by single linkage. This revealed three distinct epitope 
candidates, indicated with red stars. These three sequences were queried against a 
database of 596 human pathogens for exact and 80% identity. Only one protein from P. 
falciparum out of all human pathogens contained both RLKEP and SNKQG. The 
probability of two array 5-mers hitting the same protein by chance is <0.001 
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Discussion: 
 First we asked whether random sequence arrays could resolve epitope sequences 
for well characterized monoclonal antibodies. We chose eight different monoclonal with 
well characterized reactivity to linear epitopes (Table 2.1). The epitopes of 5 of 8 
monoclonal antibodies were readily resolved. After verifying our method with 
monoclonals antibodies, we applied the technique to serum from cohorts infected with 
different human diseases. These samples were chosen to evaluate our ability to detect 
eptiopes across a broad range of pathogens. Two normal cohorts, one consisting of 
human normal samples and another consisting of pooled normal samples, were also 
included as controls. Epitopes consist with response to infection by Dengue, Malaria and 
possibly 3 other pathogens were identified. Finally, we compiled a list of human 
pathogen proteomes in order to test whether our discovered sequences were present in 
proteins from the pathogen of interest and whether pathogen identification in an 
uncharacterized serum sample is feasible. 
The monoclonal experiments were designed to test whether 330,000 random-
sequence peptides could correctly find a linear epitope. Peptide arrays are unique in that 
they provide binding information and also non-binding information, giving an overall 
picture of antibody specificity. Five monoclonals (HA, DM1A, 4C1, Ab1 and FLAG) 
bound only peptides that were related to their target. P53Ab1 essentially bound a single 
sequence RHSVV, did not tolerate substitutions, and did not cross react with additional 
peptides. HA, 4C1, FLAG, and DM1A tended to allow substitutions in certain positions 
to varying degrees dependent on the sample. P53Ab8 bound sequences similar to the 
epitope, but these were overshadowed by sequence dissimilar distracter sequences 
 52 
(Figure 2.3A). Two antibodies (A10, 2C11) seemed to only bind sequence dissimilar 
peptides. These differences in apparent binding may reflect true variation in antibody 
cross reactivity characteristics, or could be a side-effect of choosing peptides randomly. 
Further studies with additional antibodies are needed to determine the extent to which the 
arrays can predict antibody specificity. Given the importance of monoclonal antibodies in 
the therapeutic pipeline (Leavy, 2010; Reichert & Valge-Archer, 2007), a quick way to 
screen out undesirable cross reactions on a simple, high throughput platform is desirable. 
In agreement with previous studies using dense peptide arrays (Edfors et al., 
2014; Forsström et al., 2014), the antibodies bound a variety of sequences, many of 
which had little or no relationship with the true epitope. This was the impetus for the 
subsequence approach, which was successful in filtering out these non-specific sequences 
in the five monoclonal antibodies (Figure 2.1) and made obvious the most significant 
binding motifs.  
These motifs, despite being pentamer sequences with only three to five amino 
acids in common with the eliciting peptide, bound very strongly to their targets, often 
over twenty fold above background (Figure 2.2). This strong, specific binding suggests 
that epitopes only require a limited number of binding residues, a phenomenon also 
observed in previous studies (Buus et al., 2012a; Sivalingam & Shepherd, 2012). There is 
likely an evolutionary optimization between simplicity (low number of binding residues) 
and specificity (the need to recognize a unique target). Given that the size of sequence 
space increases exponentially with the number of residues, an antibody does not require 
many residues to maintain global specificity to a target. 
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 Previously, we attempted epitope mapping on smaller arrays with 10,000 
peptides, with modest success for monoclonal antibodies but no predictive power in the 
case of patient sera (Halperin et al., 2011). These data show that this was most likely due 
to a sparse representation of peptide sequences, with only 0.5% of pentamers represented 
in triplicate. The arrays used in this study provided a much denser sampling of this space, 
with 27% of pentamers represented. This improved sampling corresponded to an 
improvement in resolving epitopes in patient sera. 
Dengue samples in particular seemed to react strongly to a particular epitope on 
the NS1 protein, shared by many strains of the virus. Because this is shared between 
strains, this antibody is likely non-protective, and serves to distract the immune system. 
This explains why this was seen in all patients tested when they were likely infected with 
different strains of the virus. 
 Malaria was an interesting cohort because multiple sequences (SNKQG, RLKEP) 
mapped to the Ring Erythrocyte Surface Antigen (RESA) protein in P. falciparum. This 
protein is associated with the membrane of newly invaded erythrocytes (Brown et al., 
1985; Foley, Tilley, Sawyer, & Anders, 1991), is an important virulence factor that 
facilitates erythrocyte attachment to blood vessel epithelium, and presents a tempting 
target for the immune system. The P. falciparum proteome is so large that it would be 
almost impossible to map the eliciting protein from a single pentamer, but in this case 
two peptides mapped to the RESA protein, improving the likelihood of a true match. A 
further sequence (DAFEY) was found in six samples and mapped to a PfEMP1 protein, 
which is one of a family of variant antigens associated with infected erythrocytes and 
thought to be important mechanisms for immune system distraction and evasion (Su et 
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al., 1995). Expression of these proteins is constantly being switched in order to evade the 
host immune response, and it is likely more antibodies against this family would be found 
in a larger study. 
 The Syphilis and Bordetella cohorts also showed consensus sequences which 
mapped to proteins, but the annotations on these are less comprehensive, and it is 
unknown if they are antigenic. They do appear to be surface associated proteins, but they 
are hypothetical and direct studies about their expression or function have not been 
reported in the literature. 
 While many individuals within a cohort shared (possibly non-protective) epitopes, 
heterogeneous responses were also observed. Two Borrelia samples bound the consensus 
sequence EDAK. While this is too short to call conclusively, it maps precisely to the 
OspF protein found in several strains of the bacterium. This is a proven antigen(B. 
Wagner et al., 2012), and the subsequence is found in a region between two trans-
membrane sections of the protein, thus it is a feasible location for an epitope. In some 
cases while the assignment may not be definitive, it may allow a reduction to likely 
candidates.  
The presence of homogenous epitopes within cohorts is promising, as these arrays 
were originally developed to monitor serum and predict the presence of the disease as 
part of a diagnostic platform. Previously we had shown that this assay is capable of 
capturing a “signature” of the immune system, aiding in the diagnosis of disease (Hughes 
et al., 2012; Kukreja et al., 2012; Legutki et al., 2010; Restrepo et al., 2012; Restrepo et 
al., 2011b; Sykes et al., 2013). While machine learning algorithms can accurately classify 
serum samples into the correct disease category, until now we have not shown that these 
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signatures contain epitope sequences. The serum samples revealed patterns consistent 
with those seen in the predictive monoclonal samples, and appear to map to antigenic 
proteins from the pathogen (Table 2.3). In the case of the two dengue epitopes, validation 
that these sequences are indeed antibody targets has previously been done by other 
groups (Y. Chen et al., 2010; Garcia, 1997), but this has not been completed for the other 
sequences, and for now they should be considered putative candidates. 
As previously mentioned, the arrays contain around 27% of possible pentamers in 
triplicate. Given this modest representation, one would predict approximately a one in 
four success rate when mapping epitopes. However, in both the monoclonal and serum 
samples, success rates were much higher with discernable epitopes revealed in over half 
of tested samples/cohorts. One likely explanation is that infected sera contain multiple 
antibodies each with unique specificities, and only a subset was “visible”. We saw some 
evidence of this when we repeated the assay in Dengue on a new array, which revealed 
an additional validated epitope in previously unrepresented space. 
Identifying eliciting proteins using sequence information gleaned from the arrays 
with the current 330K peptides per array is challenging. These arrays contain a relatively 
limited amount of sequence information compared to what is available in genome or 
transcriptome annotation studies. A typical BLAST search of a pentamer against a 
database of human pathogens is likely to be dominated by spurious and insignificant 
results. The arrays tend to reveal only consensus motifs that are present on the array, and 
not exact sequences. Second, the array only provides ample coverage of sequence space 
up to five amino acids, limiting the lengths of epitopes that can be reasonably discovered. 
Even given these limitations we have demonstrated that it is possible to identify likely 
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antigenic proteins using combinatorial random sequence peptide arrays. Interestingly, 
epitope candidate pentamers gleaned from the arrays were much more likely to match 
pathogenic protein sequences than randomly drawn array pentamers (data not shown). 
This indicates that epitopes are actually much less diverse than random or even life-space 
sequences, supporting the idea that antigen space is intrinsically convergent (Campo et 
al., 2012). It is also fairly straightforward to increase the number of peptides many fold.  
The techniques underlying this technology are highly amenable to high-
throughput manufacturing. Given that we identified different epitopes by using two 
different libraries, is likely larger arrays would achieve the sensitivity required for apriori 
pathogen identification. The approach seems promising in that true epitopes were 
revealed along with several previously undiscovered linear sequence segments in 
antigenic proteins. Such an approach could help identify antigenic hot spots within 
proteins and immunodominant epitopes with high resolution using an assay that is 
significantly cheaper in time and labor than display techniques, facilitating high 
throughput screening of serum and monoclonal antibodies. 
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CHAPTER 3 
IMMUNOSIGNATURES FOR DENGUE DIAGNOSTICS 
 
This chapter contains significant contributions from Xiao Wang, who designed 
the original study and collected most of the array data (CIM10K). My contribution was to 
design the classification methodology using best practice machine learning principals and 
make it available for others to use. I evaluated Xiao’s raw data using this methodology 
and wrote the results including figures. I also included additional data from new, larger 
arrays (CIM330K), using this to identify Dengue epitopes and evaluate the WHO subtype 
samples. 
Abstract 
Dengue Fever and Dengue Hemorrhagic Fever represent emerging infections 
affecting many nations throughout the world. Though accurate diagnostics are essential 
for epidemiological studies and tracking, existing FDA approved methods are hampered 
by dengue antigen cross reactivity in sera from individuals with other infections. In order 
to overcome this problem, we tested the ability of an antibody profiling technology based 
on non-natural sequence peptide microarrays called immunosignatures to distinguish 
primary and secondary Dengue infection from infections of Malaria , West Nile Virus 
and from non-infected people using sera. Classification using support vector machines 
and a rigorous cross-validation scheme resulted in good metrics for distinguishing 
between Dengue and other diseases (AUROC: ~0.92, sensitivity: ~0.96, specificity: 
~0.76), and also perfect classification of a small number of primary versus secondary 
infections. Further analysis revealed cohort specific amino acid biases and consensus 
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sequences to known and unknown Dengue epitopes. Immunosignature microarrays may 
be a promising technique for Dengue diagnostics and epitope mapping. 
Introduction  
Dengue fever (DF) and Dengue hemorrhagic fever (DHF) are emerging infections 
in over one hundred tropical and subtropical nations around the world. It is estimated that 
there are ~400M infections per year (Murray, Quam, & Wilder-Smith, 2013). Accurate 
and prompt diagnostics are important for epidemiological tracking and evaluation of 
Dengue epidemics. Since secondary infection is a risk factor for DHF (Kliks, Nisalak, 
Brandt, Wahl, & Burke, 1989; Rigau-Pérez et al., 1998), diagnostics that can separate 
primary from secondary infection are of principal importance. Over the past several 
years, several IgM and IgG ELISA-based assays have been developed with useful 
sensitivity and specificity for both predicting infection and differentiating primary versus 
secondary infection (Guzmán & Kourı,́ 2004). Despite these promising advances, these 
ELISA-based diagnostics for Dengue often show cross reactivity to other flaviviruses, 
such as West Nile Virus (WNV), Japanese Encephalitis Virus (JEV) and Yellow Fever 
Virus (YFV)  (Banoo et al., 2008; Hunsperger et al., 2009; Schwartz, Mileguir, 
Grossman, & Mendelson, 2000), and possibly even Malaria antigens (Hunsperger et al., 
2009). In order to overcome these deficiencies, we tested a peptide microarray consisting 
of over 10,000 peptides chosen from random sequence space as a platform for 
specifically differentiating dengue from other related disease and uninfected subjects.  
 Peptide microarrays have proved useful for measuring changes in the humoral 
immune system. These multiplexed assays, known as immunosignatures (Sykes et al., 
2013), measure antibody binding to thousands of peptide sequences in a single assay, and 
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have been employed for predicting vaccine efficacy (Legutki et al., 2010), distinguishing 
between related pancreatic diseases (Kukreja et al., 2012), mapping monoclonal epitopes 
(Halperin et al., 2011), and mapping epitopes from infectious disease sera (manuscript 
submitted). Unlike most assays which measure a single biomarker target, 
immunosignatures seek to capture the unbiased signature of the humoral immune system 
and to associate this pattern with a disease using well understood machine learning 
algorithms. It is a single method for multiple diagnostics, and as such may not be as 
susceptible to cross reactivity as ELISA-based assays or assays using natural peptide 
sequences (manuscript submitted). 
Methods 
Serum Sources 
 Samples tested here include Dengue (Seracare PVD-201), Malaria (Seracare DS-
774) and West Nile Virus (Seracare, various) as well as Non-Infected samples collected 
from laboratory volunteers and randomly chosen for testing. See Table 3.1 for details. 
 
Disease Sample Min Max Range Mean 
Country 
of 
Collection 
Dengue 201-01 220 65535 65315 1540.0 Colombia 
Dengue 201-02 202 65535 65333 2383.1 Honduras 
Dengue 201-03 254.5 53863.5 53609 2572.1 Honduras 
Dengue 201-04 175.5 56359 56183.5 1445.8 Honduras 
Dengue 201-05 201 56124 55923 1469.3 Honduras 
Dengue 201-06 212 65535 65323 1589.2 Honduras 
Dengue 201-07 330 62266.5 61936.5 2084.5 Colombia 
Dengue 201-08 275 65535 65260 3367.4 Honduras 
Dengue 201-09 239 65535 65296 2242.8 Honduras 
Dengue 201-10 218 65535 65317 3181.6 Ecuador 
Dengue 201-11 225 65535 65310 1604.8 Honduras 
Dengue 201-12 213.5 65535 65321.5 1435.3 Honduras 
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Dengue 201-13 180.5 65535 65354.5 1147.4 Honduras 
Dengue 201-14 227.5 61502 61274.5 1432.9 
United 
States 
Dengue 201-15 194 65254.5 65060.5 1428.5 Honduras 
Dengue 201-16 190 65535 65345 2408.6 Ecuador 
Dengue 201-17 191 62409.5 62218.5 1196.8 Colombia 
Dengue 201-18 257.5 65535 65277.5 1856.5 Honduras 
Dengue 201-19 212 64339.5 64127.5 1913.0 Ecuador 
Dengue 201-20 183.5 65535 65351.5 3085.2 Ecuador 
Dengue 201-21 214.5 65535 65320.5 1527.9 Ecuador 
Malaria HP-10 160.5 63018.5 62858 4408.8 Honduras 
Malaria HP-11 440.5 63008.5 62568 10119.7 Honduras 
Malaria HP-17 93.5 14290 14196.5 775.6 Honduras 
Malaria HP-7 155 49734 49579 3490.1 Honduras 
Malaria HP-8 162.5 41997 41834.5 2876.2 Honduras 
Malaria HP-9 165.5 42974.5 42809 3300.7 Honduras 
Malaria MA-34 257.5 65535 65277.5 2492.0 Honduras 
ND ND-134 204 65535 65331 1478.5 US 
ND ND-149 283.5 65535 65251.5 2648.6 US 
ND ND-153 211.5 61388 61176.5 2060.6 US 
ND ND-154 209.5 65535 65325.5 1533.6 US 
ND ND-155 251.5 65535 65283.5 1939.2 US 
ND ND-157 185 48285.5 48100.5 1286.0 US 
ND ND-158 322.5 60912.5 60590 2006.4 US 
ND ND-159 289 60124 59835 1896.5 US 
WNV WNV-2 203 41665 41462 1956.3 Unknown 
WNV WNV-3 190 65535 65345 1589.8 Unknown 
WNV WNV-1 275 65535 65260 2115.7 Unknown 
WNV WNV-4 200 45378 45178 1736.1 Unknown 
WNV 
WNV-
9147710 299 62588 62289 2225.8 Unknown 
WNV 
BMI-
140433 287 65535 65248 3458.0 Unknown 
WNV 
BMI-
141170 222 65535 65313 1623.2 Unknown 
WNV 
BMI-
145662 235.5 65535 65299.5 2776.6 Unknown 
 
Table 3.1: Descriptive Statistics for Each Sample: Twenty one Dengue samples, seven 
Malaria samples, eight Non-Infected samples, and eight West Nile samples were run on 
the array. Dengue, Malaria and West Nile samples were collected from Colombia, 
Ecuador, United States and Honduras while Non-Infected samples are non-endemic and 
collected from volunteers at Arizona State University. WNV stands for West Nile Virus 
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and ND stands for Non-Infected Donor. The metrics show the minimum, maximum and 
dynamic range of measurements collected for the IgG based assay. 
 
Array Sources 
 CIM10K arrays consists of 10,000 peptides (Sigma-Aldrich, St. Louis, MO) 
printed on a glass slide. These arrays contain a fixed number of peptides, generated to 
cover as much as possible the space of linear peptide sequences, thus maximizing the 
chances of representing an arbitrary linear epitope. For epitope determination studies a 
new array produced by Healthtell, Inc (Chandler, AZ) (HT330K) containing over 
330,000 features was used. HT330 peptides average 12 amino acids in length.   
Primary v Secondary Infection Determination 
 Dengue samples were determined either as primary or secondary infections based 
on the results of the Panbio ELISA IgG/IgM Duo Assay and were all from Ecuador 
where the virus has been endemic since the 1980s (San Martín et al., 2010). 
Assay Conditions 
The assay conditions for the CIM10K arrays have been described in (Legutki et al., 
2010) and for the HT330K arrays in (Legutki et al., 2014). Briefly, the process for the 
CIM10k is:  
a. Slides are first washed in a pre-wash solution (7.73% acetonitrile, 33% 
isopropanol, 0.55% TFA), then thrice washed in 1xTBST followed by three 
washes in ddH20, then dried by centrifuge.  
b. Incubation is handled using the Tecan Automated Slide Processing System. Slides 
are blocked for 1 hr in blocking solution (30% BSA, 6.9 uL mercaptohexanol, 
25uL Tween 20 in 50mL PBS). Slides are then treated with 1:500 sera diluted in 
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blocking buffer (30% BSA, 25uL Tween 20, 50mL PBS) for 1 hr, followed by 
5nM goat anti-human IgG in blocking buffer for 1hr, followed by 5nM 
Alexaflour647 conjugated streptavidin for 1hr.  
c. Slides are scanned using an Innoscan 910 Microarray Scanner (Innopsys; 
Carbonne, France) at appropriate wavelengths matching emission of the tertiary 
dye.  
For the HT330 array the process is:  
a. Prior to assay, arrays are washed in 100% DMF for one hour, then introduced to 
PBST incubation buffer (3% BSA in Phosphate Buffered Saline, 0.05% Tween 
20) over a period of six hours to allow the solvent phase to be completely 
transitioned to aqueous phase. The arrays are then processed by incubating in the 
presence of antibodies or serum and detected by fluorescent antibody. 
b. Residual DMF is removed by two 5 min washes in distilled water.  Arrays are 
equilibrated in PBS for 30 min and blocked in incubation buffer (3% BSA in 
Phosphate Buffered Saline, 0.05% Tween 20 (PBST).  Arrays are washed and 
briefly spun dry prior to loading into the multi-well gasket (Array-It, Santa Clara, 
CA).  Incubation buffer is added to each well (100ul) and 100 ul of 1:2500 diluted 
sera is added for a final concentration of 1:5000.  Arrays are incubated for 1hr x 
RT with rocking then washed with PBST and 1% BSA in PBST using a BioTek 
405TS plate washer.   
c. Anti-human IgG-DyLight 549 (KPL, Gaithersburg, MD) is added to a final 
concentration of 5.0 nM.  Following 1hr x RT with rocking, unbound secondary is 
removed by washing in PBST followed by washing in distilled water.  The arrays 
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were removed from the gasket while submerged, dunked in isopropanol and 
centrifuged dry (800xG, 5 min). Arrays are scanned at 533nm using an Innoscan 
910 array scanner (Innopsys, Carbonne, France). Features were aligned and 
extracted using GenePix Pro 6.0 (Molecular Devices, Sunnyvale, CA). 
Alignment, Data Extraction and Normalization 
Slides were aligned and data extracted using GenePix Pro 6.0, and slides with >80% 
correlation between replicates were chosen for analysis. Slides with poor correlation were 
assayed again. Per-slide fluorescence intensities were normalized to the 50th percentile in 
order to remove variation caused by small differences in dye concentration or PMT and 
laser variation.  
Cross Validation 
All classification results reported here were “leave one from each class out” cross 
validated. One instance for each class was randomly selected and set aside for model 
testing. The rest were used for feature selection and model training. This process was 
repeated iteratively until the class membership of each instance has been predicted at 
least once. 
In order to rule out over-fitting as a driver of classification results, this same 
procedure was repeated with randomly shuffled class labels. This means that for each 
column in the array matrix, the true class label was removed and replaced with a 
randomly chosen class label. Proportions for each class were kept the same as those from 
the true labels. 
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Feature Selection 
Selecting peptides relevant to a particular disease of interest is of principal 
importance for immunosignatures. T Tests between relevant groups (Dengue v Non-
Infected, Primary v Secondary, Dengue v Non-Infected, Malaria, WNV) are used to 
select peptides that are significantly different between groups (p values typically were 
10-6 or less for significant peptides). P values were Benjamini and Hochberg FDR 
corrected to account for multiple hypotheses. All significant features were used for 
classification.  
SVM Classification 
 The SKLearn package (Python 2.7) was used to train and test linear kernel SVM 
models.  Randomized cross validation was employed where the dataset is repeatedly 
split into training and test sets at random such that the test set contains one sample 
from each cohort (leave one from each class out). Then, peptides are selected and an 
SVM model is trained using only data from the training set. The model then predicts 
the test set, producing sensitivity and specificity estimates. To produce a negative 
control on this procedure, the same steps were repeated on a dataset with the class 
labels (DENGUE, NON-INFECTED, etc) randomly shuffled.  The procedure for both 
the true and shuffled labels was repeated 100 times, and the mean specificity and 
sensitivity values were used as the classification result. The program used for 
classification can be downloaded at https://github.com/joshuaar/CIM-
Scripts/blob/master/classif2.py. Confidence intervals were estimated using a 
bootstrapping procedure with the mean calculated from 10,000 bootstrap samples 
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from the cross validation results. The 5th and 95th quantiles from this calculation 
samples are reported as the confidence interval. 
Sequence Enrichment for Epitope Determination 
Enriched subsequences from the signatures within the highest binding peptides 
were found and used to identify conserved motifs. The top 500 peptides by normalized 
fold change between a dengue sample and the non-infected cohort were searched for 
enriched subsequences (k-mers) of length five or greater. Enrichment probabilities were 
approximated with the binomial distribution. All enrichments with P < 0.005 were 
selected and used to produce motif cartoons with WebLogo(Crooks, Hon, Chandonia, & 
Brenner, 2004). Code for calculating enrichments can be downloaded at 
https://github.com/joshuaar/CIM-Scripts/blob/master/CalcEnrichments.py. 
Results 
Dengue infected versus non-infected sera (IgG) 
 The first and most basic question was whether IgG based immunosignatures can 
distinguish Dengue positive sera from non-infected sera.. Twenty one Dengue serum 
samples collected from Colombia, Honduras, Ecuador and the United States were 
compared to eight non-infected samples collected from the United States. The 
classification procedure was applied to these data, and Figure 3.1 shows the cross-
validated results for this test. Overall accuracy of ~0.90 (CI: 0.87, 0.94) was achieved 
using this method, with approximately 0.83 specificity (CI: 0.77, 0.89) and 0.98 
sensitivity (CI: 0.93, 0.99). The same procedure applied to the same data with randomly 
shuffled labels resulted in classification no better than random, with an overall accuracy 
of ~57% in balanced test sets, indicating our method is not over fitting the data. 
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Dengue vs. non-infected sera (IgM) 
 IgG is a specific biomarker for Dengue, but often titers are low in primary 
infections and IgG is seldom used in existing diagnostic techniques. We tested an IgM 
based immunosignature for classification accuracy between dengue and non-infected 
sera. Accuracy was slightly higher in this test, averaging 0.95 (0.94 specificity, 0.96 
sensitivity). Shuffled labels yielded an accuracy of ~55%, indicating over-fitting is 
unlikely. These results are summarized in Figure 3.1. It is interesting to note that the 
peptides used for IgM classification are different from those used in IgG classification 
(P=0.79). 
3.1A 
True Labels Randomly Shuffled Labels 
 
 
Dengue vs. Non-Infected (IgG) Specificity Sensitivity Accuracy 
True Labels 
0.83 (CI: 0.77, 
0.89) 
0.98 (CI: 0.95, 
1.0) 
0.905 (CI: 
0.87, 0.94) 
Randomly Shuffled Labels 
0.13 (CI: 0.09, 
0.17) 
0.79 (CI: 0.75, 
0.82) 
0.57 (CI: 
0.54, 0.59) 
 
Dengue vs. Non-Infected (IgM) Specificity Sensitivity Accuracy 
True Labels 
0.94 (CI: 0.90, 
0.98) 
0.96 (CI: 0.93, 
0.99) 
0.95 (CI: 
0.93, 0.98) 
Randomly Shuffled Labels 
0.15 (CI: 0.09, 
0.21) 
0.96 (CI: 0.92, 
0.99) 
0.55 (CI: 
0.53, 0.59) 
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3.1B 
 
 
Figure 3.1: Dengue vs. Non-infected Classification Results – (3.1A) Top shows ROC 
curves for the binary classification scheme (Dengue vs. non-infected). Average and 
standard deviations of sensitivity, specificity and accuracy are reported from leave one 
from each class out cross validation. Shuffled labels refer to the fact Dengue and Non-
Infected labels were shuffled randomly such that the data no longer represent true class 
memberships. This is a way to rule out model over fitting as a driver of classification 
results. (3.1B) Overlap between peptides selected for the IgG based assay and those 
selected for the IgM based assay (FDR Corrected P < 0.05). Under the hypergeometric 
distribution, the overlap is not significant (P=0.79) indicating that IgM and IgG assays 
use distinct sets of peptides. 
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Dengue Versus Non-Infected, WNV, Malaria (IgG) 
Encouraged by the single class performance of the assay, additional cohorts of 
West Nile Virus and Malaria infected sera were added and classified using the same 
procedure.  Overall accuracy fell from 0.90 to 0.79 (CI: 0.75, 0.82), but was still well 
above the uninformative accuracy of 0.25. For Dengue, sensitivity in this test was 0.96 
(CI: 0.93, 0.99) and specificity was 0.76 (CI: 0.73, 0.80). Shuffled labels only resulted in 
an accuracy of 0.23, which is in line with the expected value for random data. 
 ROC curves and sensitivity/specificity estimates for each class are shown in 
Figure 3.2. These are substantially better than what could be expected by random chance 
and as in the binary classification result, the cross validation procedure appears rigorous 
as it cannot classify randomized labels better than random chance. Details on selected 
peptides are given in Table 3.2.  
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True Labels Randomly Shuffled Labels 
 
 
Disease Specificity Sensitivity 
 
Disease Specificity Sensitivity 
WNV 
0.99 (CI: 
0.98, 0.99) 
0.47 (CI: 
0.39, 0.55) 
 
WNV 
0.92 (CI: 
0.89, 0.95) 
0.03 (CI: 0.01, 
0.06) 
ND 
0.97 (CI: 
0.95, 0.98) 
0.8 (CI: 0.73, 
0.86) 
 
ND 
0.90 (CI: 
0.88, 0.93) 
0.08 (CI: 0.04, 
0.13) 
Mal 
0.98 (CI: 
0.97, 0.99) 
0.91 (CI: 
0.86, 0.95) 
 
Mal 
0.92 (CI: 
0.89, 0.95) 
0.08 (CI: 0.04, 
0.13) 
Den 
0.76 (CI: 
0.73, 0.80) 
0.96 (CI: 
0.93, 0.99) 
 
Den 
0.23 (CI: 
0.19, 0.27) 
0.76 (CI: 0.69, 
0.83) 
Overall Accuracy: 0.79 (CI: 0.75, 0.82) Overall Accuracy: 0.23 (CI: 0.21, 0.26) 
   Figure 3.2: Multidisease SVM ROC curve for real labels and shuffled labels:  
(3.2A) A multiclass SVM was trained and tested with four classes: West Nile Virus 
(WNV), non-infected Non-Infected Donor (ND), Malaria (Mal), and Dengue (Den). The 
left side ROC indicates real labels and predicts performance of the model on new 
samples. The right side is the SVM tested on randomly shuffled class labels, and should 
be unpredictive. These curves show there is a real difference between random labels and 
true labels, indicating the model is not over-fitted.  
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Significant Peptides for Each Class P<0.05 
Disease Uncorrected FDR Bonferroni 
Dengue 4269 ± 400 1024 ± 723 134 ± 150 
Malaria 4869 ± 140 1253 ± 181 237 ± 56 
WNV 1279 ± 160 6 ± 14 5 ± 7 
Non-
Infected 1384 ± 280 1 ± 1 3 ± 2 
 
Table 3.2: Number of Peptides Selected Using Different Multiple Testing Correction 
Procedures: Data was split into training and test sets such that one instance from each 
class was placed in the test set. Features were selected from the remaining instances using 
Welch’s T-Test. The number of peptides significant by this test varied depending on 
which multiple testing correction was used. Uncorrected refers P < 0.05, FDR refers to 
Benjamini and Hochberg FDR < 0.05, and Bonferroni refers to P < 5.26 x 10-6. Dengue 
and Malaria produced the most significant peptides, and were also the best classified 
(AUC Dengue = ~0.92, AUC Malaria = ~1.0). 
 
ELISA Results (IgG, IgM) 
Panbio ELISA results were collected from Seracare and were used to call primary 
versus secondary infections (Table 3.3). Three samples showed a low IgG response and a 
high IgM response, characteristic of a primary infection. These predicted primary 
samples were used in a further classification scheme for diagnosing primary versus 
secondary infection. 
Significant Peptides (P<0.05) For Dengue 
Subtypes 
Sample Uncorrected FDR Bonferroni 
Dengue 1 7065 5996 8 
Dengue 2 574 6 3 
Dengue 3 3957 0 0 
Dengue 4 755 8 1 
Non-
Infected 1147 5 3 
 
Table 3.3: Significant Peptides Between Dengue Subtypes: Subtype prediction is an 
important problem in Dengue diagnostics. In order to test whether peptides could 
differentiate subtypes, peptides were selected with Welch’s T Test and multiple testing 
corrections were applied. Uncorrected refers P < 0.05, FDR refers to Benjamini and 
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Hochberg FDR < 0.05, and Bonferroni refers to P < 5.26 x 10-6.  All subtypes showed 
significant peptides in the strict Bonferroni multiple testing regime except for Dengue 3.  
 
Dengue Primary versus Secondary Infection Prediction (IgG) 
 The three predicted primary samples were labeled appropriately and the SVM 
model was trained on these newly labeled classes. ROC curves along with sensitivity and 
sensitivity estimates for primary versus secondary are shown in Figure 3.3. These gave 
almost perfect AUROC scores, achieving 1.0 for secondary vs. primary and non-infected, 
0.94 for non-infected vs. primary and secondary, and 0.98 for primary vs. non-infected 
and secondary. Sensitivity for detecting DHF high risk secondary infection from non-
infected and primary was 0.8 (CI: 0.72, 0.85) and specificity was 0.89 (CI: 0.86, 0.93). 
Again the cross validation scheme appears valid as the procedure with randomly shuffled 
labels non-predictive results. 
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True Labels Randomly Shuffled Labels 
 
Disease Specificity Sensitivity 
 
Disease Specificity Sensitivity 
Primary 
1 (CI: 0.99, 
1.0) 
1 (CI: 0.99, 
1.0) 
 
Primary 
0.97 (CI: 
0.95, 0.99) 
0.02 (CI: 
0.01, 0.05) 
Secondary 
0.89 (CI: 
0.86, 0.93) 
0.8 (CI: 
0.73, 0.86) 
 
Secondary 
0.2 (CI: 
0.15, 0.25) 
0.7 (CI: 0.66, 
0.80) 
ND 
0.9 (CI: 
0.86, 0.93) 
0.8 (CI: 
0.72, 0.85) 
 
ND 
0.75 (CI: 
0.71, 0.80) 
0.1 (CI: 0.05, 
0.15) 
Overall Accuracy: 0.86 (CI: 0.83, 0.89) 
 
Overall Accuracy: 0.32 (CI: 0.25, 0.31) 
      
Figure 3.3: Primary vs. Secondary SVM ROC curve for real labels and shuffled 
labels – A multiclass SVM was trained and tested with three classes: Primary dengue 
infection (Pri), secondary dengue infection (Sec) and Non-Infected Donor (ND). The left 
side ROC indicates real labels and predicts performance of the model on new samples. 
The right side is the SVM tested on randomly shuffled class labels, and should be 
unpredictive. These curves show there is a real difference between random labels and true 
labels, indicating the model is not over-fitted. 
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Classification Summary and Dengue Subtype Prediction 
 Each classification experiment yielded good performance relative to randomly 
shuffled labels under the current scheme. This performance may also extend to subtypes 
of Dengue. Unfortunately, only one sample of each subtype (Dengue 1-4) could be 
procured from the World Health Organization making a classification experiment 
impossible. Though the sample size is small, single sample T-Tests picked significant 
peptides that survive strict (Bonferroni) multiple testing correction (Table 3.4) in all 
samples except for Dengue 3. There were eight peptides that distinguish Dengue 1 from 
all other subtypes and non-infected, three that distinguish Dengue 2 from others, and one 
that distinguishes Dengue 4 from others. This is a modest number, but the sample sizes 
were extremely small and the multiple testing correction strict. The other classification 
tests used an FDR < 0.05 cutoff, and the number of features selected varied depending on 
the test. In the case of the binary scheme (Dengue vs. Non-Infected) 352 peptides were 
selected in the IgG assay and 816 were selected in the IgM assay. There were only 28 
peptides common between the two, indicating no significant overlap between the 
informative peptides from IgG versus IgM (P=0.79). 
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Dengue Duo IgM and IgG Capture ELISA 
  
Sample Country 
Panbio ELISA 
IgG 
Panbio ELISA 
IgM Prediction 
PVD201-10 Ecuador  0.4 5.8 Primary  
PVD201-16 Ecuador  0.7 5.8 Primary  
PVD201-20 Ecuador  0.7 5.8 Primary  
PVD201-01 Colombia  2.4 5.8 Secondary  
PVD201-02 Honduras  1.2 0.2 Secondary  
PVD201-03 Honduras  1.3 1.1 Secondary  
PVD201-05 Honduras  4.1 0.8 Secondary  
PVD201-06 Honduras  4.5 0.7 Secondary  
PVD201-07 Colombia  7 5.8 Secondary  
PVD201-08 Honduras  2.6 0.9 Secondary  
PVD201-13 Honduras  1.3 0.3 Secondary  
PVD201-15 Honduras  1.3 0.4 Secondary  
PVD201-17 Colombia  2.3 5.8 Secondary  
PVD201-18 Honduras  2.3 0.3 Secondary  
PVD201-21 Ecuador  4.3 5.8 Secondary  
PVD201-04 Honduras 0.5 0.4 False Negative 
PVD201-09 Honduras 0.7 0.3 False Negative 
PVD201-11 Honduras 0.5 0.2 False Negative 
PVD201-12 Honduras 0.9 0.2 False Negative 
PVD201-14 USA 0 0 False Negative 
PVD201-19 Honduras 0.6 0.8 False Negative 
 
Table 3.4: ELISA Results for Predicting Primary and Secondary Infection: The 
Dengue Duo IgM and IgG capture ELISA is a technique for diagnosing dengue infections 
and differentiating primary from secondary infections. In primary infections, the IgM 
response is high, while the IgG response is low. In secondary infections, the IgG response 
is also high, and depending on the course of infection, the IgM may be low. Three 
samples were identified as having a low IgG response. These were predicted primary and 
used for classification. 
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Cohort Specific Amino Acid Bias 
 These results support the idea that immunosignatures could serve as a platform for 
classifying at least small cohorts of multiple infectious diseases. However, very little is 
known about which peptides each cohort prefers. In order to determine if any amino acid 
biases exist between cohorts, a multiple linear regression model was fit to an amino acid 
count matrix as explained in (Greiff et al., 2012).  The coefficients on this model tended 
to cluster in a cohort specific manner, as evidenced by a principal component plot on the 
model coefficient weightings (Figure 3.4).  This was true particularly for malaria, which 
showed decreased binding to cationic amino acids and increased binding to anionic 
amino acids. 
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              Principal Component Plot of  Amino Acid Linear Model Coefficients 
 
Figure 3.4: Amino Acid Linear Model Coefficients show Cohort Specific Variation: 
A linear model based on amino acid counts for each peptide was fit to the multiclass log-
transformed and normalized data. Some amino acids show clear biases toward a 
particular cohort. Top shows all amino acids that had significant differences in their fitted 
coefficients between cohorts. Malaria especially has differential binding to several amino 
acids. Top shows a principal component plot of the same coefficients, showing cohort 
Cohorts 
Dengue 
Malaria 
Non-Infected 
WNV 
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specific variation along several amino acid axes. Samples differ primarily along the 
Arginine/Lysine and Aspartic/Glutamic acid axes.  
 
Epitope Determination on 330K Arrays (IgG) 
 A subset of the dengue and non-infected samples were run on an array (HT330K) 
containing over 330,000 sequences and 27% of all possible 5-mers within its peptides 
(Legutki et al., 2014). These arrays engender the possibility of mapping epitopes to 
Dengue. Enrichment analysis revealed significant subsequences (P < 0.005) in seven of 
the twenty one dengue samples tested, with the conserved sequence AVH found in three 
samples (PVD201-07, PVD201-08, PVD201-16). Previous experiments (Mol. Cell 
Proteomics, Submitted) have shown this conserved sequence corresponds to the linear 
epitope AVHAD in the NS1 protein of all four strains of the virus (Y. Chen et al., 2010). 
Another likely epitope DANXK was also found, but it does not clearly map to the virus 
and has not been reported in the literature. These results are summarized in Figure 3.5. 
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Figure 3.5: Consensus Sequence Determination on HT330K Arrays: Enrichment 
analysis was performed on a per-array basis for subsequences of length 5 or greater. 
Seven of the twenty one Dengue samples tested contained statistically significant 
subsequences (FDR < 0.005). Three samples (PVD201-7, PVD201-16, PVD201-20) 
contained the consensus sequence AVH. Previous experiments done in our group have 
shown this to correspond to the linear epitope AVHAD on the Dengue (1-4) NS1 protein 
(Richer et al, manuscript accepted, Y. Chen et al., 2010). Those found in PVD201-04 and 
201-06 did not seem to represent a consensus motif but showed a clear bias for the C-
terminal residues and GSG linker. PVD201-03 revealed what appears to be an epitope but 
does not map convincingly to the Dengue virus. Inter-alignment refers to the mean 
gapless alignment score by the Smith Waterman algorithm.  
 
  
Inter-alignment 18.1 14.2 
Number significant 7 3750 
Sample ID PVD201-03 PVD201-04 
 
  
Inter-alignment 15.1 16.6 
Number significant 17 3 
Sample ID PVD201-06 PVD201-07 
 
  
Inter-alignment 19.8 13.7 
Number significant 204 1138 
Sample ID PVD201-08 PVD201-16 
 
 
Inter-alignment 13.8 
Number significant 2156 
Sample ID PVD201-20 
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Discussion 
The PVD201 Dengue panel was evaluated for performance on the diagnostic 
CIM10K arrays under several different classification conditions. First, single class IgG 
and IgM classification performance was evaluated against a panel of non-infected sera. 
Next, multiclass IgG performance was assessed with the addition of West Nile and 
Malaria cohorts. Then, using predictions obtained from PanBio ELISA results, the 
platform was evaluated for classification between primary and secondary infections. In 
each case, SVM “leave one from each class out” classification was performed and 
specificity and sensitivity were estimated with a bootstrapping procedure. Subtype 
classification could not be preformed due to lack of samples, but the WHO panel of 
Dengue subtypes was evaluated for statistically significant differences between subtypes. 
Additionally, the samples from each cohort were individually fit to a linear model based 
on amino acid counts similar to what was done by Greiff and colleagues (Greiff et al., 
2012). Finally, the dengue samples and some of the non-infected samples were run on the 
new CIM330K arrays (Legutki et al., 2014) and dengue-specific consensus sequences 
were identified. 
 Classification results were encouraging considering this is an early stage 
diagnostic and existing, approved diagnostics are generally cross reactive. The 
PanbioIgM/IgG test employed here for example produced 0.28 false negative rate and is 
known to be cross reactive to other flaviviruses and malaria (Banoo et al., 2008; 
Hunsperger et al., 2009; Schwartz et al., 2000). The FDA approved InBios Detect IgM 
Capture ELISA reports 0.94 specificity and 0.92 sensitivity (Namekar et al., 2013), but 
the manufacturer acknowledges cross-reactivity with other flaviviruses and warns users 
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about this fact ("DENV DetectTM IgM CAPTURE ELISA," 2012). None of the ELISA 
based methods is capable of differentiating Dengue strains. The peptide array matched 
these results (sensitivity: 0.96, specificity: 0.94) in the single class test and also achieved 
0.76 specificity and 0.96 sensitivity in a classification problem including West Nile Virus 
and Malaria samples. While this specificity leaves something to be desired, it is an 
improvement over existing techniques and with additional samples could be refined from 
its current experimental iteration into a rigorous and accurate diagnostic. It is a unique 
feature of immunosignatures that new data has the potential to improve the diagnostic. 
 Distinguishing primary infection from secondary was an important result from 
this study. It is puzzling, however, that primary infections were classified with high 
sensitivity and specificity (1.0, 1.0) in spite of the low IgG ELISA (Table 3.3). As an IgG 
based assay, immunosignatures should not pick up the IgM/IgG ratio differences that 
characterize primary versus secondary infections. A possible explanation is that the 
sensitivity of the arrays detects an IgG response not evident in the InBios ELISA, which 
uses recombinant proteins. Another, less likely but interesting possibility is that there is 
another IgG response to pathogen infection that does not include specific antibodies 
generated against pathogen targets. In other words, there may be an innate component to 
the IgG response that occurs in primary infections before mature B-cells appear.  
 The amino acid model revealed consistent binding across cohorts to each residue, 
with the exception of charged residues. These varied significantly for the Malaria cohort 
which showed increased binding to anionic residues relative to the other cohorts. This 
could reflect the extraordinary antigenic variation possessed by P. falciparum (Anders, 
1986; Pasternak & Dzikowski, 2009; Scherf et al., 2008). In contrast to the other 
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diseases, P. falciparum and the other Malaria causing protists have a family of var genes 
that provide antigenic diversity in order to evade the host immune system (Gardner et al., 
2002). Perhaps this host-pathogen interaction produces this charge differential. 
Alternatively, it could be caused by fluctuations in pH within the sample solutions. The 
latter seems unlikely considering these samples were highly diluted (1:500) into the same 
buffer solution before being applied to the array, and the arrays would need to be highly 
sensitive in order to pick up any pH differences. 
 An application of this technology in addition to diagnostics is epitope mapping. 
This is an area of active research in our group, and well designed experiments can reveal 
exact pentamer sequences corresponding to pathogen epitopes (Mol. Cell Proteomics, 
Submitted). The present study contains an early iteration of the 330K arrays which 
revealed a consensus trimer to a known linear, immunodominant NS1 epitope (Y. Chen 
et al., 2010). This partially validates an underlying assumption of this assay, which is that 
different infected immune systems often produce antibodies to the exact same or similar 
sequence on the pathogen. More data on this subject would be of great utility for refining 
feature selection methodology and improving array design as a diagnostic platform. 
 This study had two major limitations: small cohorts and non-endemic non-
infected samples. It is true that additional sample variation in the form of larger cohorts 
could dramatically change the SVM model and classification rules, but the technology is 
adaptable in that more information becomes available about how dengue serum reacts to 
the peptide arrays. Thus, each sample run not only produces a diagnostic result, but also 
an additional sample which could be used to improve the test. If new subtypes are 
discovered, the same arrays could be used to detect this. The second limitation arises 
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from the use of non-endemic non-infected samples. This can affect classification results, 
but in this case there was an endemic Malaria cohort included which was successfully 
separated from Dengue.  
 There is a growing list of examples of immunosignatures classifying a diverse set 
of target disease states from non-infected or other clinically relevant diseases (Hughes et 
al., 2012; Kukreja et al., 2012; Legutki et al., 2014; Restrepo et al., 2011a; Sykes et al., 
2013). This technology is maturing and deserves more attention as a diagnostic platform. 
We still have a poor understanding of why this technique works so well for such a wide 
variety of diseases, and which sequences are driving these results. Improved modeling 
techniques for relating sequence information to feature intensity would be essential for 
understanding the mechanisms underlying immunosignatures. 
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CHAPTER 4 
A SIMPLE KINETIC MODEL FOR IMMUNOSIGNATURES 
Abstract 
 
 High throughput assays involving multiple receptors and multiple ligands are 
common in modern biology. The most prominent examples of these are expression 
arrays, protein arrays, and peptide arrays. While these are useful assays, users often 
assume their kinetic behavior is similar to what one would expect in an experiment using 
a single receptor. This chapter challenges this assumption, developing a simple first order 
kinetic model for multiple-receptor multiple-ligand kinetics. This model is developed and 
tested in the context of the immunosignature assay:  non-natural sequence peptide 
microarrays designed to measure and quantify circulating antibodies in blood or sera. The 
model unveils several surprising kinetic phenomena. According to the model, these 
assays are highly sensitive to context: each individual ligand-receptor interaction is 
sensitive to all the other receptors present on the array. There is also a critical balance 
between total receptor (peptide) and total ligand (antibody) concentration. Finally, there 
is a very interesting crossover effect observed under certain assay conditions, whereby 
ligand-receptor association curves are non-monotonic (they initially increase, then 
decrease) due to context-dependant competition. This result is counter to behavior under 
single receptor conditions, but has been verified in experiments involving antibody-
peptide interactions on peptide microarrays. This work explains a number of previously 
poorly understood and unexpected results, and paves the way for further experiments 
aimed at optimizing high throughput platforms. 
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Introduction 
 Peptide arrays have proven useful as a method for finding high affinity ligands 
(Diehnelt et al., 2010), characterization of monoclonal and polyclonal antibodies 
(Halperin et al., 2011) and as a diagnostic method using immunosignatures (Halperin et 
al., 2011; Legutki et al., 2010; Restrepo et al., 2012; Restrepo et al., 2011b; Sykes et al., 
2013). These assays may involve ~109 antibody species at unknown concentrations in 
addition to a deliberately complex peptide coated surface (Legutki et al., 2014). Due to 
this complexity, the biophysics behind peptide-antibody binding in peptide array based 
assays is poorly understood (Stafford et al., 2012). There are reams of (unpublished) 
experimental data showing that immunosignatures are highly dependent on assay 
conditions in surprising ways, indicating a better kinetic model is needed to explain and 
design appropriate assay conditions. This work reviews the surprising findings from 
previously collected immunosignature data, defines a kinetic model of a peptide 
microarray assay which explains these findings, and tests the model against some 
recently collected data. 
 An immunosignature assay involves screening a large number of peptides against 
serum samples, then picking a subset of “informative” peptides for use as a diagnostic. A 
natural idea is to create a second array containing only this informative subset in order to 
improve reproducibility, ease analysis, and generally optimize the method. This was 
attempted in The Center for Innovations in Medicine (CIM) by several people (Bart 
Legutki, Krupa Navalkar, Xiao Wang and others), and these efforts all concluded that 
informative peptides resulting in good classification in the large array did not result in as 
good a classification when the sub-array was used, despite the fact that they contained the 
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same peptides and were run under the same assay conditions (Navalkar et al., 2014). 
Closer analysis revealed that peptide intensities from the sub-array were less correlated 
with their corresponding peptides from the larger array (unpublished). These experiments 
showed context-sensitivity indicating a kinetic aspect to these assays that is as-yet poorly 
understood. 
 A second experiment involved the use of PepPerPrint arrays (Figure 4.1), which 
were manufactured using a different method than those used previously in CIM. These 
arrays are produced using a proprietary process and are optimized for epitope mapping. 
Due to this requirement, the density (number of peptides per unit area per feature/spot) 
could be low in order to minimize cross-reactivity with mimotopes (but actual density is 
unknown). Peptide arrays from CIM (CIM10K) are printed on aminosilane glass slides 
(Legutki et al., 2010), and seek to maximize density which seems to result in an improved 
ability to measure low affinity antibody-peptide interactions.  The same sera and 
monoclonal antibodies were applied to these two different arrays under the same assay 
conditions, and binding to surface peptide was detected using a fluorescently labeled 
secondary antibody. Despite using the same assay conditions and having some of the 
same peptide subsequences, almost no fluorescence was observed using the PepPerPrint 
arrays compared to the CIM10K either using serum or using monoclonal antibody as the 
ligand. This suggests a fundamental difference between arrays printed on aminosilane 
and those synthesized by PepPerPrint, most likely related to the density of each peptide 
within each spot.  
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Figure 4.1: PepPerPrint Arrays vs. CIM10K: Reproduced with permission from Sykes 
et. al. (Sykes, Legutki, & Stafford, 2013). This figure compares the same samples run on 
PepPerPrint arrays versus aminosilane slides. PepPerPrint arrays are inferred to be much 
less dense (fewer peptides per unit area) than the aminosilane slides.  
 
 An additional experiment (Navalkar, 2014) involved an array containing almost 
5000 peptides from various pathogen proteomes. Two versions of this array were created: 
one including influenza peptides and another leaving them out. This consisted of around 
1% of the total peptides on the array, and the others were kept constant between the two 
versions. The addition of influenza peptides greatly changed the classification results and 
the pattern of binding. Further analysis revealed that the arrays without influenza peptides 
had a higher average fluorescence than those containing the influenza peptides (Figure 
4.2). It appeared as though influenza peptides were “stealing” reactivity from the other 
peptides. This effect was particularly consistent among the low intensity peptide-antibody 
complexes.  
Another important point about these assays is that most antibody-peptide 
interactions on these arrays are low affinity (micromolar range) in solution (data not 
shown). This is expected since these peptides are random and most have no relationship 
to an epitope to a given antibody. There is a density effect that needs to be explained, 
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allowing us to observe low affinity interactions even at very small concentrations of 
antibodies. Some hypothesize that high peptide density at the surface artificially increases 
this affinity. Others believe that surface affinities are similar to those measured in 
solution, and the density effect can be explained by simple thermodynamic laws related 
to the total concentration of peptide (number of binding sites) being so large such that the 
reaction is driven towards antibody-peptide complex formation. The model generated 
here tests both possibilities. 
 These results and observations constitute a theme that has affected 
immunosignatures from the start, which is that peptide context and assay conditions 
matter in unexpected ways. If immunosignatures are to become a reliable and robust 
diagnostic method, a better understanding of the kinetic and biophysical aspects of the 
assay is needed. To this end the following sections review classical receptor-ligand 
kinetics and develop a model for peptide-antibody interactions on a peptide array. This 
model is compared to the existing data available and experiments are proposed that 
would test the model. 
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Figure 4.2: Effect of Additional Peptides on an Array: Reproduced with permission 
from Krupa Navalkar. This experiment tested two different arrays against the same 
biological sample. Arrays with influenza peptides added yielded lower overall signal for 
the rest of the peptides on the array as compared to the array without influenza peptides. 
This indicates a context dependence whereby the final signal of any given peptide 
depends on all the other peptides on the array.  
 
Modeling Receptor-Ligand Kinetics 
Single Receptor with a Single Ligand 
Consider a system consisting of a single receptor species and a single ligand species in 
solution.  
 
Such a system has well a well defined dissociation constant (affinity) which depends on 
two kinetic constants  and . 
 
The above assumes an equilibrium has been reached between  and . 
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The first order kinetic rate equations for ,  and  are 
 
 
 (1) 
Since the three species are interdependent and can be expressed in terms of constants and 
one of the species, this system is separable, and has an analytical solution. The equation 
for predicting  at time  is: 
  (2) 
This treatment is common in kinetic assays such as SPR, and is the common mental 
model of practitioners of kinetic assays. The ligand is added to excess such that it is not 
significantly depleted during the assay, and equation (2) is then fit to experimental data in 
order to determine kinetic rates. immunosignatures are a far more complicated situation 
and it will be shown that this regime does not directly translate to assays involving 
multiple receptors and multiple ligands. 
Multiple Receptors with a Single Ligand 
Consider a system consisting of n peptides (receptor) and one ligand (antibody). 
This is the situation with monoclonal antibodies on an array (assuming each peptide 
binds an antibody only one way). 
  
The rate equations for this system are as follows: 
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This is the situation when monoclonal antibodies are applied to an array containing n 
peptides. This is closer to reality than the single receptor-single ligand model, but it can 
be further generalized to include the possibility of multiple ligands as well as multiple 
receptors. 
Multiple Receptors with Multiple Ligands 
Finally, we come to the situation in immunosignatures, where multiple antibodies 
are interacting with multiple peptides in competition. This formulation was inspired by 
work done by Dr. Neal Woodbury (unpublished). 
 
The rate equations underlying this system are: 
 (3) 
  (4) 
  (5) 
 
Surface Considerations 
 The above equations assume all species are in a well mixed solution. In reality the 
receptors are peptides on a surface, fixed at the end of the linear sequence (N or C 
terminus depending on the manufacturing process). The most obvious concern is 
diffusion, which may limit the rate at which ligands can access peptides at the surface. 
This may artificially slow kon, but a spatial concentration gradient during incubation is 
unlikely due to constant applied agitation, so spatial effects are ignored here. Other 
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effects, such as density are more likely to play a large role in binding behavior and are 
considered below. 
Density 
 The density of peptide on a spot is unknown but thought to be high, possibly 1 
peptide per nm2 (Neal Woodbury, unpublished).  Recall from equation 1 (and Le 
Chatelier's Principle), the rate of complex formation depends on both  and  . If   is 
high, this drives up the rate of complex formation and shifts equilibrium conditions 
toward the complex. The role of density in immunosignature assays is highly suspected 
due to the results of the PepPerPrint experiments (Figure 4.1) (Stafford et al., 2012) and 
experiments on NSB slides which have a known, fixed density (Navalkar, 2014). 
Picking Parameters 
 Equations 3,4, and 5 describe kinetics of a peptide array system, with many 
simplifying assumptions. The model treats peptides and antibodies as if they are floating 
around in solutions, ignoring the surface entirely. Also it does not consider blocking 
competition, which may dampen any low affinity binding effects. Still, it may be a useful 
model for understanding how changes in assay conditions affect observed results. 
The question now becomes how to parameterize the model. Here due to lack of 
some important data, some assumptions can be made. First, we are interested primarily in 
how assay conditions and relative incubation times change the binding profile (e.g. what 
happens when you change assay volume or double incubation time). Since the actual 
values of Kon and Koff are unknown, we take a “best guess” approach and focus on the 
ratio Kd for which we have a better idea of what is expected. This means that estimating 
time to equilibrium is beyond the scope of this model as parameterized here, but this is 
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not an important factor for the questions being evaluated. We assume Kon are constant at 
0.001s-1 and need to generate a matrix of Koff  values such that Kd’s fall within an 
expected range.  
 In solution, this range likely is loaded heavily toward the high micromolar range 
with some small number of nanomolar affinities. The distribution is unknown, and would 
ideally be obtained from detailed measurements which do not yet exist. Later we discuss 
approaches for obtaining these detailed measurements. For now, we simply assume the 
Kd values are Pareto distributed. This distribution was named after the Pareto, or “80/20” 
rule. Though the actual proportions vary based on its parameter α, intuitively this means 
that 80% of antibodies are low affinity and 20% are high affinity. 
 
Figure 4.3: Pareto Distribution and Properties: The Pareto distribution has two 
parameters: α and xm. xm specifies a lower bound on the distribution while alpha dictates 
the shape of the curve. We are interested in generating micromolar to nanomolar 
affinities between 1 nM and 1 mM, with loadings in the uM range. To generate these 
values, this distribution must be modified such that generated values fall within a user-
defined range. Figure reproduced from Wikipedia (Public Domain). 
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We generate the Koff matrix assuring that Kd values fall within a user-set range. This is 
derived as follows: 
 
 (6) 
Equation 6 is a function of three arguments which generates a matrix of Kd values: 
   (7) 
Where the shape of Kd is the same shape as the input matrix X of Pareto distributed 
values, and where l and h are the low and high bounds of Kd in the distribution (say, 
between 100nM and 1M). Then the actual koff values used in the simulation can be 
computed easily: 
   (8) 
This generates a matrix of off rates which can be use to parameterize equations 3, 4, and 
5. Now the initial concentrations of peptide and antibody can be set to mimic different 
assay conditions. The initial conditions tested are designed to evaluate the following 
situations: 
 The effect of volume 
o In this model, increased volume would decrease the effective peptide 
concentration, since the number of peptides on the surface remains fixed. 
Thus, to simulate a doubling of volume we simply halve the initial free 
concentration of each peptide. How does this affect the binding profile 
with all else remaining constant? 
 
 Ratio of peptide concentration to antibody concentration 
o This is related to the volume effect. There are three possible regimes here: 
 Regime A:  antibody is the limiting reagent 
 Regime B:  antibody and peptide are roughly equal 
 Regime C:  peptide is the limiting reagent 
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 As volume changes,  decreases, meaning that if 
immunosignatures work in regime A or B, the assay could be 
volume sensitive in that changes could cause it to fall into the 
middle or bottom regime. 
Method: Volume Experiment 
Several human serum samples were tested on the same arrays containing over 10,000 
non-natural sequence peptides (CIM10Kv3). These were tested under standard dual-
channel (IgG, IgM) experimental conditions (see chapter 3 on Dengue Diagnostics). The 
only experimental parameter varied between replicates was the solution volume 
containing the primary antibody (the serum), which was varied at 240uL and 600uL. 
Primary antibody dilution was 1:1000 corresponding to approximately 66nM (assuming 
sera contains ~10mg/ml antibody). The objective was to test the sensitivity of array 
results to total volume, which these assays normally would be insensitive to under 
traditional modes of thinking about assays like these. These experiments were conducted 
by Phillip Stafford and the Peptide Array Core. 
Method: Incubation Time Experiment 
25nM of monoclonal antibody (p53Ab1) was applied to the CIM10Kv2 array 
containing 10,000 non-natural sequence peptides. This was run under standard assay 
conditions (Dengue Diagnostics, Chapter 3, Halperin et. al. (Halperin et al., 2011)) with 
the exception that the incubation time in one of the conditions was increased to 16 hours.  
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Method: Kinetic Simulations 
Simulations of the kinetic system given in equations 3,4, and 5 was conducted 
using Euler’s method. The code for accomplishing this is hosted at: 
https://github.com/joshuaar/CIM-Scripts/blob/master/pepKineticModel.py 
It has a simple command line interface for varying parameters. 
  
 96 
Results 
Effect of Peptide Dilution Under the Model: A Testable Prediction 
First I designed a testable prediction under the model and evaluate it against 
experimental data. One such prediction is to observe the effect of peptide dilution while 
keeping antibody concentration fixed. In a real experiment, one could achieve this by 
varying the volume of the primary antibody solution (which effectively dilutes the 
peptides at the surface), while keeping antibody concentration fixed. Under the model, 
the distribution of equilibrium complex loadings for each peptide should be sensitive to 
the ratio of total antibody to total peptide unless one of the two is present to sufficient 
excess. I tested 5 different peptide concentrations relative to a fixed 5nM antibody 
concentration. Each condition used 200 peptides, 20 antibodies, and Kd values ranging 
from 10 to 100nM.  
The choice of Kd here is arbitrary, as this only affects the concentration ranges at 
which the equilibrium distribution is sensitive to change. After simulating these 
conditions under the model, the variance of the peptide loadings at equilibrium was 
calculated. This can be thought of as a virtual array experiment, where 20 antibodies are 
assayed against 200 peptides, the reaction is stopped at equilibrium and complex 
concentrations are detected via fluorescence. These conditions and variance results are 
given in Table 4.1. The distributions at equilibrium are visualized in Figure 4.4. 
[Ptotal] (nM) 5000 500 50 5 0.5 
[Abtotal] (nM) 5 5 5 5 5 
N Ab 20 20 20 20 20 
N Peptide 200 200 200 200 200 
Variance 1.03 x 10-10 3.52 x 10-9 3.32 x 10-7 2.15 x 10-6 1.55 x 10-6 
Table 4.1: Variance Results for Peptide Dilutions: These are the equilibrium variances 
for each experimental condition tested under the model. There is a clear trend of 
decreasing variance as peptide concentration decrease relative to antibody concentration. 
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As shown earlier, this also corresponds to lower overall binding. While the lower overall 
binding could be compensated for by better scanning lasers and PMT settings, the 
variance trends cannot be changed through better imaging techniques.  
 
 
Figure 4.4: Generated Distributional Trends Under the Kinetic Model: Under the 
model, the variance in equilibrium peptide loadings decreases as peptide concentration is 
decreased relative to antibody concentration. Top left: 500nM peptide, 5nM antibody. 
Top right: 50nM peptide, 5nM antibody. Bottom left: 5nM peptide, 5nM antibody. 
Bottom right: 0.5nM peptide 5nM antobody.  All x-axis scales have the same width but 
different locations, and refer to the distribution of equilibrium peptide-antibody complex 
concentrations for the 200 tested peptides.This provides a hypothesis that can be tested 
experimentally. If immunosignature experiments exist in regime A, they should be 
volume sensitive. These distributions were generated under the model allowing all 
complexes to reach equilibrium. 20 antibodies with a total concentration of 20 nM were 
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run against 200 peptides with total concentrations ranging from 5000 to 0.5 nM. Based on 
these results, variance becomes insensitive once peptide is sufficiently concentrated 
(5000nM and 500nM distributions are nearly identical, 5000nM not shown). 
 
The simulations show that unless peptide is extremely in excess, the equilibrium 
distribution is sensitive to volume of the primary antibody solution (as this effectively 
dilutes peptide on the surface). To see if this takes place in reality, an experiment was 
designed on the 10Kv3 arrays and Sera.  
Experimental Results: Volume Experiment 
Experiments varying volume at a fixed antibody concentration effectively dilute 
or concentrate the effective peptide concentration. Thus, it is possible to test whether this 
kinetic model has bearing on reality. The experiment is simple. Place some sera on an 
array at a fixed concentration and incubate under standard conditions. Do several 
replicates, each at different volumes. If there is a significant difference in the distribution 
of intensity values, then current immunosignature conditions most likely exist in antibody 
limiting conditions (regime A). In both the IgG and IgM cases, the total variance was 
sensitive to volume (IgG: P=0.0024, IgM: P=0.00029), indicating that regime A is the 
most likely situation for immunosignatures, and the model appropriately captures this 
fact. These results are summarized in Figure 4.5. 
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Figure 4.5: Volume Dependence on Total Variance of Array Results:  The results 
shown here are consistent with those predicted by the model if conditions are in regime 
A. Higher volumes effectively dilute peptide concentrations, resulting in a lower 
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concentration of peptide relative to antibody.  The model predicts that this would result in 
an overall reduction in variance, which is very clearly observed here. The fact that these 
peptides are stuck on a surface rather than floating around in solution does not seem to 
change this fundamental law, and is further evidence that immunosignatures exist in 
regime A. 
 
Context Sensitivity and The Crossover Effect 
 There are two strange phenomena which have been observed experimentally on 
these arrays which I believe to be related. One is context sensitivity, which was covered 
in the introduction and means that the equilibrium fluorescence intensity of each peptide 
depends on every other peptide on the array. The second observed phenomenon is the 
“crossover effect” whereby some peptides show high fluorescence intensity at short 
incubation times, but low intensity at long incubation times. Both of these are 
unexpected, but the model sheds light on what conditions could give rise to these effects. 
An example of the crossover effect is shown in Figure 4.6. It will be shown that the 
kinetic model developed here can explain this crossover effect as well as context 
dependence if certain conditions are met. 
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Figure 4.6: Crossover Effect in Monoclonal Antibody: The crossover effect is when 
initially high intensity peptides decreased in intensity as the assay is allowed to run to 
equilibrium. Here is an experimental result where a monoclonal antibody was incubated 
on the CIM10K array, and peptides were ranked by their intensities at 16 hours. It is clear 
that some peptides which have very low intensity at 16 hours were nearly saturated at 1 
hour. The kinetic model explains these results if certain conditions are met. 
 
Behavior Under Different Kd, Peptide and Antibody Concentrations 
 In order to explain context sensitivity and the crossover effect, a number of 
different experimental conditions were simulated under the model. These are given in 
Table 4.2. It will be shown that when peptide is sufficiently in excess (conditions 1, 2, 7, 
13), crossover effects due to context sensitivity are observed. “Sufficient excess peptide” 
is dependent on the Kd matrix of the antibody peptide interactions, but it is always the 
case that given enough peptide, crossover effects and context dependence can be 
observed. 
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 Several kinetic systems were tested under different conditions: 
Hypoth
esis 
Regime Condition N Abs N Peptides [Abtotal] [Peptidetotal] Kon Koff 
X A 1 20 20 5nM 5000nM 0.001 nM-1s-1  
 
0.01 – 0.1 s-1 
See eqn. 8 
A 2 20 20 5nM 500nM 0.001 nM-1s-1 
A 3 20 20 5nM 50nM 0.001 nM-1s-1 
B 4 20 20 5nM 5nM 0.001 nM-1s-1 
C 5 20 20 500nM 5nM 0.001 nM-1s-1 
A 6 1 20 5nM 500nM 0.001 nM-1s-1 
Y A 7 20 20 5nM 50000nM 0.001 nM-1s-1  
A 8 20 20 5nM 5000nM 0.001 nM-1s-1  
A 9 20 20 5nM 500nM 0.001 nM-1s-1  
1-10 s-1 
See eqn. 8 
 
A 10 20 20 5nM 50nM 0.001 nM-1s-1 
B 11 20 20 5nM 5nM 0.001 nM-1s-1 
C 12 20 20 500nM 5nM 0.001 nM-1s-1 
Z A 13 20 10 5nM 100nM 0.001 nM-1s-1 0.01 – 0.1 s-1 
Table 4.2: Experimental Conditions Tested: Each experimental condition is divided 
into one of three regimes. Regime A refers to where peptide is present in excess, regime 
B is where peptide and antibody are roughly equal, and regime C is where antibody 
appears in excess. These conditions were chosen to test the effect of these ratios on 
equilibrium distributions. 
  
As mentioned previously, there are two competing hypotheses about the role of 
density on peptide arrays. The first states that the high density artificially decreases koff by 
some unknown mechanism. I call this hypothesis X. The other hypothesis states that this 
mechanism is unnecessary, surface affinities are similar to those measured in solution, 
and the observed binding is simply due to excess peptide on the surface and known 
thermodynamic laws.  We call this hypothesis Y. There is also the question of what 
happens when fewer peptides are represented on the array with the total peptide 
concentration kept constant. These situations are considered below. 
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Figure 4.7.1: Hypothesis X, Regime A, Condition 1:Extremely Dense Peptide, 20 
antibodies with 20 peptides 
This tests an absolutely extreme case, whereby there is 1000x more peptide than antibody 
on the array. Total antibody is completely depleted very rapidly due to the massively 
excess peptide concentration, after which they come off their initial targets and settle on 
those interactions for which they have the lowest Kd. In this range, antibody is almost 
totally depleted at equilibrium.  
N 
Abs 
N Peptides [Abtotal] ([Abj]) [Ptotal]  ([Pi]) Kd 
20 20 5nM (0.25nM) 5000nM (250nM) 10 – 100 nM 
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Figure 4.7.2: Hypothesis X , Regime A, Condition 2:Dense Peptide, 20 antibodies with 
20 peptides 
While still in regime A, in this test there is only 100x more peptide than antibody. 
Behavior is similar to the 1000x case, but the initial depletion is slower and there is a 
more pronounced “crossover” effect, indicating that under these conditions it becomes 
very critical at which point the assay is stopped. 
N 
Abs 
N Peptides [Abtotal] ([Abj]) [Ptotal]  ([Pi]) Kd 
20 20 5nM (0.25nM) 500nM (25nM) 10 – 100 nM 
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Figure 4.7.3: Hypothesis X , Regime A, Condition 3:  Moderately Dense Peptide, 20 
antibodies with 20 peptides 
Here peptides are 10x more concentrated than antibodies. At this point, antibodies are not 
depleted at equilibrium, and the bound concentration varies only by around 0.02 nM. This 
regime is unlikely to result in a good immunosignature. 
N 
Abs 
N Peptides [Abtotal] ([Abj]) [Ptotal]  ([Pi]) Kd 
20 20 5nM (0.25nM) 50nM (2.5nM) 10 – 100 nM 
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Figure 4.7.4: Hypothesis X , Regime B, Condition 4: Equality Peptide, 20 antibodies 
with 20 peptides 
Here total peptide and antibody are equal. Most antibody is left unbound at these 
conditions, and this is unlikely to be a useful regime.  
N 
Abs 
N Peptides [Abtotal] ([Abj]) [Ptotal]  ([Pi]) Kd 
20 20 5nM (0.25nM) 5nM (0.25nM) 10 – 100 nM 
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Figure 4.7.5: Hypothesis X , Regime C, Condition 5:Excess antibody, 20 antibodies 
with 20 peptides 
Here peptide concentration remains low, but 100x more antibody are added in order to 
force binding. As expected, saturation of peptide happens quickly for all affinities.  
N 
Abs 
N Peptides [Abtotal] ([Abj]) [Ptotal]  ([Pi]) Kd 
20 20 500nM (25nM) 5nM (0.25nM) 10 – 100 nM 
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Figure 4.7.6: Hypothesis X , Regime A, Condition 6: 100x excess peptide, 1 antibody 
with 20 peptides 
This test is identical to condition 2, which showed the interesting crossover effect, with 
the exception that only one antibody is used instead of 20. At  this tight range of Kd 
values, this crossover effect is still observable. As with the 20x20 case, initial depletion 
time is similar, but there is a longer period of re-arrangements as loadings are focused on 
the few peptides with the lowest Kd values. This occurs even when the range of Kd values 
is restricted to the low nanomolar range. This behavior is similar to that observed in 
Figure 4.6, if the 1 hour cutoff was relatively early in the reaction and spot saturation 
happens at around 0.2 on the graph below. 
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N 
Abs 
N Peptides [Abtotal] ([Abj]) [Ptotal]  ([Pi]) Kd 
1 20 5nM (5nM) 500nM (25nM) 10 – 100 nM 
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Figure 4.7.7: Hypothesis Y , Regime A, Condition 7:  Hyper-Dense Peptide, 20 
antibodies with 20 peptides 
This situation is extreme, but it illustrates the point that affinity values only inform the 
meaning of “excess peptide” at which context dependant binding behavior occurs. This 
looks very much like condition 2, despite the fact that Kd values are an order of 
magnitude larger. 
N 
Abs 
N Peptides [Abtotal] ([Abj]) [Ptotal]  ([Pi]) Kd 
20 20 5nM (0.25nM) 50000nM (2500nM) 10 – 100 uM 
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Figure 4.7.8: Hypothesis Y , Regime A, Condition 8:  Very Dense Peptide, 20 
antibodies with 20 peptides 
Here we begin to see a trend. Density of peptide is very important to the behavior of the 
assay, regardless of what Kd values are. One can achieve resolution of very low affinity 
interactions if the peptide concentration is high enough, but context dependence becomes 
less important. 
N 
Abs 
N Peptides [Abtotal] ([Abj]) [Ptotal]  ([Pi]) Kd 
20 20 5nM (0.25nM) 5000nM (250nM) 10 – 100 uM 
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Figure 4.7.9: Hypothesis Y , Regime A, Condition 9:  Dense Peptide, 20 antibodies 
with 20 peptides 
N 
Abs 
N Peptides [Abtotal] ([Abj]) [Ptotal]  ([Pi]) Kd 
20 20 5nM (0.25nM) 500nM (25nM) 10 – 100 uM 
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Figure 4.7.10: Hypothesis Y , Regime A, Condition 10:  Moderately Dense Peptide, 20 
antibodies with 20 peptides 
N 
Abs 
N Peptides [Abtotal] ([Abj]) [Ptotal]  ([Pi]) Kd 
20 20 5nM (0.25nM) 50nM (2.5nM) 10 – 100 uM 
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Figure 4.7.11: Hypothesis Y , Regime B, Condition 11:  Equality Antibody and 
Peptide, 20 antibodies with 20 peptides 
N 
Abs 
N Peptides [Abtotal] ([Abj]) [Ptotal]  ([Pi]) Kd 
20 20 5nM (0.25nM) 5nM (0.25nM) 10 – 100 uM 
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Figure 4.7.12: Hypothesis Y , Regime C, Condition 12:  Excess Antibody, 20 
antibodies with 20 peptides 
N 
Abs 
N Peptides [Abtotal] ([Abj]) [Ptotal]  ([Pi]) Kd 
20 20 500nM (25nM) 5nM (0.25nM) 10 – 100 uM 
  
This is interesting because at low affinities, the assay is much more tolerant of excess 
antibody, and differentiation can still happen without all peptide sites becoming saturated 
as was the case in condition 5. 
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Figure 4.7.13: Hypothesis Z, Regime A, Condition 13: 5 peptides, 20 antibodies 
This condition is to test the effect of fewer peptides, but more effective concentration of 
each while keeping [Ptotal] constant. This is a timely question, as new arrays in our Center 
are being developed that do just this, and it is an open question how this will effect the 
ability to do immunosignaturing. Here, there are 5 total peptides each at 100nM, bringing 
the total to 100nM total peptide (100x compared to total antibody).  This seems to bring 
the assay closer to condition 1, with a quicker saturation time and a wider distribution. 
N 
Abs 
N Peptides [Abtotal] ([Abj]) [Ptotal]  ([Pi]) Kd 
20 5 5nM (5nM) 500nM (100nM) 10 – 100 nM 
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 Discussion 
 This work reviewed existing anomalies in immunosignature datasets, and 
endeavored to explain these through a kinetic model incorporating multiple antibodies 
and multiple peptides. A testable prediction related to volume sensitivity was generated 
under the model, and this was shown to correspond well to experimental data. Then a 
number of conditions were simulated in order to determine which conditions give rise to 
context dependant binding and the “crossover effect” which have been observed in many 
different immunosignature experiments. These conditions also evaluated two competing 
hypotheses about the Kd ranges likely to be present on the surface of a peptide array. 
 The kinetic model developed here is very simple and does not account for many 
aspects of this assay. Diffusion is ignored and peptides are treated as if they are floating 
around in solution. This seems appropriate for the questions being answered, as the 
model explains very succinctly some phenomena that were previously puzzling.  
First, it is very clear under the model that as peptide concentration decreases, in 
general less variation in binding is observed on the array. This trend is independent of the 
unknown Kd matrix in a multi-antibody, multi-peptide experiment. The hypothesis that 
high peptide densities somehow decrease values in the Kd matrix relative to what they 
would have been in solution is not needed in order to explain this trend.  
Second, this model also explains the context dependant behavior observed from 
sub-array experiments (Navalkar et al., 2014), superarray experiments (Figure 4.2) and 
in the incubation time experiments (Figure 4.6). Conditions 1, 2, 7, 13, though varying 
widely in their kinetic and experimental parameters, all showed this effect clearly. This is 
due to peptide being present in sufficient excess such that antibody is initially depleted. 
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Once this occurs the peptide-antibody complexes undergo a back reaction and 
rearrangement. While equilibrium is eventually reached, this is a very different process 
than that governed by single ligand, single receptor kinetics as given in equation 2. 
Equation 2 is the intuitive way that most scientists think about binding kinetics, but when 
multiple receptors and multiple ligands are involved, the laws are instead governed by 
equations 3, 4, and 5 which result in very different behavior.  These previously strange 
results can be explained by nothing more than simple kinetic theory, and are not 
surprising. 
While the crossover effect and context dependence can be explained by the 
model, the jury is still out on which hypothesis about the Kd matrix (Hypothesis X or 
Hypothesis Y) is true. Under Hypothesis X, the crossover effect is observed at a lower 
peptide density (500nM) than under Hypothesis Y (50,000nM). These numbers should be 
taken with a grain of salt, since they are dependent on a number of unknown factors, but 
it is clear that crossover and context dependence would be observable at lower peptide 
densities if Hypothesis X were true.  
 Regardless of the content of the Kd matrix, these results imply that a good 
immunosignature assay depends on antibody-limiting conditions. If antibody is not 
limiting, peptides will be more likely to saturate at equilibrium (though this depends on 
the Kd matrix and exactly how limiting the peptides are), resulting in low discrimination 
ability and low variance. As shown in the volume experiment (Figure 4.5) and the 
corresponding simulations (Figure 4.4) variance significantly decreases as peptide 
concentration decreases relative to antibody concentration. This is a bad thing for 
immunosignatures, which attempt to resolve minute quantities of antibodies with 
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potentially low affinities. This could be potentially mitigated by having higher peptide 
“concentrations” by adding surface sites. 
 Further experiments might involve a thorough determination of pairwise on and 
off rates (or at least Kd) for single antibodies with single peptides spotted on a surface. 
This would determine a detailed Kd matrix. Once this is accomplished for a number of 
antibodies and peptides, an array could be prepared containing multiple characterized 
peptides, and incubated with characterized antibodies. Incubating these arrays at various 
times, volumes and antibody concentrations would validate the model proposed here and 
inform refinements. 
 An alternative approach is to skip the pairwise characterization and simply 
assume a constant Kon and a parametric distribution with parameters θ for generating the 
Koff matrix. This matrix would not be measurable directly, so the best that could be 
accomplished is a maximum likelihood estimate for θ based on observed data. There 
many methods to fit these parameters to data which are beyond the scope of this 
investigation.  
 High throughput assays are important to biology, but the physics underlying them 
is poorly understood. This paper is an attempt to point others in the right direction for 
further investigation. Some things are clear: antibody concentration is likely limiting 
under immunosignature conditions, and these assays likely rely on this fact. Under these 
conditions, equilibrium complex concentrations depend heavily on context as determined 
by a Kon and Koff matrix. The content of these matrices are unknown, and currently the 
data does not exist to determine these conclusively. This paper simply guessed at these 
important system parameters, with the goal of pointing out general trends. with proper 
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experiments, the full behavior of the system could be characterized with the application 
of designing optimal immunosignature assays. 
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CHAPTER 5 
A COMPOSITIONAL LINEAR MODEL EXPLAINS ARRAY VARIANCE 
Abstract 
 Immunosignatures using non-natural sequence peptide microarrays is a promising 
technique for disease diagnostics, showing remarkable sensitivity and specificity for 
several different infectious and chronic diseases including cancer. The mechanism 
underlying this performance is poorly understood. In order to address this, we fit a simple 
linear model based on amino acid compositions to several published immunosignature 
datasets to identify trends, dependencies and enrichments of certain amino acids. Charged 
amino acids play an important role in the resulting binding profile in all datasets tested, 
and show a mild ability to predict infections or cancers from normal sera.  This cationic 
charge effect is reduced or eliminated at high pH. 
Introduction 
Immunosignatures at its core is a technique for quantifying the interactions of a 
complex analyte (sera containing antibodies with varying specificities) with a chemical 
space. However, little is known about how antibodies interact with this chemical space 
and even the very notion of “chemical space” is it this point vague. In the context of 
peptide arrays, we intuitively understand this as all possible linear peptides, of which a 
certain subset will bind antibodies. This chapter builds a framework for understanding 
how antibodies interact with peptides sequences, which amino acids are favored and dis-
favored by various monoclonal and serum samples, and how these weightings change 
across batches (arrays are manufactured in batches). 
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The antibody repertoire and the process by which it is generated is extremely 
complex, and encompasses specificities and affinities to a wide variety of antigens 
(Nobrega et al., 1998). Further, antibodies are known to bind with proteins, sugars, 
nucleic acids, and small molecules while being negatively selected against self-antigens. 
Despite this complexity, there may be some sequences or motifs that antibodies generally 
prefer as an ensemble. So far very little work has been done either in our Center or in the 
wider scientific community to profile which sequences, amino acid densities and motifs 
that antibody mixtures prefer.  
Grieff, et. al. made an attempt to relate amino acid frequencies to array signals 
using a very simple linear model on 255 peptides, and found that this explained up to 
50% of the signal variance in serum samples, but not in monoclonal samples (Greiff et 
al., 2012). They predicted an “ensemble effect” whereby antibodies bind peptides based 
on amino acid content in addition to a specific interaction with a target, this phenomenon 
being only observed in complex mixtures. With the advent of new arrays, we have the 
opportunity to test this model on a much larger set of samples and peptides, and assess its 
usefulness for explaining how antibodies bind peptides, and what factors are contributing 
to the observed signals. 
The method described in (Greiff et al., 2012) is a very coarse grained model. It 
explains binding in terms of sequence content, but says nothing about sequence order 
(motifs). Despite the simplicity, it does seem to explain a surprising amount of the 
variance in array experiments. This warrants a closer look using much larger arrays in 
both sera and monoclonal samples. 
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Methods 
Enrichment Analysis 
 Enrichment or over-representation analysis is an approach to finding elements 
from a discrete distribution that occur more frequently than expected. It is commonly 
used in microarray, next-gen sequencing and proteomics experiments (Huang, Sherman, 
& Lempicki, 2009; Subramanian et al., 2005). Typically in high throughput experiments 
such as these one has a large number of measurements, and a much smaller subset of 
“interesting” measurements. In the context of peptide arrays, we have a set of peptides 𝑆 
and a much smaller set of interesting peptides  𝑆𝑥 determined by their differential or 
absolute binding. These are the “top n” peptides for a given statistical test. Checking for 
over-representation of peptides is not very interesting because each peptide on the array 
is unique. Instead, we compute properties of the peptides which are less unique, such as 
amino acid or k-mer frequencies. For example, one might select the top 100 peptides on 
an array by signal intensity, then ask the question “is the subsequence RHSK” appearing 
in these 100 peptides more than expected by random chance?” This same idea can also be 
expanded to check all possible subsequences in these top 100 peptides given certain 
constraints (say all 3 to 5-mers). 
P values for each k-mer are calculated according to the hypergeometric distribution, and 
corrected for multiple hypotheses at 5% FDR. 
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𝑃𝑖 =
(
𝐾𝑖
𝑘𝑥𝑖
) (
𝑁 − 𝐾𝑖
𝑛 − 𝑘𝑥𝑖
)
(
𝑁
𝑛
)
 
𝑃𝑖 P value for the hypothesis that the ith k-mer occurs in  𝑆𝑥 with a frequency 
predicted by random chance 
𝐾𝑖 Total number of occurrences of the ith k-mer in 𝑆 
𝑘𝑥𝑖 Number of occurrences of the ith k-mer in  𝑆𝑥 
𝑁 Total number of occurrences of all k-mers in S 
𝑛 Total number of occurrences of all k-mers in  𝑆𝑥 
Table 5.1: Hypergeometric Symbols for Calculating Enrichments  
Regression Modeling 
 A simple linear model predicting intensity (or log-normalized intensity) based on 
amino acid frequencies is given. 
Direct model:     ?⃑? = 𝑿?⃑⃑⃑? + 𝜀 
?⃑? An 𝑛 ∗ 1 vector of signal intensities, where 𝑛 is the number of peptides on the 
array. 
𝑿 A 𝑛 ∗ 𝑘 matrix of amino acid counts, indicating how many of each amino acid is 
in each peptide, where k is the number of amino acids present on the array plus 
one dimension for the intercept. Some datasets use peptides which are all the 
same length. In these cases isolucene is not considered in order to avoid perfect 
multicollinearity of variables. 
?⃑⃑⃑? A vector of weights, fit by ordinary least squares. 
𝜀 An error vector, assumed to be normally distributed. 
Table 5.2: Explanation of variables used in linear regression model 
This amino acid linear model (AALM) is an attempt to explain array binding only 
through amino acid frequencies. When fitting the above model to the CIM10K data, the 
equation must run through the origin. This is because each peptide on these arrays is the 
same lengths, resulting in perfect multicollinearity and a useless model if an intercept is 
used. 
 
Monoclonal Spiking Experiment 
 Normal mouse serum was diluted 1:500. This solution was aliquotted into six 
vials. To five of the vials, differing amounts of affinity purified anti-GFOD polyclonal 
antibody was added such that vials contained 0.1nM, 1nM, 2.5nM, 5nM and 10nM of the 
 125 
spiked antibody in addition to the diluted serum. The sixth vial contained only serum as a 
negative control, and a seventh vial contained only 40nM anti-GFOD as a positive 
control. Each of these seven prepared sample was incubated in duplicate on the CIM10K-
V2 array for 1 hour primary incubation and 1 hour with anti-mouse IgG  conjugated with 
Alexa-647 dye as a secondary and washed. Arrays were scanned with an Agilent-C 
microarray scanner and aligned with GenePix Pro 6.0. 
Datasets 
 Several datasets were compiled to assess the linear model and enrichment strategy 
across several batches and experiments. These include: 
Chip Set and Samples Description 
HT152 – Sera IgG seven infectious disease cohorts and normal 
sera. Over 330,000 peptides synthesized 
using NSB-9 wafers (3nm distance between 
peptides within a spot) 
HT22 – Monoclonal IgG eight monoclonal antibodies. Over 330,000 
peptides. These peptides are longer than 
HT152 peptides and synthesized on 
standard wafers. 
HT22 – Sera IgG seven infectious disease cohorts and normal 
sera. Over 330,000 peptides. These 
peptides are longer than HT152 peptides. 
CIM7-18 – Sera and Monoclonal IgG small cohorts including monoclonals, 
normal, and three infectious diseases. 
About 10,000 peptides. 
CIM10K – Dengue v Normal v WNV v 
Malaria 
Four small cohorts run on CIM10K arrays, 
Spring 2013. About 10,000 peptides. 
CIM10Kv3 – Dog Cancers Cohorts of dogs with cancer (used for AA 
enrichments only). About 10,000 peptides 
with some D-amino acids mixed in 
Table 5.3: Description of peptide array datasets used in this study: HT152 and HT22 
and CIM7-18 each contain over 330,000 random sequence peptides, but each contains a 
different library of peptides. CIM10K and CIM10Kv3 both have over 10,000 random 
peptides, but CIM10Kv3 has dextro amino acids.  
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Results 
 There are two analyses that were performed on several immunosignature datasets. 
The first involved fitting a linear model (AALM) to each dataset and testing various 
hypothesis about the model. The second involved calculating sequence enrichments for 
several lists of selected peptides. These methods are related in that they both explore the 
role of sequences in determining observed binding. 
Compositional Linear Model Fitting 
 
This assay shows binding of serum antibodies to a large number (tens to hundreds 
of thousands) of addressable peptides. An obvious question is, which peptide sequences, 
amino acids, and motifs do antibodies prefer to bind in general? Does this vary between 
batches, samples, cohorts and protocols? Almost nothing is known about which 
sequences monoclonal antibodies and sera prefer.  
The first question is whether a simple compositional linear model can explain 
array binding at all. Figure 5.1 shows compositional model (AALM) fit quality to many 
samples on several array batches. Serum samples have R2 values ranging from 0.3 to 0.7, 
while monoclonal antibodies tend not to fit well (R2 < 0.1). There were no significant 
differences in model fit between classes (e.g. Dengue vs. Normal), or for IgM vs. IgG, 
but there were significant differences between array batches. 
Coefficient values for each amino acid varied both between and within batches. 
Within batches coefficient variation was dominated by the cationic effect (response to 
positively and negatively charged amino acids) (Figure 5.2).  
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Figure 5.1 - Coefficients of determination for AALM:  These plots show R2 values for 
AALM on different batches and biological samples. These range from around 0.2 to 0.6 
for serum samples, and do not fit well with monoclonals (R2 < 0.1). Polyreactive 
monoclonal antibodies fit the AALM better than high affinity monoclonals, and 330K 
arrays seem to drive a better fit than 10K. 
  
330K Array Model Fit - Various Batches
S
er
um
 Ig
G
: H
T-
15
2
S
er
um
 Ig
G
: H
T-
22
S
er
um
 Ig
G
: C
IM
7-
18
m
A
b 
Ig
G
: C
IM
7-
18
m
A
b 
Ig
G
: C
IM
7-
22
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Sample Batch
C
o
e
ff
ic
ie
n
t 
o
f 
D
e
te
rm
in
a
ti
o
n
10K Array Model Fit - Various Batches
S
er
um
 Ig
G
: 1
0K
V
2 
D
en
gu
e 
S
tu
dy
S
er
um
 Ig
G
: 1
0K
V
3 
D
og
s
m
A
b 
Ig
M
: 1
0K
V
2 
P
ol
yr
ea
ct
iv
e
m
A
b 
Ig
G
: 1
0K
V
2
0.0
0.1
0.2
0.3
0.4
Sample Batch
C
o
e
ff
ic
ie
n
t 
o
f 
D
e
te
rm
in
a
ti
o
n
330K Array Model Fit - IgM vs IgG
Ig
G
: C
IM
7-
18
Ig
M
: C
IM
7-
18
0.0
0.1
0.2
0.3
0.4
0.5
Samples
C
o
e
ff
ic
ie
n
t 
o
f 
D
e
te
rm
in
a
ti
o
n
A B 
C 
 128 
5.2A 
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5.2B 
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Figure 5.2: PCA and Plots of AALM Coefficients: (5.2A) principal component plot 
reveals batch specific effects on several amino acid axes, most notably the R/K and E/D 
axis. This is particularly apparent in the HT-152 and HT-22 datasets, where samples are 
splayed out in a line reflecting variation in response to charged residues These wafers 
also worked best so far as a diagnostic in infectious diseases (data not shown) . (5.2B) 
These are model coefficients for each dataset tested, and show a view of the data without 
dimensionality reduction. 
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The importance of charged amino acids in both between batch and within batch 
variation begs the question regarding the effect of pH on the amino acid binding profile. 
An experiment was designed to test the pH effect on residue specific binding, where a 
single serum sample was run at varying pHs from 6 to 9. Higher pH values resulted in 
lower binding overall for both IgG and IgM. This effect was most heavily loaded on the 
charged amino acids, particularly Arginine and lysine (Figure 5.3 top). 
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Figure 5.3: AALM Coefficients at Varying pH in Normal Sera: These plots show the 
coefficient trends as pH changes. There is a general downward trend in binding overall, 
most significantly involving the anionic residues aspartic and Glutamic acid. 
 
 
 Perhaps a more direct measure of the pH sensitivity involves the isoelectric point 
of the peptide. Here, instead of quantifying the loadings on each residue, pI is simply 
plotted against pH to reveal any dependence. Overall binding did not change significantly 
between pH 9 and pH 6 for IgM, but IgG showed significant changes especially among 
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the peptides with higher pI (Figure 5.4). The AALM and pI results together suggests pH 
has an important effect on IgG binding to the basic amino acids lysine and Arginine.  
Figure 5.4: Effect of Isoelectric Point on Binding Intensity to Normal Sera at 
Varying pH: Plots showing pI (x axis) versus intensity for a normal serum sample at pH 
6 and pH 9. IgG shows significant pH sensitivity, with higher reactivity to peptides with 
pI greater than 6. 
 
 Compositional models like AALM are also useful for revealing quality issues 
with arrays. Wafer HT-22 had issues with anomalous histidine binding, which becomes 
apparent when coefficient loadings are examined (Figure 5.5). Monoclonal antibodies 
which should not fit the model showed consistant loadings on histidine. Surprisingly, this 
did not seem to affect the ability to determine epitopes, as several of the histidine binders 
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(DM1A, AB1) also showed very clean epitopes when motif detection was applied to 
these data.  
 
Figure 5.5: Normalized linear model coefficients from wafer HT4-22 for all nine 
tested monoclonal antibodies: Four of these (left) were strong N-terminal histidine 
binders which resulted in a high R2 value. This seems to be driving the fit, and was a 
known problem with this batch of arrays. The other five monoclonal antibodies had a 
very poor fit, with R2 values in the range of ~0.02 for the direct AALM. 
 
These results are in agreement with those previously reported by (Greiff et al., 
2012). Complex mixtures of antibodies fit a linear model fairly well, while monoclonal 
antibodies do not. This preference for sera warrants further investigation, particularly to 
answer the question of whether there is any disease specific effect on coefficient 
loadings. To test the effect of a disease perturbation of the antibody mixture, a spiking 
test was devised intended to mimic the effects of an infection causing production of 
immunodominant antibodies (Frank, 2002). 1:500 diluted healthy BALB/C mouse serum 
was spiked with differing amounts of affinity purified anti-GFOD antibody. It can be 
seen from this experiment that R2 decreases dramatically as more anti-GFOD is spiked in 
(Figure 5.6).  
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Figure 5.6: Coefficients fitted values GFOD Spiking Experiment: 1:500 diluted 
normal mouse serum (NMS) was spiked with varying quantities of anti-GFOD affinity-
purified polyclonal antibody. Increasing concentrations of spiked antibody dramatically 
reduce fit, even when the same concentration of NMS is still present in the background. 
Biased solutions of antibodies have a fundamental difference in binding as compared to 
unbiased solutions, and this may be relevant in disease diagnostics. 
 
 Another interesting question is whether loadings change significantly between 
batches or array samples. The same normal human serum sample (ND134) was run on 
multiple array batches for quality control. When these data are fitted independently to the 
AALM, it is clear that loadings are dependent on the production batch, though there is 
also a clear and consistant trend (Figure 5.7) with respect to these loadings. The effect of 
basic residues Arginine and lysine is again clear, but surprisingly this effect is at times 
reversed. In batch 118, lysine and Arginine have a negative contribution to binding, while 
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Glutamic and aspartic acid exhibit a positive effect; the opposite of what is normally 
observed. 
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Figure 5.7: Coefficients fitted values across batches for Normal Donor 134: One 
normal sample was run across multiple batches of the array and fit to the log-transformed 
AALM, resulting in a general trend of amino acid binding. R2 values ranged from 0.72 to 
-15
-10
-5
0
5
10
15
20
25
30
35
R K G P A Q V N S Y H E D W F L
Changes in Coefficients between Batches: 
ND134 Batches 25 to 126
25
108
118
124
126
-20
-15
-10
-5
0
5
10
15
20
25
30
35
R K G P A Q V N S Y H E D W F L
Changes in Coefficients between Batches: 
ND134 Batches 135 to 152
135
136
142
152_IgG
152_IgM
 137 
0.93. A charge reversal effect is seen in batch 118 involving R,K,E and D, indicating that 
assay conditions (probably pH) have a strong effect on the amino acid binding profile. 
 
 
 
Figure 5.8: Residuals for AALM fit on CIM7-18 Wafer: Residuals reflect a linear 
trend, indicating that a linear model does not explain  the variance equally over the range 
of intensity values. 
 
 
Figure 5.9: Coefficients of Determination for Piecewise Discontinuous Model: Model 
fit is not distributed equally amongst the intensity range. Low and high intensity peptides 
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fit better, and while there are fewer peptides in the middle range, there are over 10,000 
peptides in each tranche. 
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Figure 5.10: Principal Component Analysis on Model Coefficients – Three Datasets: 
Log-transformed AALMs were fit to each sample from CIM10K (top), HT152 (bottom 
left) and HT22 (bottom right). The two bottom studies involved seven infectious disease 
cohorts and one normal cohort, while the top study was done on smaller arrays with three 
disease and one normal cohort. In all three cases, separation can be seen between normals 
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and some diseases, though in the two 330K studies this effect is subtle. The effect is 
pronounced in the 10K study, where malaria samples clearly separate from the other 
cohorts. This might be evidence for cohort specific variation in terms of the AALM, or it 
could be due to systematic sample effects due to the fact that each cohort came from a 
different supplier. 
 
 
 
Figure 5.11: ROC Performance (Normal vs. Disease) on Wafer HT-22 for Dipeptide 
Motif RR: ROC analysis on the dipeptide motif RR reveals a weak predictive ability for 
normal samples, indicating the possibility of an ensemble difference between normal and 
infected samples in terms of their response to Arginine residues. 
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Enrichment Analysis 
 
 The AALM fit in the previous section reveals a strong role for charged residues in 
binding determination. It would be interesting to know whether these residues (or others) 
are enriched in selected peptides used for immunosignature diagnosis. Very little is 
known about the sequences selected for prediction, as no comprehensive statistical 
analysis of these sequences has ever been reported. Enrichment analysis was conducted 
for three disparate immunosignature datasets. These were intentionally selected to cover a 
wide variety of platforms and samples to see if any general trends arose. Charged amino 
acids were enriched in all three tested datasets, but cationic ones were only enriched in 
the two human datasets, while dogs showed enriched anionic residues. Surprisingly, 
proline was enriched in all three datasets, though only slightly in dogs. These results are 
summarized in Figure 5.12. Further analysis revealed these enriched charged amino 
acids exist only in the down peptides (lower in disease than in normal). This is a 
remarkably stable phenomenon, present in all three diverse datasets (Table 5.4).  
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Figure 5.12: Enrichment P Values for Each Residue, Three Experiments: Three 
immunosignature datasets (all IgG based) were tested for enrichments within significant 
peptides (Normal vs. Disease, FDR < 0.05). Cationic amino acids were highly enriched in 
the two human datasets (Dengue and Infections), while anionic ones were enriched in 
dogs. Proline was significantly enriched in the human datasets, and nonsignificantly 
(slightly) enriched in dogs. In general, charged amino acids and prolines are often 
enriched in immunosignatures. These results agree with and confirm the principal 
component plots in Figure 5.10, which illustrate this phenomenon in terms of AALM 
coefficients.  
 
Discussion 
 A variety of datasets encompassing monoclonal and immunosignature 
experiments in humans and dogs were compiled in order to do a meta-analysis of 
sequence dependencies with the goal of elucidating the role of sequence composition in 
immunosignatures. First, a compositional amino acid linear model (AALM) was 
constructed and fit to each dataset, and loadings for each amino acid were examined and 
compared across datasets. Then, enrichment analysis was conducted on the same datasets 
in order to determine which amino acids appeared more often than expected in 
immunosignatures. These findings indicated a strong role for charged amino acids and 
possibly pH. Thus, an experiment was designed to test the effect of pH on binding 
profile. 
 The results from this meta-analysis indicate a strong role for charged residues in 
determining final binding intensity. This dependency is most clearly visible on the low 
end of the intensity spectrum (0 to 10000) and also at the very high end (~65000). In both 
these ranges, a simple linear model explains up to 50% of the within-array variance 
(Figure 5.9). Considering the high noise in these datasets (correlation between technical 
replicates averages 0.85), this is a remarkably good fit.  
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 The errors are clearly not normally distributed (Figure 5.8), indicating there are 
additional unmodeled intensity-dependant variables contributing to binding. This 
indicates there is an opportunity to explain more variance in terms of additional latent 
variables. 
 While it is clear that charged amino acids are important determinants of array 
binding, it is less clear whether these models can inform and improve immunosignatures. 
It is unlikely that compositional models such as the AALM can inform disease vs. disease 
classification (Figure 5.10), there is some evidence that it could predict normal vs. 
disease (Figure 5.11). This result is rather surprising, as one would expect that binding 
based solely on charge differential would be rather non-specific. There have been several 
previous studies in our lab (Muskan Kukreja, Kurt Whittemore, unpublished data) 
showing a mild predictive ability for disease vs. normal, and we have termed this strange 
phenomenon the AbStat, or immune temperature. The results shown here indicate that the 
AbStat may be due in part to a difference in charge affinity between normal and disease 
sera. This is very surprising and unintuitive, because if it is true, it implies we are 
measuring a previously undiscovered kind of network effect on the humoral immune 
system. Perhaps a nonspecific class of antibodies exists with a similar role as 
antimicrobial peptides. It is also interesting that the amino acids that show up enriched 
consistently in the down peptides are the same ones which appear en-masse in 
antimicrobial peptides (K,R,P,G) (Zasloff, 2002).  
 These charged amino acids are strongly affected by pH in IgG based assays. As 
pH increased, cationic amino acids contributed less to binding (Figure 5.3) and anionic 
amino acids were largely unaffected. Further, there was a pI specific drop in intensity at 
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high pH assays (Figure 5.4). This is expected, and suggests a way to reduce or eliminate 
the cationic effect in these assays. It is unknown how pH affects immunosignatures.  
 The cationic effect observed on these arrays has interesting properties, and the 
presence of significant peptides containing enriched cationic and aromatic amino acids 
warrants further investigation. The major question surrounding these is whether or not 
this arises from antibodies directed towards a particular antigen(s), or if it is a nonspecific 
consequence of being infected. This could be shown with a simple experiment which 
removes disease-specific antibodies by treating infected sera with pathogen-coated 
magnetic beads. If charged amino acid containing peptides drop in intensity after 
purification, then this is a pathogen specific effect. Otherwise, there is likely some other 
mechanism causing these enrichments. This would have to be repeated with several 
samples and several diseases, as the effects observed here are somewhat weak, requiring 
several samples. It is also interesting to note that this effect was observed in the Dog 
dataset, which consisted of cancers and normal samples (Figure 5.12), only here it was 
anionic residues rather than cationic ones which were enriched. 
 Very little modeling has been done on peptide microarrays, and these results 
indicate that even the simplest variables have explanatory power. If immunosignatures 
are ever to be understood on a system-wide mechanistic level, quantitative statistical 
models are the way forward. The next step is explaining within-array binding in terms of 
motifs or subsequences rather than single amino acids, then extending this to include 
multiple samples from different diseases to explain between-array and between-class 
variance. The models tested here are a first step, but they are very basic and deserve more 
attention to be brought into practical use.  
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Infections - HT22 - Downs 
   seq n_enriched n_library p_binom frac p_adjusted 
A 10891 129092 1.11E-16 0.084366 1.00E-15 
G 32179 415597 1.11E-16 0.077428 1.20E-15 
K 12278 100615 1.11E-16 0.12203 1.50E-15 
P 12867 146545 1.11E-16 0.087802 2.00E-15 
S 17414 210675 1.11E-16 0.082658 3.00E-15 
R 14293 130838 1.11E-16 0.109242 6.01E-15 
V 8987 125975 0.660673 0.07134 1 
Q 4270 60357 0.797064 0.070746 1 
N 6067 93250 1 0.065062 1 
E 6682 137037 1 0.048761 1 
D 6018 114500 1 0.052559 1 
F 3407 70925 1 0.048037 1 
H 6839 129910 1 0.052644 1 
L 6090 102543 1 0.05939 1 
W 2932 113671 1 0.025794 1 
Y 4664 94086 1 0.049572 1 
            
Infections - HT22 - Ups 
   seq n_enriched n_library p_binom frac p_adjusted 
F 7394 108827 1.11E-16 0.067943 1.50E-15 
K 10595 128429 1.11E-16 0.082497 2.00E-15 
L 7979 130167 1.11E-16 0.061298 3.00E-15 
S 18996 292848 1.11E-16 0.064866 6.01E-15 
Y 7475 135275 3.55E-12 0.055258 3.84E-11 
A 8630 162883 0.000279 0.052983 0.002512 
G 27936 542251 0.064068 0.051519 0.495077 
Q 4141 80003 0.198274 0.051761 1 
R 8117 158223 0.354876 0.051301 1 
P 8351 162821 0.360757 0.051289 1 
N 6003 123086 0.999898 0.048771 1 
V 6962 145097 1 0.047982 1 
E 2587 147001 1 0.017599 1 
D 3367 134464 1 0.02504 1 
H 8439 183676 1 0.045945 1 
W 7131 184997 1 0.038547 1 
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Dogs - CIM10Kv3 - Downs 
   seq n_enriched n_library p_binom frac p_adjusted 
D 156 2624 0.000442 0.059451 0.031836 
E 152 2653 0.00218 0.057294 0.078424 
P 134 2358 0.004859 0.056828 0.116534 
Q 136 2617 0.055 0.051968 0.989373 
T 118 2293 0.082609 0.051461 1 
G 258 5315 0.135252 0.048542 1 
S 256 5337 0.183831 0.047967 1 
A 110 2302 0.2843 0.047785 1 
N 113 2381 0.307425 0.047459 1 
K 109 2323 0.353454 0.046922 1 
C 134 2941 0.477209 0.045563 1 
R 93 2123 0.625899 0.043806 1 
H 104 2521 0.838992 0.041253 1 
V 89 2179 0.841942 0.040844 1 
L 92 2275 0.869467 0.04044 1 
M 93 2301 0.872158 0.040417 1 
I 78 2001 0.914229 0.038981 1 
W 66 2010 0.997334 0.032836 1 
F 71 2252 0.999508 0.031528 1 
Y 146 4237 0.999853 0.034458 1 
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      Dogs - CIM10Kv3 - Ups 
   seq n_enriched n_library p_binom frac p_adjusted 
L 17 5610 0.004177 0.00303 0.30054 
V 15 5503 0.016069 0.002726 0.578122 
R 14 5756 0.04428 0.002432 1 
C 13 6989 0.229265 0.00186 1 
T 9 5237 0.327947 0.001719 1 
P 9 5288 0.338655 0.001702 1 
A 9 5398 0.361958 0.001667 1 
F 10 6112 0.386642 0.001636 1 
I 9 5556 0.395772 0.00162 1 
K 9 5658 0.417707 0.001591 1 
H 9 5958 0.48199 0.001511 1 
G 19 12294 0.500212 0.001545 1 
E 7 4809 0.503677 0.001456 1 
S 18 12357 0.603837 0.001457 1 
N 6 4897 0.66891 0.001225 1 
Q 6 5024 0.694535 0.001194 1 
M 6 5155 0.7196 0.001164 1 
W 6 6178 0.867522 0.000971 1 
Y 14 12093 0.877836 0.001158 1 
D 4 4937 0.898153 0.00081 1 
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      Dengue - CIM10Kv2 - 
Downs 
   seq n_enriched n_library p_binom frac p_adjusted 
K 924 4053 1.11E-16 0.227979 7.99E-15 
H 789 4066 1.01E-08 0.194048 3.63E-07 
D 735 3761 1.13E-08 0.195427 2.72E-07 
Q 681 3748 0.000201 0.181697 0.00362 
S 1384 8031 0.000775 0.172332 0.011147 
M 669 3781 0.002313 0.176937 0.027744 
P 530 2956 0.002454 0.179296 0.025223 
G 1327 7780 0.003365 0.170566 0.030264 
E 663 3874 0.024548 0.171141 0.19626 
N 594 3544 0.088116 0.167607 0.634035 
A 596 3617 0.174553 0.164777 1 
C 687 4311 0.455556 0.15936 1 
R 482 3107 0.691926 0.155134 1 
T 556 3617 0.778577 0.153719 1 
V 494 3673 0.999942 0.134495 1 
L 449 3597 1 0.124826 1 
W 403 3379 1 0.119266 1 
F 392 3661 1 0.107075 1 
I 391 3692 1 0.105905 1 
Y 734 6612 1 0.11101 1 
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Dengue - CIM10Kv2 - Ups 
   seq n_enriched n_library p_binom frac p_adjusted 
P 1019 5119 3.97E-09 0.199062 2.85E-07 
Y 2006 10694 8.58E-09 0.187582 3.09E-07 
R 1053 5333 9.84E-09 0.19745 2.36E-07 
W 1031 5292 1.40E-07 0.194822 2.52E-06 
H 967 4988 7.21E-07 0.193865 1.04E-05 
G 1735 10305 0.274023 0.168365 1 
K 756 4506 0.381503 0.167776 1 
C 941 5628 0.411142 0.1672 1 
M 681 4123 0.550842 0.165171 1 
F 844 5175 0.700919 0.163092 1 
S 1655 10152 0.785457 0.163022 1 
T 692 4399 0.926707 0.157308 1 
A 706 4579 0.978532 0.154182 1 
L 720 4785 0.996874 0.15047 1 
Q 653 4383 0.997911 0.148985 1 
N 624 4200 0.997947 0.148571 1 
D 619 4261 0.999722 0.145271 1 
I 605 4350 0.999997 0.13908 1 
V 606 4443 1 0.136394 1 
E 487 4045 1 0.120396 1 
      Table 5.4: Enrichment tables for three immunosignature datasets on diverse 
platforms: These tables list enrichment scores for each amino acid. The column labels 
are as follows: seq – amino acid, n_enriched – amino acid counts in significant peptides, 
n_library – amino acid counts in the entire array, p_binom – binomial approximation of 
the p-value for enrichment, frac – fraction of the total counts in the significant peptides, 
p_adjusted – FDR corrected p-value. Down refers to those peptides lower in intensity on 
average in disease as compared to normals, and up refers to those that are higher in 
intensity in disease relative to normals. Charged amino acids were enriched in down 
peptides in all three datasets, while aromatics predominated in the up peptides. 
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CHAPTER 6 
PROTOMAPPER: SOFTWARE FOR RAPID DISCOVERY OF MOTIFS 
Preface 
This chapter contains a number of terms that may be unfamiliar to the uninitiated, 
but nonetheless precise. It is important to understand that these terms are commonly used 
and not limited to one domain. They are about as domain specific as “Microsoft Word”, 
“Western Blot”, or “ELISA”. As previous chapters have assumed the reader is familiar 
with these terms, this chapter assumes the reader is familiar with the following terms. 
Regular Expressions 
Regular Expressions are a concise language used to represent patterns in strings. For 
example, the regular expression DOGS|CATS would match the following two strings: 
1. DOGS 
2. CATS 
However, if we expand this regular expression as follows, we can make it more flexible. 
Consider the expression .*(DOGS|CATS).*. The dot (.) means match any character in the 
alphabet, and the star (*) means that the preceding character can be repeated any number 
of times. So this expression would match an infinite number of strings containing either 
the words DOGS or CATS 
1. I like DOGS 
2. I like CATS 
3. I like DOGS but not CATS 
… 
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Regular expressions are flexible and can be combined in complex ways to match many 
different types of strings. The basic concepts are well stated by Wikipedia: 
en.wikipedia.org/wiki/Regular_expression. 
In general the “building blocks” of regular expressions consist of the following: 
Boolean “or” 
grey|Grey|gray matches either the words grey, Grey, or gray 
Grouping 
Parentheses can be used to nest, or group regular expressions. For example (AB)* would 
match 
AB 
ABAB 
ABABAB 
… 
 
Quantification 
Quantifiers act upon the preceding character or group. Here are some examples: 
? – match zero or one of the preceding element 
* - match zero or more of the preceding element 
+ - match 1 or more of the preceding element 
There are other quantifiers not covered here. 
Finite Regular Expression 
A finite regular expression is any regular expression that matches a finite number of 
strings. Many regular expressions match an infinite number of strings (for example any 
expression containing a *). This chapter concerns itself with a method for rapidly 
matching finite regular expressions. 
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Grep 
Grep is mentioned several times in this chapter. This is a well known program used to 
match regular expressions on Unix based systems. It is so commonly used that there are 
grep functions in many major programming languages such as R and Python. This is a 
highly optimized O(n) algorithm and software for matching regular expressions. Again, 
Wikipedia contains an excellent introduction to this program: 
http://en.wikipedia.org/wiki/Grep. 
Big O Notation 
Big O notation is used to state the time complexity of an algorithm relative to its input. 
The time it takes an O(n) algorithm to complete will increase approximately linearly as 
the size of its input increases. Similarly, an O(n2) algorithm time will increase as a 
function of the square of its input. Again, Wikipedia contains an excellent introduction 
http://en.wikipedia.org/wiki/Big_O_notation. 
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N-Gram 
An N-gram is simply a sequence of characters of length N. For example, a trigram is any 
string of length 3. The language of all trigrams can be described with the following 
regular expression: (…). This chapter uses the word trigram often to describe an indexing 
strategy. This means that trigrams are used to rapidly retrieve documents containing that 
trigram. 
Naïve 
Naïve, as used in this chapter, means “the most obvious method available”. Here it is 
used to refer to those methods that do not use extra information in the form of an index to 
match (finite) regular expressions. 
 
 The terms defined above are important for understanding what this chapter is 
about. This chapter is entirely concerned with a strategy for rapid matching of regular 
expressions, which is useful for, but not limited to, certain biological applications. The 
primary result is that this strategy is much faster than grep or any other naive method for 
certain subclasses of regular expressions.  
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Abstract 
Biologists have been using regular expressions to represent and search for motifs 
for many years. Databases such as ProSite gather patterns representing common 
biological motifs, but tools for searching these patterns against the known sequence 
information are naïve methods. Though efficient and O(n), this is not good enough for the 
current size of the database if one is to run a web server at reasonable cost, a problem that 
will only continue to worsen. In this manuscript we test a trigram indexing strategy based 
on Apache Lucene that can resolve low complexity finite regular expressions at speeds 
that are logs faster than even the most optimized naïve methods. Benchmarking against 
grep (a standard and highly optimized O(n) method for regular expression matching) was 
conducted, and patterns requiring fewer than 6025 index lookups resulted in search times 
much faster than grep. With further optimization, this method would be good replacement 
for naïve systems such as ScanProSite which are showing their inefficiency under the 
growing size of the publically available sequence information. Source code is available 
under the BSD License at https://github.com/joshuaar/Protomapper-Search. 
Introduction 
Short, linear patterns in peptide sequences are highly common in nature, including 
linear antibody epitopes (Buus et al., 2012a), conserved signal peptides (Chaddock et al., 
1995), and peptide-protein binding motifs (Bähler & Rhoads, 2002). Locating specific 
patterns in a database is useful in proteomic studies, immunological epitope 
identification, and sequence based protein retrieval. BLAST, a commonly used technique 
for finding similar sequences, provides limited capability for regular expression pattern 
searches, but is not ideal for patterns with variable lengths or with position specific 
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substitution allowances. The Protein Information Resource (a website for searching 
biological databases) has recently retired its pattern matching service, and ScanProsite 
(Gattiker, Gasteiger, & Bairoch, 2002), while useful and flexible, uses naïve 
methodology and was developed over a decade ago when the amount of publically 
available sequence information was much lower. Today UniProtKB contains over 300GB 
of sequences, which are not easily searchable using standard regular expression search 
utilities such as grep or previously developed bioinformatics tools. More recently, a 
search utility for rapid, exact peptide matches has been developed using similar 
technology (C. Chen et al., 2013), but fast regular expression based queries remain 
elusive. This paper describes, tests and provides a reference implementation for an 
indexing strategy and method of fast regular expression matching.  
While regular expression matching fundamentally has linear time complexity 
(Sipser, 1996), in practice, performant search over large databases is challenging. None 
of the major SQL databases provide strong support for regular expression searching over 
long strings of text (such as peptide sequences), and popular “out of the box” solutions 
such as Solr and Apache Lucene are optimized for search over human readable text 
consisting of short words separated by whitespace. A new, scalable and general approach 
is needed, and this paper develops one such method that could meet this need for a rapid 
engine matching a finite subset of the regular expressions. We have made this tool 
available under the BSD license (https://github.com/joshuaar/Protomapper-Search). This 
method draws inspiration from Cho et. al. (Cho et al., 2003), Google Code Search (Cox, 
2012 ), and Chen et.al. (Chen et al., 2013), consisting of an expression compiler which 
produces Lucene queries to a trigram index of sequences.   
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Cho was the first recorded regular expression indexing engine. It analyzes the 
expression to find a number of trigram lookups, and then returns a superset of documents 
for additional matching. Google Code Search employed a similar strategy, but included 
optimizations for special cases, taking special care to analyze prefixes and suffixes of the 
expression to construct optimal queries. Chen created a peptide search engine using 
Lucene, which only matches exact sequences. The method discussed here combines the 
method from Chen with those from Cho and Google Code Search. 
Methods 
Protomapper uses two underlying databases. The first is from NCBI’s FTP site, 
and includes proteomes of bacteria and viruses organized by strain. The second is 
UniprotKB, which contains over 40 million sequences, many redundant. These databases 
are indexed using Apache Lucene, and fields include the peptide sequence, accession 
number, protein description, and organism.  
The protein sequences are passed through Lucene’s NGramTokenFilter. This 
generates overlapping trigrams of the sequence, allowing the search space to be indexed 
in terms of trigrams. The structure is that of an inverted index (Figure 6.2A) which 
means that one can look up sequences by trigram at O(1) time complexity. This index 
structure follows a similar approach to previous methods such as PeptideMatch (3-mers) ( 
Chen et al., 2013), UniPept (6-mers) (Mesuere et al., 2012) and SANS (suffixes) 
(Koskinen & Holm, 2012), though these methods were not designed for pattern matching. 
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Figure 6.1: Context Free Grammar Recognized by the Query Compiler: This is the 
language recognized by the query compiler. It is a context free grammar and a subset of 
the regular expressions. Each string in this language is also a regular expression, but not 
every regular expression is in this language. This grammar is equivalent to the “finite 
regular expressions”.  Finite regular expressions refer to those expressions such as 
(A[XYZ]C) that match a finite number of strings (as opposed to something like (A.*C) 
which matches an infinite number of strings). 
 
This index structure is conducive to limited regular expression matching, where 
the query speed is dependant primarily on the complexity of the pattern, not the number 
of sequences contained in the database. In order to search the index for regular expression 
matches, we developed a compiler for converting query strings into Lucene 
MultiPhraseQuery and BooleanQuery objects, which directly read the index resulting in a 
list of matching sequence identifiers. The grammar recognized by the compiler a finite 
subset of the regular expressions and is given in Figure 6.1. It allows the user to match 
finite length wildcards (say, for example any character repeated between 0 and 20 times), 
variable length gaps and character substitutions at high speed. The compiler goes through 
three steps. The first two steps modify the query string to remove “or” symbols (|) and 
length ranges, replacing those with a list of query strings. The final step converts each 
query string into a Lucene Query which searches the index for matching strings, 
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completing the compilation process. An example of how a query string is converted into 
a Lucene query is given in Figure 6.2B. 
 
Figure 6.2: Indexing and Query Compilation Procedures: (A): Input sequences are 
processed and inserted into an inverted trigram index. Each trigram window from the 
sequence corresponds to a key in the index. Each trigram key maps back to a set of 
pointers to the sequences containing that trigram. This enables O(1) lookups of any given 
trigram, and facilitates the construction of more complex queries. (B) Complex finite 
regular expressions must be transformed into a series of index queries. This requires a 
multistep procedure where boolean and ranged regular expressions are converted into 
simpler but equivalent versions. These simplified regular expressions are converted into 
MultiPhraseQueries which consist entirely of trigram lookups. These queries are then 
pruned so as to use as few index lookups as possible.  
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 The compiler and web interface are written in Scala, and all communication 
between the client and the database is done through a simple RESTful API. Details about 
architecture and API syntax are given in Figure 6.3. The index and querying system is 
built using Apache Lucene 4.0, and the API and interface are served through the Play 
framework. These two functions are decoupled such that the search methods could be 
embedded into existing databases and APIs in a flexible way. 
 
Figure 6.3: Protomapper Architecture: This block diagram shows the various modules 
within Protomapper and how they interact. The Web interface communicates with the 
Play API. The API communicates with the search module and also the underlying Lucene 
Access module in order to compile and process queries. The searcher embeds a compiler 
to deal with turning user strings into compiled queries. The Lucene access module 
handles all reading and writing to the Lucene index.    
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Results 
Protomapper is up to three orders of magnitude faster than naïve methods and 
existing pattern searchers. The catch is that query duration in Protomapper increases 
exponentially with more complex queries which is a major limitation. Complexity refers 
in this case not to time complexity, but the number of times the system must access the 
index for trigram lookups. A complexity score of 1000, for example, corresponds to 1000 
Lucene trigram lookups. In Lucene parlance this involves querying 1000 PhraseQuery 
objects against the index. We compared Protomapper query durations to grep (a naïve 
method) for varying database sizes and query complexities. For both search methods, 
there is a clear log-log linear relationship between query complexity and duration. For 
low complexity queries, Protomapper is several logs faster than grep, but at higher 
complexities the situation is reversed. The inflection point remained relatively constant 
for each database size tested, so it would be relatively straightforward to design a query 
optimizer around the complexity score. In all cases, the inflection point was at around 
log(complexity)=3.78, which corresponds to 6025 trigram lookups. Protomapper is an 
effective strategy for queries with fewer lookups than this. A table of example queries 
and their corresponding complexities is given in Table 6.1. 
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Complexity 
Log-
Complexity Expression 
3 0.477121255 AVHAD 
4 0.602059991 SNKQRLP 
5 0.698970004 KQRLSGGGGGGG 
9 0.954242509 DFKHKWLAAAAARRRRLLLLPPPP 
17 1.230448921 [IL][RQ][TC][MR][MK] 
24 1.380211242 AVHAD..DDR 
31 1.491361694 {10,10}A{10,10}R{10,10}L{10,10}M{10,10}O{10,10}P 
36 1.556302501 
YK[DE][SG]TLI[IML]QL[LF][RHC]D 
[LF]T[LS]W[TANS][SAD] 
64 1.806179974 A.D.R.LL.P 
66 1.819543936 DDR.{2,23}.HRT 
89 1.949390007 
G[FYIL][DE][LIVMT][DE][LIVMF] 
PSYG[LIVMA][VAGC]TPRGGL[LIVMAGN] 
152 2.181843588 
{2,2}(G[FYIL][DE][LIVMT][DE][LIVMF]PSYG[LIVMA] 
[VAGC]TPRGGL[LIVMAGN]) 
197 2.294466226 [EQ][LNYH].[ATV][FY][LDAM][T]W[PG]N 
253 2.403120521 [IL].[RQ].[TC].[MR].[MK] 
421 2.624282096 [IL].[RQ].[TC].[MR].[MK][IL].[RQ].[TC].[MR].[MK] 
527 2.721810615 C.PC..CCP..C[PEG] 
2131 3.32858345 [LIVM].[SADN]..C.R[LIVM]....[GSC]H[STA] 
2773 3.44294987 C...C..[LMF]...[DEN][LI].....C 
3655 3.562887381 [FILV]Q...[RK]G...[RK]..[FILVWY] 
4684 3.670616886 C...C..[LMF]...[DEN][LI].....CC...C..[LMF]...[DEN][LI].....C 
5589 3.74733411 
[LIVMTR].[LIVMT][LIVMF].[GATMC][ST][NS] 
....[LIVM]D..[AS][LIFAV].{1,3}R 
16444 4.216007468 
[TG][STV]........[LIVMF]..R...[DEQNH]..S....[IFY] 
.......[LIVMF]...[LIVMF].....I.....[LIVMFA]..[LIVMF] 
30586 4.485522684 
{2,2}([TG][STV]........[LIVMF]..R...[DEQNH]..S 
....[IFY].......[LIVMF]...[LIVMF].....I.....[LIVMFA].. 
[LIVMF]) 
Table 6.1: Various Queries and their Complexity Scores: These queries are ordered to 
increasing complexity. Complexity refers to the number of trigram lookups required to 
resolve the pattern within the index. A log complexity score between 3 and 3.5 takes 
approximately equal time whether the index or naïve methods are used. Log complexities 
above 3.5 are slower using the index, and scores below 3 are faster using the index. 
Figure 6.4 summarizes the benchmarking tests giving rise to these cutoffs. The 
complexity score would be the basis of a query optimization system, whereby different 
methods could be selected based on analysis of the query.  
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Since the index is constructed on trimers, queries that contain many gaps run slower 
since many possible trimers could occur at the gapped position. Also, variable length 
queries using the x{a,b} syntax are compiled to BooleanQuery objects, which also 
increase the number of index lookups required. An analysis of various queries and their 
speed is given in Figure 6.4.  
 The user interface allows several options. Searches can be directed towards the 
entire database, or a specific subset of organisms. Results are returned as a paginated 
table, and the most prevalent genera are given in a pie chart. Results can be downloaded 
as a fasta file for storage and later retrieval.  We also provide a simple API that returns 
JSON formatted results, and source code which can be incorporated into existing projects 
or used as a command line application.  
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Figure 6.4: Protomapper vs. Grep (naïve method): Benchmark tests comparing the 
Protomapper index versus grep. Grep is a mature and optimized linear method for 
matching regular expressions, and is a standard utility in most linux distributions. For low 
complexity queries (less than 6025 index lookups) Protomapper is logs faster than grep. 
However, speed decreases exponentially with increasing index lookups, causing very 
poor performance for high complexity queries. In such cases, a query optimizer should 
search using naïve methods. Both grep and protomapper search more slowly in large 
databases, affected more severely.  
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Discussion 
 An indexing strategy was designed in order to rapidly search peptide motifs 
across a large database of protein data. This employed a trigram index and the Lucene 
search library along with a pattern compiler. Motifs are encoded as finite regular 
expressions and compiled into queries which can be directly executed on Lucene’s 
engine. The system was benchmarked against the naïve pattern matcher grep, which is 
the standard and most optimized method for these types of searches. Finally a web and 
command line interface named Protomapper was constructed to allow easy access to the 
system. Protomapper is fast for low complexity patterns, but speed decreases 
exponentially with increased pattern complexity. 
 These results (Table 6.1) highlight an important issue surrounding these types of 
indexing strategies. Only a few strategies exist in the literature (Cho & Rajagopalan, 
2002; Cox, 2012 ), and they all run into the same fundamental flaw: regular expressions 
are arbitrarily complex, so there is no indexing strategy that is guaranteed to be faster 
than naïve methods (which are, admittedly, highly mature and optimized). The best that 
can be achieved is a system optimized for some portion of the regular expressions. In this 
method, un-nested, finite regular expressions were chosen as the language (Figure 6.1 for 
precise generative definition). This guarantees at least that patterns can be matched solely 
through interrogation of the index, and makes the problem easier to analyze. The second 
restriction is that patterns fall below a certain complexity threshold, guaranteeing the 
impossibility of querying intractable patterns.  
In practical terms, this means that this system would be useful for looking up any 
peptide containing less than 6025 non-overlapping trigrams. Any peptide less than 18,075 
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amino acids in length would result in efficient lookup. Of course, this system does not 
just match exact sequences, but patterns as defined by the language in Figure 6.1. This 
creates a much more complex situation as to which patterns would be useful under this 
system. Table 6.1 contains a number of patterns color coded by whether lookup time 
would be faster than naïve methods using this system. 
There are several optimizations that could be employed in order to accommodate 
high complexity patterns. Currently, the compiler resolves the expression entirely through 
index lookups. That is, after the index is interrogated, the results returned exactly match 
the regular expression and there is no need for further processing. While this works well 
when the number of index lookups is low (<6025), it quickly becomes intractable for 
queries that require more lookups. However, for most patterns, a reasonable superset of 
results could be returned using far fewer lookups. A strategy might be to truncate the 
pattern such that fewer than 6025 lookups are employed. Given the nature of finite 
regular expressions, this method would return a superset that contains a small fraction of 
the original database, but does not exactly match the pattern. Then, on this restricted 
subset the naïve method (such as grep) could be employed resulting in an overall 
reduction in query duration as compared to the full naïve method.  
The other indexing strategies mentioned (J. Cho & Rajagopalan, 2002; Cox, 2012 
) are very similar to this one. The distinguishing factor of Protomapper is that it is built 
on top of Lucene and its patterns can be resolved using only index lookups. The other 
difference is that Protomapper restricts itself to only a portion of the regular expressions 
which simplifies the problem without sacrificing too much expressive power for its 
intended application of motif searching. With further optimization this would be an 
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excellent candidate to replace tools such as ScanProSite. The source code is available for 
download and modification under the BSD licence. 
https://github.com/joshuaar/Protomapper-Search 
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Figure 6.5: User Interface Screenshot: Users select a database, add multiple patterns 
and search. The distribution of organisms is shown in a pie graph, and results are 
displayed in a table below. These can be downloaded in fasta format. The program is also 
available as a command line application for use in server-side procedures.  
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CHAPTER 7 
CONCLUDING REMARKS 
 
Immunosignatures are incredibly complex assays that still are barely understood. 
This issue extends to array-based and high-throughput assays in general where scientists 
struggle to apply their expertise in single experiments and multiply these thousands of 
times. It is clear that this transition is not straightforward and gives rise to unexpected 
statistical, computational and physical concerns. This thesis reviewed and pointed out 
some of these difficulties, as well as providing some solutions to some of them using the 
immense computational power at the disposal of the modern scientist. In the future, these 
types of approaches will become even more important as yet more of the scientific 
process is automated with machines. We are in a transition period, and this is glaringly 
apparent in medical and biological research where sequencing, IT infrastructure, and high 
throughput assays are changing the way discoveries are made, published, and validated. It 
is important to embrace this model, where problem finding is just as important as 
problem solving and requires the same level of investment. Hypothesis driven science 
still rules, but the science of finding hypotheses and testing them on the existing data is 
still in its nascent phase.  
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COVARIATE MODULES FOR DIMENSIONALITY REDUCTION 
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Introduction 
 Batch to batch variation is a problem for microarray based assays. This has been 
true since RNA expression arrays were invented and has continued as the technology 
expands into protein and peptide based microarrays. Next generation sequencing has been 
touted as a solution to this problem, but this is only applicable to RNA or DNA profiling, 
as protein and peptide based assays still rely on microarrays. Further, there are over 1.2 
million samples of microarray data in the Gene Expression Omnibus database (GEO) that 
remains underexploited due to this issue. Methods such as ComBat attempt to solve this 
problem, but these are unsuitable for use in blinded tests as they require class labels in 
addition to batch labels as inputs. A general approach is needed for doing meta-analyses 
of noisy array data, be it peptide, protein or DNA/RNA.  
Idea 
 Arrays consist of many measurements, not all of which are independent. There are 
many hidden groups of features that vary together or do not vary much at all. The 
CIM330K array may have 330,000 features, but it does not have 330,000 independent 
features, so the measured information is likely much less than is immediately apparent. If 
we could group features into clusters or “modules” of features with high covariance, 
perhaps these groupings could be used to reduce batch variation. 
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Method 
 Finding groups of similar features reduces to a clustering problem. There are 
many ways to do this, all of which suffer from similar issues. The main question is how 
many clusters should be formed based on the data? Hierarchical clustering avoids this 
problem completely by constructing a tree structure to represent the relationship between 
two instances, however the tree must be cut at a subjective point in order to create 
discrete clusters. K-means makes this subjectivity explicit by requiring the user to select 
how many clusters the data should be split into.  
Dirichlet mixture modeling, which we use in this experiment, attempts to solve 
this problem by assuming an infinite number of possible clusters, and assigning instances 
to a discrete subset of these. Even this method invites a certain degree of subjectivity in 
that it takes a single parameter 𝛼, known as the concentration parameter. If 𝛼 is large then 
many clusters are formed, if it is small then fewer clusters are formed. A prior 
distribution can also be placed over 𝛼 if there is a good reason to do so, but in this 
preliminary experiment 𝛼 is simply set to 1. See Figure 1 for more details. Once clusters 
are found, the data must be reduced by computing the mean of the cluster measurements. 
In an experiment with 𝑛 samples, 𝑚 peptides and 𝑘 identified modules (clusters) the 
resulting transformed matrix would be 𝑛 𝑏𝑦 𝑘. The value in the 𝑖𝑡ℎ row and 𝑗𝑡ℎ column 
corresponds to the mean measurement of peptides in cluster j for sample i. 
We selected two batches under which the same samples were run. These were the 
CIM7-18 and CIM7-30.  Each contained a group of nine common Dengue and Malaria 
samples, and also seven distracter samples unique to each batch for a total of 16 samples 
in each batch. The data from CIM7-18 was used to define the peptide modules.  
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 In order to measure the effect of this transformation on batch effects, correlation 
ranks were used. Correlation coefficients for each of the nine samples occurring in both 
batches were computed against each of the 16 samples from the other batch. These 
coefficients were ranked from highest to lowest, and the rank of the true identical sample 
was recorded for each before and after transformation. In this way, improvement relative 
to other samples could be assessed, since the number of variables is greatly reduced after 
transformation which may affect absolute measures of correlation. These absolute 
measures were also recorded and compared. A paired T Test was used to assess whether 
improvement was statistically significant. 
 
Figure A1.1: Plate diagram for general form of the Dirichlet process mixture 
model used in this experiment: This is a general form of the exponential family 
Dirichlet process mixture model. The parameters in realization of the model used in this 
experiment is as follows. The Dirichlet concentration hyperparameter 𝛂 = 𝟏, 
hyperparemeter 𝛌 refers to the way the Gaussian mixtures were initialized (diagonal 
covariance matrix, normally distributed means). 𝐕𝐤 is an infinite dimensioned categorical 
distribution draw from the dirichlet process, 𝛈𝐤
∗  refers to a set of Gaussian parameters 
drawn according to 𝛌. 𝐙𝐧 is a cluster index 1 … ∞ drawn from 𝐕𝐤, which is used to select 
the parameters 𝛈𝐤
∗ . Together these generate the data under the model, 𝐗𝐧 which 
corresponds to a vector of measurements for a single peptide across all samples. These 
parameters can be fit with a Gibbs sampling process. See http://scikit-
learn.org/stable/modules/generated/sklearn.mixture.DPGMM.html for more details on the 
actual process used. 
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Results and Discussion 
 Setting the number of mixture components to 100 yielded 59 modules (clusters) 
of peptides in the data tested. This produced a 59 x 16 matrix (modules x samples) for 
each of the two tested batches. Correlations between the 9 pairs of identical samples from 
each batch were compared before and after module-based transformation. There was a 
modest but significant improvement in correlation rank (P=0.016). The average rank 
improvement was 1.2. Correlations were greatly improved in the module transformed 
data, but this is not helpful information because the transformed data has far fewer 
dimensions (summarized in Figure A1.2). These results are very subtle, but the clustering 
method is also very crude. An optimization procedure could be designed seeking 
hyperparameters 𝛌 and 𝛂  such that the rank improvement is maximized.  A slight 
reformulation of the model used here could accomplish this. 
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Figure A1.2: Correlation comparisons of module transformed versus raw 
data: Transformation showed a modest but significant improvement in rank, and a large 
improvement in correlation. Rank is likely more informative than correlation, as 
transformed correlation values are of much lower dimensionality than raw values and 
represent a vector of averages, thus are more likely to be higher by chance. 
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APPENDIX B 
ALGORITHM FOR PARALLEL MASK DESIGN 
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Introduction 
 Recently there has been a lot of success developing mask based photolithographic 
synthesis of non-natural sequence peptide arrays (Legutki et al., 2014). In developing 
immunosignature based diagnostics it is important to cover as much sequence space as 
possible in order to provide a diverse surface on which antibodies can interact to create 
disease-specific patterns. This study examines the Artificial Immune System (a flavor of 
genetic algorithm) as an array generation method with the objective of maximizing 
measures of peptide diversity.  
The process for achieving this optimal array is not straightforward for two 
reasons. First, there are multiple definitions of “complex surface” depending on the 
window length considered. For example, if 12-mers are considered the unit of diversity, 
then it is very easy to put down an array of 330,000 unique peptides since there are 1612 
possible 12-mers in the current 16 amino acid synthesis scheme. This may be misleading, 
however, because these 12-mers could have hidden redundancies and biases at the 
subsequence level in the pentamer and hexamer windows of each peptide. What we are 
really interested in is maximizing the number of linear antibody binding sites on the 
surface, which are more poorly understood. Recent studies of linear epitopes using large 
combinatorial arrays have shed some light on this issue (Buus et al., 2012a), with the 
average monoclonal antibody requiring around 5 to 7 amino acids (but as few as 3) for 
strong binding (Figure 1.7). This study attempts to maximize the number of unique 5-
mers represented on the array. 
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 The second reason an optimal array is difficult, even if an objective function can 
be found, is in the nature of the array synthesis. These are made using a mask based 
photolithographic process whereby a single amino acid is placed on a portion of array 
spots at each step. If one wants to make Q number of peptides of length M using N 
masks, one can imagine N masks stacked on top of each other with Q spots for potential 
holes on each. As one looks down through this stack of masks, there would be M holes in 
each spot (Figure A2.1) such that after all synthesis steps have been completed, the array 
consists entirely of peptides of length M. Due to this process, it is not straightforward to 
synthesize arbitrary peptides, since there are restrictions inherent in the combinatorial 
process of mask based synthesis. It is difficult to start from an optimal list of peptides and 
synthesize those exactly using masks. 
 In order to address this issue, we treated this as a combinatorial optimization 
problem and took inspiration from the natural system these arrays were designed to 
study:  the clonal expansion and selection process that produces high affinity IgG 
antibodies. 
 
Figure A2.1: Overview of array synthesis (adapted with permission from (Legutki et 
al., 2014): The arrays considered here employ a mask based synthesis process, whereby 
amino acids are washed over the surface one at a time, and light flowing through holes in 
a mask directs the synthesis. By repeating this process with differing masks and amino 
acids, complex surfaces can be created. 
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Method 
 Genetic algorithms are intuitive and simple to implement, though their properties 
are difficult to analyze mathematically. They can be summarized in the following steps: 
1. Initialize a population with random parameters. 
2. Compute the objective function (the function we are trying to optimize) for each 
member of the population. The objective function in this case is simply the 
number of unique pentamers represented. 
3. Take the “fittest” (highest objective function evaluation) individuals and use them 
for the next generation, and throw away the rest. 
4. The fittest individuals produce a number of offspring to recapitulate the original 
population size. This can optionally involve a mating function for combining 
characteristics from multiple fit individuals,  or one can simply “mutate” the 
parameters randomly to mimic VDJ recombination.  
5. The new population shares characteristics of the parents (the fittest members of 
the previous generation) and additionally adds some random characteristics to 
explore more parameter space. 
6. Repeat steps 2-6 until convergence. 
The implementation used in this study more closely resembles bacterial 
replication or clonal selection, as it omits the mating function. The virtual array 
consists of 100,000 12-mer peptides. Thus each peptide has 12 – 5 +1 = 8 pentamer 
windows for a total of 800,000 possible unique binding sites. This is the upper bound 
on the number of unique pentamers that can be represented on this virtual array. The 
algorithm was tested against a naïve implementation that simply generated C arrays 
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using randomly assigned holes and amino acid orderings. C refers to the number of 
total “individuals” generated in the clonal selection process. These randomly 
generated arrays serve as a baseline control, indicating the best that can be done 
naively using the same number of computational steps.  C in this test was 16 x 10000 
= 160,000 (16 generations, 10,000 individuals per generation) 
 Unlike many optimization methods, the genetic algorithm (especially the clonal 
expansion variety) is highly amenable to parallelization. Each generation can be 
generated and the objective function evaluated on a separate core. Only the fitness 
selection step must be run in series, and this is an extremely rapid step. 
Results 
 The algorithm was tested while varying the available number of masks between 
40 and 240. For each mask length, the clonal expansion algorithm performed 
significantly better than naïve. At 40 masks, the naïve method generated 61,311 ± 
11,879 unique 5-mers, while the clonal algorithm generated 120,589 sequences after 
16 generations. The improvement was greatest at 120 masks, with the naïve method 
generating 502,900 ± 33,058 and the clonal method generating 697,743 pentamers, a 
1.38 fold improvement. Parallelism was also successful, with speedup following a 
predicted near-linear trend. These results are summarized in Figure A2.2. 
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Discussion 
 Combinatorial optimization problems are difficult. The search space in this case is 
extremely large, and there are likely many local maxima. The objective function 
landscape is likely very “jagged” with a non-obvious and possibly unimportant global 
maximum. Our focus is on generating arrays that are good enough, not necessarily 
optimal, and for this task the clonal selection algorithm is clearly better than naïve 
methodology. That said, there are many other ways to accomplish this task including 
more rational top-down methods. 
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Figure A2.2: Clonal Expansion Algorithm (AIS) versus Naïve: Top shows clonal 
expansion algorithm (AIS) versus the naïve approach. At all mask lengths the AIS 
outperformed naïve methodology. It also scaled well, with speedup following a mostly 
linear trend (bottom). Spark refers to Apache Spark, a software package for running 
distributed operations on multiple cores or machines. Scala parallel collections refers to 
another, less scalable but more lightweight software library for parallelization. These 
tests were implemented using Scala on OpenJDK build 24.65. 
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APPENDIX C 
MEASURING OFF RATES ON ARRAYS 
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Introduction 
 Understanding the kinetics of immunosignatures is of principal importance to the 
assay. One of the unknowns which was discussed in Chapter 4 is the effect of peptide 
density on the dissociation constant Kd. Peptide density is proportional to spotting 
concentration, which refers to the concentration of peptide included in the spotting plate 
used for array manufacturing. Lower concentrations deposit less peptide on the surface, 
though the exact final peptide surface density is unknown and very difficult to measure. 
In this experiment spotted  two peptides at varying concentrations and assayed binding 
against approximately 25nM of p53Ab1 at flow rates of approximately 50uL/s in a 130uL 
flow chamber using to the method developed by Matt Greving (Matthew P Greving et al., 
2010). One of the peptides contained the epitope for this antibody, RHSVV, and the other 
contained this sequence with one substitution RHSVK. Both peptides were 20 amino 
acids long and are listed below. 
Peptide 1: RHSVVSGSGRHSVVSGSGSC 
Peptide 2: EHHYPVRHSVKTQDKVMGSC 
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Figure AC.1: Flow cell Array Images 
Using the method developed in (Matthew P Greving et al., 2010), I used the DNAScope 
to measure off rates of a single antibody with two different peptides. In the image above, 
the top set of peptides are repeated spots of RHSVVSGSGRHSVVSGSGSC and the 
bottom set is EHHYPVRHSVKTQDKVMGSC. Each row corresponds to a different 
concentration of spotted peptide. The top row of each block was spotted at 2mg/ml of 
peptide. Each subsequent row was serially diluted such that it had half the concentration 
of the row above. The antibody used was 25nM of p53Ab1, which was continually 
flowed over the surface of the array using a recirculating pump mechanism. The epitope 
for this antibody is RHSVV. The top spots contain this exactly and the bottom ones 
contain this with one substitution (RHSVK). The left figure shows a time slice while 
antibody is being flowed over the surface, and the right figure shows a different time slice 
during the wash step (buffer only). By taking several measurements over time, 
association and dissociation curves can be observed. 
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Concentrations of the rows 1 to 4: 2 mg/mL, 1 mg/mL, 0.5 mg/mL, 0.25 mg/mL 
 
 
Concentrations of the rows 5 to 8: 0.125 mg/mL, 0.063 mg/mL, 0.031 mg/mL, 0.016 
mg/mL 
 
Figure AC.2: Association and Dissociation Curves of Selected Spots - Epitope: 
These are spots from the top block containing RHSVVSGSGRHSVVSGSGSC. At high 
peptide concentrations (top) off rate appears linear due to a saturation effect (likely 
optical). At low concentrations (bottom) a single component decay curve is observed. 
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Off rate estimation 
 
 A natural question from these data is how the off rate koff  is affected by decreased 
spotted peptide concentration. From Figure AC.2 there are two concentrations: 0.125 
mg/mL and 0.063 mg/mL where decent off rate exponential curves could be fit. Off rate 
units are in terms of fluorescence intensity, not standard molar or nanomolar quantities. 
That is to say, these are arbitrary units. Even so, it should be possible to tell from the 
exponsntial fits whether off rates are significantly different between these two spotting 
concentrations. Consider the following equation for exponential decay (a typical model 
for dissociation): 
 
Where y is the intensity at time t, c is a constant and t is time in minutes. This equation 
can be linearized as follows: 
  
This is a simple linear equation and can be fit with standard methods and used to estimate 
confidence intervals on k (the off rate in terms of arbitrary units). If there is a significant 
difference, then spotting density has an effect on off rate. Fitting the linearized equation 
to data from Figure AC.2 yields the following estimates for k: 
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Spotting Conc. k estimate Lower 95% Upper 95% R Squared 
Row 5: 0.125 mg/mL 0.0116 0.0113 0.0120 0.983 
Row 6: 0.063 mg/mL 0.0148 0.0144 0.0153 0.982 
Table AC.1: Off Rate Estimates at Two Spotting Concentrations: The confidence 
intervals for these two off rates (arbitrary units) do not overlap, indicating that spotting 
density could have an effect on off rates, though this effect is slight and these data are 
preliminary. 
 
 
 
Figure AC.3: Linearized Off Rate Estimation: This is a graph of the linear fit shown in 
Table AC.1. The data follow a linear trend and a slight difference exists due to spotting 
density. 
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Concentrations of the rows (1 to 4): 2 mg/ml, 1 mg/ml, 0.5 mg/ml, 0.25 mg/ml 
 
 
Concentrations of the rows (5 to 8): 0.125 mg/ml, 0.063 mg/ml, 0.031 mg/ml, 0.016 
mg/ml 
Figure AC.4: Association and Dissociation Curves of Selected Spots - Substitution: 
These are spots from the bottom block containing EHHYPVRHSVKTQDKVMGSC 
with a single substitution from the epitope. At all peptide concentrations the off rate is 
rapid, but slows after an initial phase indicating a two component off rate. The 
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mechanism underlying this is unknown, but could indicate cooperative binding as 
discussed in experiments from (Halperin, 2011) 
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